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General introduction 
 
1.1.Background 
 
The common occurrence of chronic diseases – such as ischemic heart 
diseases (IHD) 1, 2, stroke 1, 2, and stomach cancer 1, 2- in most populations and the 
attendant mortality, loss of independence, impaired quality of life, and social and 
economic costs are compelling reasons for public health concern. Although 
mortality from IHD 3, stroke 4, and stomach cancer 5 have fallen substantially in 
western Europe over recent decades, IHD and stroke remain among the leading 
causes of death in Europe 6-9. Furthermore, elderly people constitute a growing 
part of the population 10 and therefore, the absolute number of deaths might 
continue to increase due to ageing of European population 11.  Together, IHD, 
stroke and stomach cancer, have figured prominently in the large shifts among 
causes of death, especially in industrial societies, during the 20th century. During 
this period, the mortality and morbidity rates of these diseases has changed 
rapidly in many countries, as a result of both increasing proportions of these 
populations attaining older ages and concurrent social changes. The 
epidemiology and prevention of these diseases involve the understanding of their 
causes, identification of means of prevention, and monitoring of populations to 
assess the changing burden of these diseases and measurable impact of 
interventions to control them. This thesis monitors seven European populations –
i.e., Denmark, England and Wales, Finland, France, the Netherlands, Norway and 
Sweden. It assesses the changing impact of the above mentioned diseases over 
time by extrapolation of observed trends in the past. It projects the future profile 
of these diseases in seven European countries.   
Cardiovascular diseases, of greatest public health concern for any country 
are those of the highest frequency now or potentially in the decades ahead. Wide 
geographic variations in rates and trends of mortality from IHD and stroke have 
been shown since the early 1950s 12, 13 and for incidence and case fatality from 
IHD by the WHO MONICA Project in the mid-1980s 14.  Particular conditions 
among the cardiovascular diseases, such as IHD and stroke, are important both as 
common causes of death and as causes of illness and disability among those who 
live with the disease and survive acute events. The epidemiologic research of past 
several decades has advanced understanding of major cardiovascular diseases to 
the point where their prevention is largely within reach, despite the increased 
knowledge on the cascade which leads to cardiovascular morbidity and death. 
The picture for cancer is less consistent. As with IHD and stroke, cancer 
also represents a major cause of death and disability - with a changing 
(geographically) pattern 1, 2, 15– mainly because of four potential explanations. 
Firstly, its etiology as a heterogeneous disease; some cancers which their 
exogenous factors apparently play dominant role, show changes according to the 
exposure involved; for example, cancers which are related to tobacco. Secondly, 
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ageing of the population; some cancers which apparently are associated with 
higher age have been introduced in recent years. Thirdly, population screening 
for some cancers; these screening programs have had some influences on 
incidence (increasing) and mortality (increasing or decreasing) of cancers. 
Finally, treatment improvements; treatment radically has changed prospects, on 
survival and morbidity, for some cancers such as hematological malignancies. 
Despite the successes in declining of malignancies’ mortality, the background of 
most cancers is still only partially understood, at least insufficiently to guide 
prevention or therapy, and to make educated rather than statistical guesses about 
the future.  
Taken together, we selected these three major diseases because of the role 
of IHD and stroke as first and second leading causes of deaths 1, 16-18, in spite of 
their declining trends in mortality in recent years 19-23; and the etiology and 
possible relation of stomach cancer with early life conditions and therefore 
potential cohort effects. In addition, as stomach cancer had only few adult risk 
factors in common with the other selected diseases, its study promised new 
insights into the effects of early life conditions 16.  
In addition, it is of limited interest to study the development of these 
diseases only in one country of region. It is obvious that results are more reliable 
and more likely to be generalizable, if more countries would be taken into 
account. Seven European countries –i.e., Denmark, England and Wales, Finland, 
France, the Netherlands, Norway and Sweden - have been selected. They seem 
suitable countries because they are heterogeneous enough, yet have a comparable 
level of wealth and socio-economic structure, and also their long-term mortality 
and population data come from data sources that are known to be of good quality 
24-26.  
This thesis monitors these seven European populations and assesses their 
changing burden of three diseases over time, and by extrapolation of results of 
observed trends in the past, project the future level of mortality from these 
diseases in seven European countries. Taken together, we expect these seven 
countries to allow for making inferences about future mortality from 
IHD/stroke/stomach cancer in countries with a similar profile. 
We aimed to study changes and trends of the above diseases, related to 
determinants. Besides the obvious factors age and gender, we were interested in 
environmental background as this is a likely source for the rapid changes 
observed. Previous studies have suggested that early life factors may be 
important determinants of the trends and geographical differences in mortality 
from diseases in adults 27. While such circumstances can not easily be measured, 
and, naturally, are unavailable for data in the remote past, it is generally accepted 
that proxies can be used for that purpose. Infant mortality rate (IMR) and gross 
domestic product (GDP) were selected because of practical reasons (availability 
of reliable data for a long-term in the past), and representativeness of these 
indices for health and economic situation of population in early life, respectively. 
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Studies have shown a strong geographical correlation between mortality from 
various causes of death in adulthood and infant mortality around the time of birth 
28, where IMR was taken to reflect the living conditions in early life 29. However, 
there is controversy about the association between early life conditions and 
mortality trends from these diseases. While several studies have shown the risk of 
IHD to be associated with adverse living conditions in early life 30-32, this finding 
has not consistently be replicated 33, 34 . Similarly, for stroke, some studies have 
observed a relation with living conditions in early life 31, 35, whereas others have 
not 9, 36. Finally, although the importance of “environment” in early life in 
determining the risk for stomach cancer have been confirmed 9, 36; however, the 
role of living conditions on mortality trends is not yet fully understood 37. 
Some studies assessed the effect of living conditions in early life on time 
trends (instead of geographical differences) on adult mortality 38, 39. These studies 
focused on the question of whether time trends in adult mortality reflect cohort 
effects or period effects. Cohort effects in turn would be suggestive of effects 
located in early life. Consequently, a useful contribution to these studies would 
be to assess cohort-specific trends in mortality in relationship to the IMR/GDP 
level at the time of birth of different cohorts. Such an analysis could contribute to 
a better understanding of mortality trend changes and the potential effect of early 
life conditions on these changes over time. 
 
1.2.The objectives of thesis 
 
The first objective is to describe the past trends in mortality from IHD, 
stroke, and stomach cancer in seven European low-mortality countries from 1950 
to 1999 and to assess the explanatory role of early life factors. The second 
objective is to estimate the future mortality trends to 2030, based on extrapolation 
of the observed mortality trends in 1980-2005, in seven European countries. 
 
 
1.3.Research Questions 
 
The main research questions addressed in thesis are: 
 
 1. How did mortality from IHD/stroke/stomach cancer develop over the 
period 1950 to 1999 across Europe? 
 
 2. How was the relation between IMR and GDP (as proxies for early life 
conditions) and mortality from IHD/stroke/stomach cancer from 1950 to 
1999 across Europe? 
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 3. What will be the impact of mortality from IHD/stroke/stomach cancer 
in 2030, if the mortality trends of these diseases from 1980 to 2005 across 
Europe were to continue in the future? 
 
1.4.Data and methods 
 
1.4.1. Data: 
 
To address the first research question of the thesis data on IHD, stroke, and 
stomach cancer mortality and population at risk, by year of death (1950-1999), 
sex, and five-year age group for these seven countries were obtained from 
national statistical offices and related institutes 40; IMR data for the period 1860-
1969 came from Mitchell for most countries 41, and from Turpeinen for Finland 
42. Historical national accounts data were used to estimate past national levels in 
gross domestic product (GDP) 43-45. To bridge different ICD revisions, a general 
concordance table were used, in which the different codes for IHD, stroke and 
stomach cancer in the successive ICD revisions were linked 40. 
For the second and third research questions, data for Denmark, Finland, 
France metropolitan, the Netherlands, Norway, Sweden and the United Kingdom 
on the number of deaths from IHD, stroke, and stomach cancer, and 
corresponding numbers of population at risk, by sex and five-year age groups for 
the years 1980 to 2005 have been obtained from national data sources (1980-
1999) 46, and Eurostat (from 2000 to 2005). In addition, all-cause mortality rates 
were obtained from the Human Mortality Database (HMD). The future 
population numbers have been obtained from Eurostat (baseline variant) 
Furthermore, the fact that the International Classification of Diseases (ICD-6 to 
ICD-10) had been revised five times during this period has also been considered.  
 
1.4.2. Methods 
 
In both parts of this thesis, sex-specific age-standardized mortality rates, 
using direct standardization with a European standard population, were used to 
describe mortality trends. Pearson correlation coefficients were frequently used to 
quantify associations. The time periods were 1950 to 1999 (and birth cohorts of 
1860 to 1939) for historic research for the research questions 1 and 2, and 1980 
to 2005 for estimating the baseline trends for the projections for question 3. 
For the historic analysis, we used age-period-cohort (APC) log-linear 
regression analysis (Poisson regression) to explore the trends of the past. For the 
future projection we used age-period (AP) log-linear regression analysis 
(Poisson regression) to estimate annual mortality changes (%). This method takes 
age differences into account. Furthermore, the impact of future mortality trends 
on life expectancy is assessed by means of the potential gained in life expectancy 
(PGLE), using cause-elimination life tables. 
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In this thesis, we refrained from using more complex models such as 
models that include data on disease occurrence and risk factors 47. These models 
have as an advantage that patients are assigned to specific disease state which in 
turn allows estimating of health state specific life tables. Such a method 
ultimately provides more detail. However, these models also demand much more 
detailed data on disease progression, and age-sex specific rates of transitions 
between health states. Precision is thus obtained at the price of higher data 
demands, more assumptions, artificial staging of the disease, and difficulty in 
accounting for period effects. In contrast, regression models of mortality trends 
have the advantages of lesser data requirement and the possibility to use long 
term historical datasets 48. Considering these advantages, we chose regression 
models, which were also recommended by Wilmoth 49 and European Association 
for Population Studies 50.  
 
1.5.Structure of the thesis 
 
The first part of this thesis; i.e., Chapters 2 and 3, aims to answer the first 
two research questions by dealing with the description of the past mortality 
trends in IHD, stroke, and stomach cancer in seven European countries. In these 
chapters, the role of period and cohort effects in the observed trends in the 
cohorts born from 1860 to 1939 was identified. Chapter 2 describes the trends of 
mortality from IHD and stroke in relation to infant mortality rate (IMR). In 
Chapter 3, we analyzed the secular trends of mortality from stomach cancer. In 
both Chapters 2 and 3, we discuss the role of early life conditions and 
environmental factors (measured with IMR and GDP at birth) in mortality from 
IHD, stroke and stomach cancer from 1950 to 1999.   
The second part of the thesis; i.e., Chapters 4 to 6, aims to answer the third 
research question on the future trends of mortality from the above mentioned 
diseases, by projecting the mortality trends towards 2030, based on the observed 
mortality trends in the time period of 1980 to 2005 in seven  European countries. 
The projected mortality rates, absolute numbers of death, potential gained in life 
expectancy (PGLE) are compared to the related figures in 2005, in order to have 
an insight about the possible burden of mortality in the future. Chapter 4 
illustrates the probable declines in IHD mortality in seven European countries. In 
Chapter 5, we extrapolate the future trend of mortality from stroke in six 
European countries. In Chapter 6, we explore the trend of mortality from 
stomach cancer in 2030.  
Chapter 7 focuses on the main discussion and elaborates on the determinants 
of the mortality decline in the past and possible projections in the coming years. 
Finally, Chapter 8 provides a summary to the thesis in English, Dutch and 
Persian (Farsi).     
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Cohort-specific trends in stroke mortality in seven European countries were 
related to infant mortality rates 
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Abstract 
Objective: To assess, in a population-based study, whether secular trends 
in cardiovascular disease mortality in seven European countries were correlated 
with past trends in infant mortality rate (IMR) in these countries.  
Study Design and Setting:  Data on ischemic heart disease (IHD) and 
stroke mortality in 1950-1999 in the Netherlands, England and Wales, France 
and four Nordic countries were analyzed. We used Poisson regression to 
describe trends in mortality according to birth cohort, for the cohorts born 
between 1860 and 1939. Pearson correlation coefficients were calculated to 
determine associations between IMR and IHD or stroke mortality.  
  Results: IHD mortality increased for successive cohorts up to 1900, and 
then started to decline. Stroke mortality levels were virtually stable among birth 
cohorts up to 1880, but declined rapidly among later cohorts. A strong positive 
association was found between cohort-specific IMR levels and stroke mortality 
rates. There were no strong cohort-wise associations between IMR and IHD 
mortality.       
Conclusion: These results support other studies in suggesting that living 
conditions in early childhood may influence population levels of stroke 
mortality. Future studies should determine the contribution of specific early life 
factors to the mortality decline in IHD and especially stroke. 
 
 
Key Words: Europe, Mortality Trends, Ischemic heart disease, Stroke, Cohort 
Analysis, Infant mortality rate 
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2.1. Introduction  
 
 While several studies have shown that the risk of ischemic heart disease 
is associated with adverse living conditions in early life16, 17, 32-34, this finding has 
not always been able to be consistently replicated 35, 36 . For stroke, some studies 
have observed a relation with living conditions in early life 16, 18, whereas others 
have not 17, 33. The ‘fetal origin’ hypothesis 37, 38 states that the risk of stroke is 
increased by maternal influences associated with poverty 37, a hypothesis, 
however, that is contested by others 39, 40. Similarly, population-based studies 
have suggested that early life factors may be important determinants of the 
trends and geographical differences in mortality from cardiovascular disease in 
adults 13, 15, 36, 41-43. For example, studies have shown a strong geographical 
correlation between mortality from various causes of death in adulthood and 
infant mortality around the time of birth, where infant mortality rate was taken 
to reflect living conditions in early life 13, 15, 36, 41-43 . One study observed that 
geographical differences in mortality from stroke in the late 20th century were 
correlated more strongly with infant mortality rates in the early 20th century than 
with current socio-economic conditions 13 .  
Previous studies have reported declining trends of IHD for developed 
countries over recent decades 44-50, while the decline in stroke mortality rates  
between 1970 and 1990 slowed to a stop for both sexes and all ages 51.  Some 
studies assessed the effect of living conditions in early life on time trends 
(instead of geographical differences) in adult mortality 22, 52. These studies 
focused on the question of whether time trends in adult mortality reflect cohort 
effects or period effects. A period effect is evident when a similar 
(approximately parallel) shift in rates is seen in each age group during a 
particular calendar period, while a cohort effect is manifested by age-specific 
rates that rise and fall in parallel when plotted against year of birth (cohort) 52. 
Cohort effects would be suggestive of effects located in early life, but clear 
evidence for such effects was lacking in most studies 22. 
 In this paper, we present results of a population-based time-series study 
that aimed to describe trends in mortality between subsequent cohorts in relation 
to living conditions in early life of these cohorts. We assessed cohort-wise 
trends of ischemic heart disease (IHD) and stroke mortality of populations in 
seven European countries, and determined whether these trends were correlated 
with developments in infant mortality rate at the time of birth of the subsequent 
cohorts. We addressed three research questions: 1) What are the trends in age- 
and sex-specific mortality from IHD and stroke in seven European countries 
between 1950 and 1999? 2) What are the trends according to birth cohort?  3) 
Do these cohort-wise trends coincide with trends in infant mortality rates in 
subsequent cohorts from 1860 to 1939? 
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2.2. Methods  
 
We obtained data on ischemic heart disease, stroke mortality and 
population at risk, by year of death (1950-1999), sex, and five-year age group 
for seven low-mortality European countries, i.e. Denmark, England & Wales, 
Finland, France, the Netherlands, Norway, and Sweden. For Denmark, Finland 
and Norway data were available only from 1951, and for Sweden, from 1952. 
For France, data were only available until the year 1997 and for Denmark, until 
1998. The data were obtained from national statistical offices and related 
institutes. See Janssen et al., 2004, for more information 23. 
In reconstructing mortality trends from IHD and stroke over the period 
from 1950 to 1999, we first ran up against the fact that the International 
Classification of Diseases (ICD-6 to ICD-10) had been revised five times during 
this same period. To reconcile these differences, we constructed a general 
concordance table, in which the different codes for stroke and for IHD in the 
successive ICD revisions were linked 23. For IHD, we selected the ICD codes 
420 and 422.1 for ICD-6 and ICD-7, 410-414 for ICD-8 and ICD-9, and I20-I25 
for ICD-10. For cerebrovascular diseases we selected ICD codes 330-334 for 
ICD-6 and ICD-7, 430-434 and 436-438 for ICD-8 and ICD-9, and I60-I69 for 
ICD 10 23, 53. For IHD, the numbers of deaths for code 422.1 under ICD-6 and 
ICD-7 were not available for Finland until 1963, and Sweden until 1961. We 
estimated these on the basis of the ratio of the number of deaths from ischemic 
heart disease with and without 422.1, calculated for the first year in which 422.1 
was coded.  
Remaining mortality discontinuities - caused by the use of three-digit 
instead of four-digit codes and by incidental changes in coding rules – were 
identified and adjusted for in our analysis (see Janssen and Kunst (2004) for 
more information) 29. We adjusted the person-years for the incidental changes in 
coding rules for stroke in 1956-58 for Finland, and for the generally applied 
coding changes in England and Wales between 1984 and 1992 29. We made 
adjustments for the mortality discontinuity in IHD due to the ICD revision from 
ICD-8 to ICD-9 in the Netherlands, and for the incidental changes in coding 
rules from 1970 onwards for Sweden 29.  
 Data on infant mortality rates (IMR), defined as the number of deaths 
during the first year of life per 1000 live-born babies, for the period 1860-1969 
were obtained from Mitchell for most countries 54, and from Turpeinen for 
Finland 25. 
  In order to describe trends in mortality between 1950 and 1999, age-
adjusted mortality rates by 10-year intervals were calculated using direct 
standardization, taking the age-specific person-years of each country in the 
1950s as standard. For describing trends over time, we looked at two periods: 
from the 1950s to the 1970s (measured by age-adjusted mortality rate of 1970s 
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divided by the age-adjusted mortality rate of 1950s) and from the 1970s to the 
1990s (measured in similar ways).  
In order to describe mortality differences between birth cohorts 1860 to 
1939, we analyzed the mortality data by means of a log-linear regression 
analysis (Poisson regression). The dependent variable was the number of deaths, 
with the person-years at risk as offset variable. We included age and cohort  
(one-year intervals in table 1, and five-year intervals in table 2 to 4) as 
independent variables. Table 3 illustrates the mortality rates in each five-year 
birth cohort relative to the mortality rates in cohort 1900-1904, thus enabling 
comparisons of the mortality rates between different cohorts to be made. These 
relative cohort mortality measures were derived from the parameter estimates of 
the cohort variable in the regression analysis.  
Only age was controlled for in these cohort analyses. In subsequent 
analyses, however, we also controlled for ‘drift’, the common linear trend, and 
non-linear period effects 55, 56 and found basically the same patterns of cohort 
differences in mortality as those shown below.  
Pearson correlation coefficients were calculated in order to quantify 
associations between cohort-specific mortality levels and the level of IMR of 
each birth cohort. These correlations were estimated by comparing cohorts 
within countries. In addition, a pooled analysis was made combining all birth 
cohorts for all countries together. We restricted all analyses to cohorts born 
between 1860 and 1939, thus excluding birth cohorts with too few deaths during 
the observation period. Additional analyses, with further restriction to birth 
cohorts born between 1875 and 1924, showed similar results to those reported 
below.   
We used SPSS for Windows (10.1) package, Excel for Windows, and 
SAS 8.0. 
 
2.3. Results  
 
Table 2.1 shows changes in mortality according to period of death, 
comparing the 1950s to the 1970s and the 1970s to the 1990s. IHD mortality 
generally increased between the 1950s and 1970s in all countries for both men 
and women, except for women in France and Finland below 45 years. These 
increases were generally followed by a decline in IHD mortality in all countries 
between the 1970s and 1990s. The latter decreases were larger among younger 
people. Mortality from stroke declined from the 1950s to the 1990s in all age 
groups in most countries, often with larger declines in more recent decades. 
 Table 2.2 shows trends in mortality by year of birth from 1860 to 1939, 
subdivided into four segments, with each segment covering 20 years (1860 to 
1879, 1880 to 1899, 1900 to 1919, and 1920 to 1939). Mortality from IHD 
generally increased with increasing year of birth between 1860 and 1899, at 
which point it started to decline.  The reversal from increasing to decreasing 
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IHD levels was more marked in France, Finland and Norway than in other 
countries. In many countries, the decline started earlier among women than 
among men. Stroke showed a more consistent pattern of decreasing mortality in 
most populations, after initial increases in many countries for the birth cohorts 
1860 to 1879. The rate of the decline in stroke mortality greatly differed 
according to birth period, country and sex, with mostly higher declines for the 
youngest birth cohorts. 
Figure 2.1 shows the trends by 5-year birth cohort in IHD, stroke, and 
infant mortality. IHD mortality increased between successive cohorts up to those 
born in about 1900, and then started to decline. Increased stroke mortality levels 
were relatively stable in birth cohorts up to 1880, but declined rapidly in 
subsequent cohorts. IMR showed a general tendency to decline, especially after 
1900, a tendency that started much later in some countries (e.g. Denmark and 
England & Wales) than in others (e.g. The Netherlands). The irregularities in the 
decline in IMR do not clearly correspond to similar irregularities in the decline 
in stroke. 
Table 2.3 shows the correlation coefficients comparing the cohort-specific 
levels of IMR with mortality trends from stroke or IHD at adult age for the 
subsequent cohorts. A variable and sometimes inverse relationship between IHD 
mortality and infant mortality was found in the different countries. On the other 
hand, there was a significant and strong positive association across birth cohorts 
between IMR and stroke mortality at adult age. The correlation coefficients were 
0.83 for Denmark and 0.93 or more for other countries.  When all countries are 
pooled, and associations across countries are also taken into account, the overall 
correlation is large for stroke (0.72) but non-significant for IHD mortality. 
 In table 2.4, correlations across countries are calculated separately for 
each 5-year birth cohort. The relationship between stroke mortality and infant 
mortality rate was slightly positive when comparing countries for birth cohorts 
born before 1900. However, for birth cohorts born after 1900 this association 
was slightly negative. The inter-country association between IHD and infant 
mortality was negative in all birth cohorts, with significant negative correlations 
for birth cohorts born before 1895. Thus, countries with higher IMR before 1895 
had lower IHD mortality rates among the same birth cohorts at adult ages. 
 
2.4. Discussion  
 
There have been relatively few studies on the possible impact of early life 
circumstances on trends in mortality from cardiovascular diseases within 
national populations. We performed a time series analysis in which special 
attention was paid to cohort patterns.  We studied trends in IHD and stroke in 
relation to IMR in birth cohorts born between 1860 and 1939 in seven low-
mortality European countries, observing a general cohort-wise decline in 
mortality from stroke in all countries and in both sexes, compared to an 
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epidemic pattern of change for IHD. While the trends in IHD mortality were not 
strongly correlated with the infant mortality rate in subsequent cohorts, strong 
and positive correlations were observed for stroke.  
However, irregularities in trends in IMR between 1860 and 1940 were not 
reflected in similar irregularities in trends in stroke in later years. The 
irregularities in secular trends in IMR reflect true and important developments in 
the past, which might have been reflected in the mortality rates of affected birth 
cohorts during their later life. However, such lasting effects are not observed in 
our study. In addition, inter-country variations in IMR levels in the past had no 
strong positive correlations with cohort levels of stroke mortality at adult age. 
 We should stress that our objectives, empirical analyses, and inferences 
all refer to the same level of analyses, i.e. national populations. In this type of 
analysis, there is a risk of ecological fallacy 57. However, this fallacy would be 
committed only if inferences were to be made towards the individual level. We 
have refrained from making such inferences, because trends in stroke mortality 
at the national level may strongly be influenced by factors that may have little 
effect at the individual level.  
The mortality and population data used in this study come from data 
sources that are known to be of good quality 58-60. Any problems with the 
coverage or completeness of death registries or population registrations are 
likely to have had no or minimal effects on our results. We made a special effort 
to deal with ICD- and other coding related changes affecting mortality trends 
from IHD and stroke that are often neglected in other studies. Even though some 
residual effects of coding problems could not be excluded, we are confident that 
these problems did not affect the results to any substantial extent 23, 53. 
The results for the oldest 5-year cohorts (i.e. birth cohort 1860-1864) 
should be interpreted cautiously, as only the mortality of those aged 85 years 
and over could be studied. Therefore, no valid comparisons can be made 
between the mortality level of this cohort and the mortality levels of younger 
cohorts, in which the mortality at younger ages could also be studied. Greater 
weight should therefore be given to results for the birth cohorts that could be 
followed across a longer age range, i.e. cohorts born after 1870 or 1875. 
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Table 2.1 – Trends in mortality from ischemic heart disease and stroke in seven 
European countries between the 1950s and the 1990s, by age and sex 
 
   Rate ratio comparing second to first period [a] 
IHD Stroke 
Male Female Male Female 
Country Age Group 
 
 
 1970s 
to 
1950s 
1990s 
to 
1970s 
1970s 
to 
1950s 
1990s  
to  
1970s 
1970s 
 to  
1950s 
1990s 
to 
1970s 
1970s 
to 
1950s 
1990s 
to 
1970s 
         
<45 1.8 0.5 2.1 0.4 1.1 0.9 1.2 0.9 
45-64 1.6 0.5 1.3 0.6 0.7 0.8 0.5 0.8 
65-79 1.6 0.6 1.1 0.6 0.6 0.7 0.4 0.7 
 
 Denmark  
80+ 1.7 0.7 1.4 0.6 0.6 0.8 0.6 0.8 
 
<45 1.7 0.4 1.2 0.5 0.9 0.6 1.0 0.6 
45-64 1.5 0.5 1.1 0.7 0.7 0.5 0.7 0.4 
65-79 1.2 0.7 1.0 0.8 0.8 0.5 0.8 0.5 
England & 
Wales 
80+ 1.1 0.8 1.0 0.8 0.9 0.6 1.1 0.6 
 
<45 1.2 0.3 0.8 0.4 1.1 0.4 0.9 0.4 
45-64 1.6 0.4 1.2 0.4 0.8 0.5 0.6 0.4 
65-79 1.5 0.7 1.4 0.7 0.8 0.6 0.6 0.5 
Finland 
80+ 1.5 1.0 1.3 1.0 0.8 0.6 0.8 0.6 
 
<45 1.8 0.8 0.7 0.8 0.7 0.6 0.6 0.6 
45-64 1.4 0.6 1.0 0.5 0.6 0.4 0.4 0.4 
65-79 1.6 0.7 1.5 0.6 0.7 0.4 0.6 0.3 
France 
80+ 2.2 1.0 2.4 1.0 1.0 0.5 1.0 0.5 
 
<45 2.4 0.5 1.4 0.7 1.3 0.6 1.6 0.7 
45-64 2.0 0.5 1.1 0.7 0.9 0.6 0.7 0.5 
65-79 1.6 0.6 1.1 0.6 0.8 0.6 0.7 0.5 
Netherlands 
80+ 1.4 0.8 1.2 0.7 0.8 0.7 0.8 0.7 
 
<45 2.0 0.5 1.2 0.7 1.2 0.5 1.3 0.5 
45-64 1.8 0.5 1.2 0.7 0.8 0.6 0.6 0.5 
65-79 1.8 0.7 1.3 0.6 0.9 0.6 0.8 0.5 
Norway 
80+ 1.8 0.8 1.5 0.7 1.0 0.7 1.0 0.6 
 
<45 1.7 0.6 1.4 0.8 0.9 0.5 0.9 0.4 
45-64 1.5 0.5 1.1 0.6 0.7 0.6 0.4 0.5 
65-79 1.6 0.6 1.1 0.5 0.6 0.7 0.5 0.6 
Sweden 
80+ 1.5 0.6 1.2 0.5 0.7 0.8 0.7 0.8 
 
[a]. Calculated as standardized death rate of the second period divided by standardized 
death rate of the first period
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Table 2.2- Trends in mortality from ischemic heart disease and stroke over  
   subsequent twenty-year birth cohorts from 1860 to 1939 in seven  
  European countries, by sex 
 
Annual change in mortality (%)  
IHD Stroke 
 
Country 
 
Birth cohorts 
Male Female Male Female 
 
 
 
1860-1879 
 
+3.76 * 
 
+4.30 * 
 
-0.79 * 
 
+0.13 * 
Denmark 1880-1899 -0.14* -0.22 * -3.02 * -4.21 * 
 1900-1919 -0.35 * -1.22 * -1.14 * -1.72 * 
 1920-1939 -2.90 * -1.48 * -0.43 * -0.91 * 
 
 1860-1879 -0.38 * -0.12 * +1.12 * +1.59 * 
England 1880-1899 +0.10 * -0.96 * -3.06 * -3.27 * 
& Wales 1900-1919 -0.05 * -0.43 * -2.02 * -2.18 * 
 1920-1939 -2.96 * -2.19 * -3.00 * -3.58 * 
      
 1860-1879 +2.41 * +2.38 * +1.78 * +2.10 * 
Finland 1880-1899 +1.22 * +0.40 * -3.47 * -4.64 * 
 1900-1919 +0.05 -1.05 * -1.65 * -2.61 * 
 1920-1939 -4.69 * -4.80 * -2.63 * -4.11 * 
      
 1860-1879 +5.90 * +7.57 * +2.48 * +3.19 * 
France 1880-1899 +1.80 * +1.13 * -3.82 * -4.03 * 
 1900-1919 -0.49 * -2.23 * -2.91 * -4.01 * 
 1920-1939 -1.75 * -1.94 * -3.37 * -3.82 * 
      
 1860-1879 -0.16 * +0.65 * -0.26 * +0.36 * 
Netherlands 1880-1899 +3.15 * +0.80 * -2.64 * -3.94 * 
 1900-1919 +0.80 * -0.55 * -1.45 * -2.52 * 
 1920-1939 -1.69 * +0.83 * -1.58 * -1.44 * 
      
 1860-1879 +3.41 * +4.27 * +1.64 * +1.95 * 
Norway 1880-1899 +0.83 * -1.37 * -2.66 * -3.64 * 
 1900-1919 -0.14 * -1.22 * -1.54 * -2.53 * 
 1920-1939 -2.80 * -1.51 * -2.08 *  -2.97 * 
      
 1860-1879 +1.99 * +2.87 * -0.39 * +1.11*  
Sweden 1880-1899 -0.36 * -2.82 * -2.83 * -3.78 * 
 1900-1919 -0.69 * -1.93 * -1.35 * +2.59 * 
 1920-1939 -2.42 * -1.50 * -2.22 * -3.10 * 
 
* Trends different from 0 with statistical significance (p < 0.01)      
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Table 2.3- Correlation between trends in IHD or stroke mortality at adult ages and 
 IMR among the birth cohorts from 1860 to 1939 in seven European countries 
 
Pearson correlation coefficient (95% CI) Country  
Sex 
 IHD and IMR Stroke and IMR 
 
Total 
 
  0.78 (0.46,0.92)  
 
0.83 (0.57,0.94) 
Male 0.42 (-0.10,0.76) 0.82 (0.55,0.94) 
 
Denmark 
 
Female 0.89 (0.70,0.96) 0.84 (0.59,0.94) 
 
Total 0.91 (0.76,0.97) 0.93 (0.80,0.97) 
Male 0.87 (0.65,0.95) 0.93 (0.80,0.98) 
England & 
Wales 
Female 0.94 (0.84,0.98) 0.93 (0.80,0.97) 
 
Total 0.28 (-0.27,0.69) 0.95 (0.87,0.99) 
Male 0.08 (-0.45,0.57) 0.97 (0.91,0.99) 
Finland 
Female 0.54 (0.04,0.83) 0.95 (0.86,0.98) 
 
Total -0.20 (-0.64,0.32) 0.95 (0.85,0.98) 
Male -0.32 (-0.70,0.21) 0.95 (0.87,0.98) 
France 
Female 0.17 (-0.35,0.62) 0.94 (0.84,0.98) 
 
Total -0.86 (-0.95,-0.63) 0.97 (0.92,0.99) 
Male -0.86 (-0.95,-0.63) 0.97 (0.92,0.99) 
Netherlands 
Female -0.64 (-0.86,-0.21) 0.97 (0.92,0.99) 
 
Total 0.23 (-0.30,0.65) 0.98 (0.93,0.99) 
Male -0.18 (-0.62,0.34) 0.98 (0.94,0.99) 
Norway 
Female 0.62 (0.17,0.85) 0.98 (0.93,0.99) 
 
Total 0.87 (0.66,0.95) 0.99 (0.96,1.00) 
Male 0.55 (0.07,0.82) 0.99 (0.96,1.00) 
Sweden 
Female 0.92 (0.77,0.97) 0.98 (0.94,0.99) 
 
Total -0.08 (-0.55,0.43) 0.72 (0.34,0.90) 
Male -0.18 (-0.62,0.35) 0.72 (0.36,0.90) 
All Countries 
Female 0.07 (-0.44,0.55) 0.72 (0.34,0.89) 
 
 CI = Confidence Interval  
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Table 2.4- Correlation between international variations in IHD/Stroke mortality at 
 adult ages and IMR for the birth cohorts from 1875 to 1925 
Birth cohort Pearson correlation coefficient (95% CI) 
 IHD and IMR Stroke and IMR 
1875-1879 -0.57 (-0.83,-0.11) 0.14 (-0.38,0.59) 
1880-1884 -0.65 (-0.86,-0.22) 0.18 (-0.35,0.62) 
1885-1889 -0.66 (-0.87,-0.24) 0.05 (-0.45,0.54) 
1890-1894 -0.62 (-0.85,-0.18) 0.07 (-0.44,0.55) 
1895-1899 -0.24 (-0.66,0.29) 0.31 (-0.22,0.70) 
1900-1904 -0.31 (-0.70,0.22) -0.10 (-0.57,0.41) 
1905-1909 -0.24 (-0.66,0.29) -0.17 (-0.61,0.36) 
1910-1914 -0.18 (-0.62,0.34) -0.18 (-0.62,0.34) 
1915-1919 -0.20 (-0.63,0.33) -0.06 (-0.54,0.45) 
1920-1924 -0.23 (-0.65,0.30) -0.16 (-0.60,0.37) 
 
CI = Confidence Interval  
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Figure 2.1- Trends in IMR and in the mortality rate ratio of IHD and 
stroke at adult ages, in five-year birth cohorts from 1860 to 1939 
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The question is whether different results would have been obtained if the 
competing causes of death phenomenon had been taken into account. Due to the 
“competing causes of death” problem, the level of mortality from both causes of 
death may be lower than it would have been without competition for the lives of 
people with common risk factors. It is impossible to correct for this common 
phenomenon in our trend analysis 61. The overall effect would have been an 
increase in the number of deaths observed for either cause of death, especially at 
the oldest ages. However, recent analyses have suggested that time trends in old-
age mortality may not be affected very much by selection (or competition) 
effects for mortality at earlier ages 62.  Peeters et al, furthermore, concluded that 
there is no support for the hypothesis that increases in the number of people with 
cardiovascular disease, as a consequence of improvements in cardiovascular 
disease survival, explain the observed leveling off of the decline in the rate of 
stroke mortality 52. 
The outcome measures in our study are mortality rates for IHD and stroke 
according to birth cohort and country. Differences in mortality rates by place 
and over time are the result of a complex interplay of many factors. In our 
analysis of associations with IMR, we were not able to control for potential 
confounders. For example, the cohort patterns of IHD mortality, which peaked 
among birth cohorts born around 1900, might be determined by smoking and 
other factors related to later phases of the life course. Similarly, the inverse 
(instead of positive) correlations between IMR and stroke in the cross-national 
analyses might have been confounded by cross-national differences in recent 
factors such as modern diet, alcohol consumption patterns, or hypertension 
treatment. Given this potential for confounding, the correlations observed in this 
study should be regarded as suggestions to be confirmed in future population-
based studies.  
The secular trends in IHD in the second half of the 20th century (an 
epidemic pattern) were very different from the steady decline in stroke. The 
factors that explain the different trends for IHD in comparison to stroke are not 
fully understood, but may be related to a relatively greater impact of smoking 
and serum cholesterol on IHD mortality compared to stroke mortality. Although 
IHD and stroke share key risk factors such as high blood pressure, tobacco use, 
and overweight 63, 64, the strength and directions of the associations may be 
different for the two diseases. The discrepancy in trends for IHD and stroke 
warns against too strong statements regarding the effect of early living 
conditions.  
Several reports have argued that declining IHD and stroke mortality rates 
are attributable to improved survival rates rather than to decreased incidence 
rates 65-69. The declining case fatality 70 may be due to advances in diagnosis and 
treatment 71, including rapid dissemination of CT and MRI technology since 
1970s 72. Studies on 10-year trends in the WHO MONICA populations show 
that two thirds of the decline in stroke mortality remains unexplained after 
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control for classical risk factors 73. A part of the unexplained trends might be due 
to changes in other risk factors, such as socioeconomic status, food 
consumption, or different combinations of some or all of these 73. Early life 
exposures might be one of the factors that contribute to trends in stroke 
mortality.  
By understanding the process of growth development, and by scrutinizing 
the growth process, factors in early life that influence susceptibility to later 
disease can be identified 74. Van Rossum reported that risk factors earlier in life 
may be of importance in stroke 75. Areas of England and Wales with high stroke 
mortality were characterized in the past by poor living standards, demonstrated 
by high infant and maternal mortality rates and short stature in the adult 
population 76. Stroke may be related to maternal influences associated with 
poverty; this suggestion is supported by recent findings that rates of stroke in 
adult life are higher among people who had low birth weight 37. Reduced fetal 
growth, i.e. the reduction in growth which begins early in gestation, is associated 
with increased risk of cardiovascular disease 76.  
 To conclude, we observed a strong relationship between cohort-trends in 
stroke mortality and cohort-trends in infant mortality in European low-mortality 
countries. Although determining the exact contribution of living conditions in 
early life to national trends in stroke mortality remains difficult to ascertain, this 
association is in line with evidence from individual level studies. It suggests that 
living conditions earlier in life may have had an effect on the mortality 
experience of national cohorts, and that changes over time in these living 
conditions may have contributed to the secular decline in stroke mortality. We 
conclude that cohort patterns should be considered when studying secular trends 
in mortality from cardiovascular diseases. Future studies on the role of early life 
circumstances should be sensitive to differences between countries and between 
historical periods in the potential impact of these circumstances. 
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Abstract  
 
Aim: To assess whether secular trends in stomach cancer mortality were 
correlated with trends in infant mortality rate (IMR) or gross domestic product 
(GDP).  
 
Methods: Data from seven European countries were analyzed. We used Poisson 
regression to describe mortality trends among birth cohorts of 1865-1939 and 
correlation coefficients to determine associations with IMR/GDP. 
 
 Results: Large differences were observed between birth cohorts in mortality 
from stomach cancer. In each country, these cohort differences were closely 
related to IMR/GDP levels at birth time. However, stronger associations were 
observed with measures of living conditions during later life. In comparisons 
between countries, stomach cancer mortality rates were not consistently related 
to national levels of IMR/GDP.  
 
Conclusion: General living conditions in childhood don’t seem to have had a 
predominant effect on secular trends in stomach cancer mortality. The mortality 
decline is likely to be related to more specific factors, such as declining H. 
pylori prevalence.  
 
 
Key Words: Europe, Mortality decline, stomach neoplasm, Infant mortality, 
Gross national product  
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3.1. Introduction   
In spite of declining incidence rates worldwide, stomach cancer is the 
second most important cause of death from cancer 7. Previous studies confirm 
the importance of “environment” in early life in determining the risk for 
stomach cancer 7, 19. Furthermore, a number of studies have shown a strong 
geographical correlation between mortality from stomach cancer in adulthood 
and infant mortality around the time of birth 14, 36. Also, mortality from stomach 
cancer showed consistent inverse socio-economic gradients and an association 
with socio-economic circumstances in childhood 77.  
Time trends of stomach cancer differ between populations and the role of 
living conditions on trends is not yet fully understood 20. To our knowledge, no 
study on trends in stomach cancer focused on birth cohorts and looked at 
measures of their association with living conditions in early life. 
 To provide new evidence on the role of living conditions in early 
childhood on trends in stomach cancer mortality, we conduct a population-based 
time-series study. The main hypothesis of our study was that living conditions in 
childhood are associated with trends in stomach cancer mortality in national 
populations.  We used data on stomach cancer mortality and population at risk 
for seven low-mortality European countries. Using these data, we tested four 
specific research hypotheses: 1) Trends in mortality from stomach cancer follow 
a cohort pattern, with lower mortality among younger cohorts. 2) Cohort trends 
in stomach cancer mortality correspond closely to cohort trends in living 
conditions in childhood. 3) For each cohort, differences between countries in 
stomach cancer mortality are closely correlated to differences in living 
conditions in childhood. 4) Stomach cancer mortality trends are associated with 
trends in living conditions in childhood rather than with trends in living 
conditions in adult life. 
 
3.2. Materials and Methods 
 
We obtained data on stomach cancer mortality and population at risk, by 
year of death (1950-1999), sex, and five-year age groups for seven low-
mortality European countries, i.e. Denmark, England & Wales, Finland, France, 
the Netherlands, Norway, and Sweden. For Denmark, Finland and Norway data 
were available from 1951, and for Sweden from 1952. Data for France were 
available until 1997 and data for Denmark until 1998. The data were obtained 
from national statistical offices and related institutes. Compared to the mortality 
information available in the WHO Mortality Bank 
(http://www.euro.who.int/InformationSources/Data/20050117_1), our data went 
further back in time, and made a more detailed distinction among upper age 
groups, which is essential for the study of mortality by birth cohort. For stomach 
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cancer, we included code 151 for revisions 6, 7, 8, and 9 of the International 
Classification of Diseases (ICD), and code C16 for ICD-10 23.  
 Data on infant mortality rates (IMR), defined as the number of deaths 
during the first year of life per 1000 live-born babies, for the period 1860-1969, 
were obtained from international compilations 78, and for Finland from a 
national publication 25.To reconstruct trends in real national GDP, i.e. GDP 
expressed at constant 1995 prices in millions of national currency units, between 
1865 and 1939, we used historical national accounts data 26. For the Netherlands, 
these historical data were available only from 1900 onwards, and for the earlier 
years data on national accounts from Statistics Netherlands were used 27. Further 
detail on the reconstruction of the time series for GDP are given elsewhere 79. 
In order to describe mortality differences between birth cohorts, we 
analyzed the mortality data by means of a log-linear regression analysis (Poisson 
regression). The dependent variable was the number of deaths, with the person-
years at risk as offset variable. As independent variables, we included age and 
cohort (one-year intervals in table 1, and five-year intervals in table 2 to 4). In 
tables 2 to 4, we expressed mortality rates of each five-year birth cohort relative 
to the mortality rates of the birth cohort 1900-1904, thus enabling comparisons 
of the mortality rates between different cohorts. These relative cohort mortality 
measures were derived from the parameter estimates of the cohort variable in the 
regression analysis.  
In these cohort analyses, control was made for age only. In additional 
analyses, we checked whether similar patterns would be observed when also 
controlling for the ‘drift’, the common linear trend, and non-linear period effects 
55, 56. These additional analyses showed basically the same patterns of cohort 
differences in mortality as those shown below.  
Pearson correlation coefficients were calculated in order to quantify 
associations between cohort-specific mortality rates and the level of infant 
mortality rate or GDP of each birth cohort. These correlations were estimated by 
comparing cohorts within countries. In addition, a pooled analysis was carried 
out combining all birth cohorts for all countries together. We restricted all 
analyses to cohorts born between 1860 and 1939, thus excluding birth cohorts 
with too few deaths during the observation period. Additional analyses, with 
further restriction to birth cohorts born between 1865 and 1924 showed similar 
results as those reported below. We used SPSS for Windows (10.1) package, 
Excel for Windows, and SAS 8.0. 
 
3.3. Results 
 
Mortality of stomach cancer decreased over the successive cohorts from 
1860 to 1939 (Table 3.1 and Figure 3.1). For Finnish men, and in France, 
however, the decline started later, i.e. from birth cohorts 1880 onwards. The 
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decline in stomach cancer over successive cohorts is generally stronger among 
women than among men. 
Figure 3.2 shows the trends in infant mortality (IMR) by five-year 
periods. The patterns were varied until about 1895. From 1895 onwards, a 
general decline in IMR emerged. In comparison with the mortality trends for 
stomach cancer, the declining trends in IMR are sharper and more stable. 
Figure 3.3 presents the trends in GDP at birth by five-year periods. An 
overall increase in GDP at birth can be observed for all countries. During 1915-
1919 a decline in GDP at birth occurred, except for England and Wales. The 
increasing trends for GDP at birth were however not simultaneous to the 
declining mortality trends for stomach cancer. Moreover, irregularities in trends 
in GDP and stomach cancer mortality did not coincide.  
Table 3.2 shows the correlation coefficients comparing the levels of IMR 
and GDP at birth with mortality from stomach cancer at adult age for the same 
cohorts. There was a significant strong positive association (correlation 
coefficients ranging from 0.70 to 0.98) between stomach cancer and IMR in all 
countries. The association between stomach cancer mortality and GDP at birth 
was strongly negative, with correlation coefficients ranging from -0.98 to -0.80. 
When the different countries are pooled, the overall correlation was positive for 
IMR (0.71) and negative for GDP at birth (-0.63). The correlation coefficients 
were generally higher among men than among women.  
In table 3.3, correlations across countries between stomach cancer 
mortality and IMR and GDP at birth are calculated for each five-year birth 
cohort separately. The relationship between stomach cancer mortality and IMR 
was positive for cohorts born after 1875 (correlation coefficients ranging from 
0.04 to 0.55), and negative for cohorts born before (correlation coefficients 
ranging from –0.55 to –0.29). The association between stomach cancer mortality 
and GDP at birth was in general negative but variable for the different birth 
cohorts (correlation coefficients ranging from –0.44 to 0.06).  
Table 3.4 shows the correlation coefficients between stomach cancer and 
IMR and GDP at birth from the pooled analysis. In this table, IMR and GDP are 
not only measured for the time of birth of each cohort, but also for older ages of 
the cohorts. There was a significant strong positive association between stomach 
cancer and infant mortality rate as measured for different ages of the cohorts 
(correlation coefficients ranging from 0.70 to 0.85). The associations were 
stronger with the IMR that applied to the time that a cohort was relatively old. 
There was a strong negative association between stomach cancer mortality and 
GDP at different ages of the cohort (correlation coefficients ranging from -0.92 
to -0.62). The associations were stronger for GDP measured at the older ages.  
 
3.4. Discussion  
In this study, the well-known cohort-wise decline in stomach cancer in 
seven European countries has been confirmed. For each sex and country, we 
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observed large differences between cohorts in mortality rates from stomach 
cancer. These differences were closely related to levels of IMR and GDP at the 
time of birth. Strong correlations between mortality trends and IMR and GDP 
were observed for each sex and country.  
However, part of our additional findings do not support our basic 
hypothesis that improvements in general living conditions in childhood had 
driven the secular decline in stomach cancer mortality in western European 
countries. First, stronger associations were observed with measures of living 
conditions during later phases of life instead of early life. Second, past 
irregularities in trends in living conditions (which reflect important historical 
phenomena such as deep economic crises) were not associated with similar 
irregularities in trends in stomach cancer mortality in later life. Finally, in 
comparisons between countries (instead of between birth cohorts), we did not 
observe a consistent association between stomach cancer mortality rates and 
national levels of IMR or GDP.  
 
3.4.1. Evaluation of data and methods 
 
 The mortality and population data used in this study comes from data 
sources that are known to have good quality 58-60. Any problems with the 
coverage or completeness of death registries or population registries are likely to 
have no or minimal effects on our results. 
We should stress that our objectives, empirical analyses, and inferences 
all refer the same level of analyses, i.e. national populations. In this type of 
analysis, there is a risk of ecological fallacy 57 but this fallacy will only be 
committed if inferences towards the individual level would be made. We refrain 
from making such inferences and we warn that trends in stomach cancer 
mortality at the national level may strongly be influenced by factors that are not 
necessarily the most important determinants of stomach cancer at the individual 
level.   
The outcome measures in our study were rates of stomach cancer 
according to birth cohort and country. Differences in mortality rates by place 
and over time are the result of a complex interplay of many factors. In our 
analysis of associations with IMR and GDP, we were not able to control for 
potential confounders. For example, the inverse (instead of positive) correlations 
of stomach cancer mortality with IMR and GDP in the cross-national analyses 
might have been confounded by cross-national differences in factors such as 
modern diet and health care services. Given this potential for confounding, the 
correlations observed in this study should be regarded with caution. 
In our analysis, the IMR and GDP were used as indicators of general 
conditions of living in different periods. These two indicators were used because 
of the availability and comparability of data for seven European countries over a 
long period of time. For a possible alternative indicator, body length, continuous 
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historical time series were only available for four countries 80. It should be 
acknowledged that both IMR and GDP are only approximate indicators of the 
concept of “general living conditions”. None the less, the IMR is one of the most 
important indicators of social development. Reidpath concluded that the IMR is 
an important indicator of health for whole populations, as structural factors 
affecting the health of entire populations also have an impact on the mortality 
rate of infants 81.  The correspondence between the findings for IMR and those 
for GDP lends support to our general conclusion that improvements in general 
living conditions in childhood are not strongly related to the secular decline in 
stomach cancer mortality in western European countries. 
 
3.4.2. Interpretation 
 
Our findings of declining patterns of stomach cancer correspond well with 
the results of previous studies 7, 14, 19, 36, 82. Differences between birth cohorts in 
rates of mortality from stomach cancer were also observed in studies that 
controlled for period effects 23, 83. 
The relation between adverse childhood social circumstances and higher 
adulthood mortality risk has been demonstrated in several studies 19, 82, 84. 
Individual-level studies showed that childhood socioeconomic position 
influences stomach cancer mortality in later life 85. The association between 
childhood social circumstances and mortality probably comes about through a 
variety of processes 86. Migrant studies also suggest the importance of 
environment in early life in determining the risk of stomach cancer 7.  
The etiology of stomach cancer is linked to environmental factors, 
including nutrition in childhood (e.g.. salt consumption, vitamin C intake) 87, 
Helicobacter pylori infection 7, 88, and interaction between these factors 89. 
Infection with Helicobacter pylori during infancy and childhood offers a 
plausible mechanism to explain the association between poor childhood 
circumstances and stomach cancer 90. Favorable developments in childhood 
nutrition might have contributed to the secular decline in stomach cancer 
mortality. 
It is important to recognize that our measures of general living conditions 
in childhood (IMR and GDP) cannot measure in detail all specific elements that 
may be relevant for stomach cancer. In case of H. pylori, we would need to 
acquire data on the prevalence of H. pylori infection in childhood in the different 
birth cohorts. These data were not available for any of the countries considered. 
Accepting that past trends in stomach cancer mortality may be strongly 
determined by past trends in the incidence of H. pylori infection, our results 
suggest that the latter trends are not closely correlated with past trends in IMR 
and GDP. 
Some of our results suggest that secular trends in stomach cancer are 
largely determined by changes in adult socioeconomic circumstances and 
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lifestyles, rather than childhood 91. For example, the marked cohort pattern of 
stomach cancer mortality, which peaked among birth cohorts born around 1875, 
might be determined by cohort-specific trends in smoking, alcohol consumption 
and other factors related to later phases of the life course. Similarly, 
improvements during the 20th century in environment and nutrition may have 
resulted in a gradually lower incidence of stomach cancer, while more accessible 
and effective facilities for cancer therapy may have helped to reduce its case 
fatality 91. 
As a conclusion, our results do not provide sufficient support for our main 
hypothesis that living conditions in childhood have a predominant effect on 
secular trends in stomach cancer mortality in national populations. Trends in 
stomach cancer mortality follow a cohort pattern, but this pattern is not 
consistently related to indicators of general living conditions in childhood. 
Trends in stomach cancer mortality seem to be determined by a set of more 
specific determinants that might operate in adult life as well as early life. Future 
studies should determine the contribution of more specific factors, such as H. 
pylori infection, instead of general living conditions in early life. 
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Table 3.1-Annual change in mortality from stomach cancer in birth cohorts born 
between 1860 and 1939 in seven European countries, by country, 20-year 
cohort group and sex 
Annual change in mortality (%) Country  Cohort 
Male Female Total 
 
 
 
1860-1879 -2.49* -4.18* 
 
-3.60* 
Denmark 1880-1899 -3.90* -5.64* -4.85* 
 1900-1919 -4.65* -4.72* -4.59* 
 1920-1939 -2.83* -1.92* -2.51* 
     
 1860-1879 -0.16 -1.39* -1.38* 
England 1880-1899 -1.11* -2.73* -1.94* 
& Wales 1900-1919 -2.85* -3.70* -2.91* 
 1920-1939 -4.71* -4.39* -4.59* 
     
 1860-1879 +0.88 -0.71 -0.43 
Finland 1880-1899 -3.75* -5.00* -4.70* 
 1900-1919 -5.36* -5.40* -5.34* 
 1920-1939 -4.98* -3.86* -4.36* 
     
 1860-1879 +1.10* +0.67* +0.46* 
France 1880-1899 -2.69* -3.72* -3.18* 
 1900-1919 -4.08* -5.28* -4.33* 
 1920-1939 -3.43* -3.82* -3.49* 
     
 1860-1879 -1.43* -2.10* -1.92* 
Netherlands 1880-1899 -1.74* -3.33* -2.72* 
 1900-1919 -1.47* -2.97* -1.97* 
 1920-1939 -1.89* -1.39* -1.55* 
     
 1860-1879 -2.46* -4.15* -3.56* 
Norway 1880-1899 -3.06* -4.28* -3.71* 
 1900-1919 -3.77* -4.11* -3.84* 
 1920-1939 -4.04* -3.57* -3.83* 
     
 1860-1879 -0.90 -2.73* -2.11* 
Sweden 1880-1899 -3.59* -4.98* -4.31* 
 1900-1919 -4.19* -4.38* -4.19* 
 1920-1939 -4.12* -3.08* -3.76* 
 
    * Trends different from 0 with statistical significant (p < 0.01). 
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Table 3.2- Correlation between stomach cancer mortality and indicators of living conditions 
at the time of birth, among 16 cohorts (born between 1860 and 1939 and followed 
for mortality in 1950-1999), per country and sex 
 
    CI, Confidence Interval. 
 
 
Pearson correlation  coefficient (95% CI) 
 
Country Sex 
 With IMR With GDP  
 
Total 
 
0.74 (0.39,0.91)  
 
-0.83 (-0.94,-0.58) 
Male 0.81 (0.53,0.93) -0.88 (-0.96,-0.68) 
 
Denmark 
Female 0.70 (0.32,0.89) -0.80 (-0.93,-0.51) 
    
Total 0.89 (0.71,0.96) -0.97 (-0.99,-0.90) 
Male 0.96 (0.88,0.99) -0.99 (-1.00,-0.84) 
England & 
Wales 
Female 0.86 (0.63,0.95) -0.94 (-0.98,-0.84) 
    
Total 0.81 (0.51,0.94) -0.98 (-0.99,-0.94) 
Male 0.77 (0.44,0.92) -0.97 (-0.99,-0.92) 
Finland 
Female 0.83 (0.56,0.94) -0.98 (-0.99,-0.93) 
    
Total 0.92 (0.79,0.97) -0.93 (-0.97,-0.80) 
Male 0.93 (0.81,0.98) -0.94 (-0.98,-0.83) 
France 
Female 0.91 (0.77,0.97) -0.92 (-0.97,-0.77) 
    
Total 0.91 (0.74,0.97) -0.86 (-0.95,-0.62) 
Male 0.94 (0.82,0.98) -0.90 (-0.96,,-0.73) 
Netherlands 
Female 0.89 (0.71,0.96) -0.84 (-0.94,-0.58) 
    
Total 0.87 (0.66,0.95) -0.84 (-0.94,-0.58) 
Male 0.90 (0.74,0.97) -0.88 (-0.96,-0.68) 
Norway 
Female 0.85 (0.62,0.95) -0.81 (-0.93,-0.52) 
    
Total 0.96 (0.90,0.99) -0.90 (-0.96,-0.73) 
Male 0.98 (0.94,0.99) -0.94 (-0.98,-0.82) 
Sweden 
Female 0.94 (0.84,0.98) -0.87 (-0.95,-0.65) 
    
Total 0.71 (0.34,0.89) -0.63 (-0.86,-0.20) 
Male 0.74 (0.38,0.90) -0.65 (-0.87,-0.23) 
All Countries 
Female 0.70 (0.32,0.89) -0.62 (-0.85,-0.18) 
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Table 3.3- Correlation between stomach cancer mortality and indicators of living conditions 
at the time of birth, among seven European countries, per birth cohort (followed for 
mortality in 1950-1999), men and women combined 
Pearson correlation coefficient (95% CI) 
 
Birth Cohort 
With IMR With GDP  
 
1860-1864 -0.55 (-0.82,-0.08) a 
1865-1869 -0.46 (-0.78,0.05) -0.26 (-0.67,0.27) 
1870-1874 -0.29 (-0.70,0.24) -0.02 (-0.53,0.48) 
1875-1879 0.04 (-0.47,0.52) -0.23 (-0.65,0.30) 
1880-1884 0.53 (0.04,0.81) -0.44 (-0.77,0.07) 
1885-1889 0.40 (-0.11,0.75) -0.40 (-0.75,0.12) 
1890-1894 0.39 (-0.13,0.74) -0.31 (-0.70,0.22) 
1895-1899 0.35 (-0.18,0.72) -0.33 (-0.71,0.19) 
1900-1904 0.49 (-0.01,0.79) -0.17 (-0.62, 0.35) 
1905-1909 0.46 (-0.04,0.78) -0.17 (-0.62,0.35) 
1910-1914 0.55 (0.08,0.82) -0.17 (-0.61,0.36) 
1915-1919 0.54 (0.06,0.82) 0.06 (-0.45,0.54) 
1920-1924 0.40 (-0.12,0.75) -0.29 (-0.69,0.24) 
1925-1929 0.36 (-0.17,0.72) -0.29 (-0.68,0.24) 
1930-1934 0.35 (-0.18,0.72) -0.33 (-0.71,0.19) 
1935-1939 0.53 (0.04,0.81) -0.34 (-0.72,0.19) 
 
CI, Confidence Interval.                
            a  Data for GDP were not available for all countries.  
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Table 3.4- Correlation between stomach cancer mortality and indicators of living conditions 
at different ages, among seven countries and 16 cohorts (born between 1860 and 
1939 and followed for mortality in 1950-1999), per sex 
 
 CI, Confidence Interval. 
a The age group for which the living conditions of a cohort were measured. E.g.  
for age group 0-4 years, we measured the IMR and GDP of the period that the 
majority of the birth cohort was 0-4 years old.   
 
 
 
Pearson correlation 
 
coefficient (95% CI) Age a Sex 
With IMR  With GDP  
 
Total 
 
0.71 (0.34,0.89) 
 
-0.63 (-0.86,-0.20) 
Male 0.74 (0.38,0.90) -0.65 (-0.87,-0.23) 
 
0-4  
Female 0.70 (0.32,0.89) -0.62 (-0.85,-0.18) 
    
Total 0.77 (0.44,0.92) -0.66 (-0.87,-0.24) 
Male 0.79 (0.48,0.92) -0.68 (-0.88,-0.28) 
5-14  
Female 0.76 (0.42,0.91) -0.64 (-0.86,-0.22) 
    
Total 0.81 (0.53,0.93) -0.73 (-0.90,-0.36) 
Male 0.82 (0.54,0.93) -0.75 (-0.91,-0.41) 
15-24  
Female 0.81 (0.52,0.93) -0.71 (-0.89,-0.32) 
    
Total 0.84 (0.59,0.94) -0.76 (-0.91,-0.43) 
Male 0.84 (0.58,0.94) -0.79 (-0.93,-0.49) 
25-34  
Female 0.84 (0.59,0.94) -0.74 (-0.90,-0.39) 
    
Total 0.85 (0.62,0.95) -0.77 (-0.91,-0.44) 
Male 0.84 (0.59,0.94) -0.80 (-0.93,,-0.51) 
35-44  
Female 0.85 (0.62,0.95) -0.74 (-0.90,-0.39) 
    
Total 0.85 (0.61,0.95) -0.81 (-0.93,-0.52) 
Male 0.83 (0.58,0.94) -0.85 (-0.95,-0.60) 
45-54  
Female 0.85 (0.61,0.95) -0.78 (-0.92,-0.47) 
    
Total 0.83 (0.56,0.94) -0.86 (-0.95,-0.63) 
Male 0.81 (0.52,0.93) -0.89 (-0.96,-0.71) 
55-64  
Female 0.84 (0.58,0.94) -0.83 (-0.94,-0.58) 
    
Total 0.81 (0.53,0.93) -0.90 (-0.96,-0.72) 
Male 0.78 (0.46,0.92) -0.92 (-0.97,-0.79) 
65 +  
Female 0.83 (0.56,0.94) -0.88 (-0.96,-0.68) 
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Fig. 3.1-Trends in stomach cancer mortality for five-year cohorts born between 
1865 and 1939 followed for mortality in 1950-1999 in seven European 
countries 
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Fig. 3.2-Trends in infant mortality rate between 1865 and 1939 in seven European 
countries 
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Fig. 3.3-Trends in real GDP per capita at 1995 US Dollars (adjusted by means of 
the purchasing power parities of 1995) between 1865 and 1939 in seven 
European countries 
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Abstract  
 
Aims: To assess the implication of a possible continuation of the decline in 
ischemic heart disease (IHD) mortality in future. 
 
Methods and Results: Annual rates of decline in IHD mortality from 1980 to 
2005 were determined for Netherlands, United Kingdom, France, and four 
Nordic countries based on regression analysis. Cause-elimination life tables were 
used to determine the impact of IHD on life expectancy at birth. The rates were 
extrapolated until 2030. In all countries, IHD mortality rates among both sexes 
declined incessantly until 2005. Age-adjusted mortality rates would have 
declined by about 50 percent in 2030 as compared to 2005 if past trends were to 
continue. The impact of IHD on life expectancy at birth would decline by about 
25 to 50 percent in most populations. The absolute numbers of IHD deaths would 
decline slowly or even increase in some countries, because of population ageing.  
  
Conclusions: If current IHD mortality trends would continue, IHD would lose 
much of its importance as a cause of premature death in the near future. As the 
incidence and disabling impact of IHD might decline to a much lesser extent, 
prevention of IHD related disability instead of mortality may become 
increasingly important in the future. 
 
Key Words: Ischemic heart disease, mortality trend, Europe, projections, 
absolute number of death, potential life-years-gained. 
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4.1. Introduction 
 
Although mortality from IHD had fallen substantially in the past decades, 
it remains the leading cause of death in Europe 1. Previous studies have 
confirmed this remarkable steady and substantial decline of mortality in western 
Europe over recent decades 2-4, especially the past 30 years 5, with greater 
decreases in some than in other countries 6. Causes of the decline are complex but 
changes in diet appear to play a major role; the more recent declines in western 
Europe also reflect improvements in modern cardiovascular treatment 5. The 
decline in IHD mortality, however, does not necessarily mean a decline in IHD 
deaths. The absolute number of IHD deaths might continue to increase due to 
ageing of European population 7-9.  
The main aim of this study is to assess the implication of a possible 
continuation of the decline in mortality from IHD in the future. Assuming a 
continuation of recent trends, we will assess what would be the rates of IHD 
mortality and its impact on life expectancy on men and women in seven 
European countries up to 2030. We also aim to explore whether a reduction in 
IHD mortality rates would offset the effects of population ageing on the future 
number of deaths from IHD. In addition, we aim to assess whether IHD mortality 
trends would be converging or diverging among European populations if recent 
trends in IHD mortality in these countries were to continue in the next 25 years. 
It should be emphasized that our study is not a prediction of future trends, 
but an exploration of possible future trends based on the extrapolation of past 
trends. This extrapolation provides a baseline scenario for scenario studies that, 
by using disease-specific population models, might aim to evaluate the specific 
impact of future changes in the prevalence of one or more IHD risk factors (e.g. 
smoking, obesity, hypertension) or in the treatment of IHD patients.  
 
4.2. Materials and Methods 
 
Data for Denmark, Finland, France metropolitan, the Netherlands, Norway, 
Sweden and the United Kingdom on the number of deaths from IHD (ICD codes 
410-414 for ICD-8 and ICD-9, I20-I25 for ICD-10 10, 11) and corresponding 
numbers of population at risk, by sex and five-year age groups for the years 1980 
to 2005 have been obtained from Eurostat (Denmark from 1999-2001, France 
from 1998-2005, and other countries from 2000 to 2005) and national data 
sources (1980-1999) 12. The historical national data for England & Wales and 
France were transformed into data for United Kingdom and France metropolitan, 
by applying age and sex-specific correction factors, based on the comparison of 
IHD mortality rates in 1995.  
To describe trends in IHD mortality between 1980 and 2005, sex-specific 
age-standardized mortality rates were calculated using direct standardization, 
taking the total EU25 population by five year age group in 2005 as the standard 
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population (source: Eurostat website). In addition, we estimated sex- and 
country- specific annual mortality changes (%) over the period 1980-2005 by 
means of age-period log-linear regression analysis. The dependent variable was 
the number of deaths, with the person-years at risk (estimated by the midyear 
population) as offset variable. We used age by five year age groups (from 0 to 
80+) (categorical) and single calendar year (continuous) as independent variables. 
Annual mortality changes (%) were calculated by this formula: 100*(exp (b)-1), 
in which b is the parameter estimate of the calendar year variable.   
To project age, sex, and country-specific mortality rates for the years 2010, 
2015, 2020, 2025, and 2030, we applied the estimated annual changes (%) in 
mortality in the period 1980-2005 for all age groups combined to average 
national age-specific mortality rates in 2000-2005 (average year used as t0). The 
formula we used (country and sex-specific): txntxnttxn cMM )1( *00 x  . Where c* is the 
annual decline (exp(b)-1) for all age groups multiplied by a ratio expressing the 
annual decline in the age groups 40-59, 60-79, and 80+ relative to the annual 
decline for all age groups (unweighted average over all countries).  
We thus assumed that the mortality trends in the past 25 years (from 1980 
to 2005) would continue for the coming 25 years, thereby taking into account age 
differences in the mortality decline.  
Future IHD mortality numbers were estimated by applying the future sex 
and age-specific rates to the projected sex and age-specific population sizes for 
the different countries up to 2030. These future population numbers have been 
obtained from Eurostat (baseline variant), except for Norway for which the data 
have been obtained from Statistics Norway (medium national Growth variant) 
(http://statbank.ssb.no/statistikkbanken).  
The impact on life expectancy is assessed by means of the potential gained 
in life expectancy (PGLE) due to IHD. For the years 2005 and 2030, we prepared 
cause-elimination life tables using projected all-cause mortality rates and 
projected IHD mortality rates for each respective projection year. All-cause 
mortality rates –obtained from the Human Mortality Database (HMD)- were 
projected using the same procedures as for IHD. 
 
4.3. Results 
Figure 4.1 shows changes in mortality rates from IHD in seven European 
countries according to year of death from 1980 to 2005. In all seven European 
countries, IHD mortality rates declined for both men and women. In each 
country, relative declines were slightly larger for men (inter-country range -2.70 
to -4.17) than for women (range -1.89 to -3.67). Relatively strong declines were 
observed in the Netherlands, Sweden and Denmark. The rank order of decline in 
countries remained about similar over time for both sexes. The decline persisted 
until 2005, with no consistent evidence for a deceleration. 
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Table 4.1 summarizes the projected IHD mortality rates and potential 
gained in life expectancy (PGLE) for IHD in seven European countries in 2030. 
In all seven European countries, age-adjusted mortality rates would have 
substantially declined in 2030 compared to 2005 if past trends were to continue. 
For most populations, the rate ratios comparing 2030 to 2005 are close to 0.50, 
indicating an about 50 percent decline in mortality rates if past trends were to 
continue. Declines larger than 50 percent are projected for men and women in 
Denmark, Sweden, and the Netherlands, and for men in the United Kingdom.  
Although the seven European countries differ in the pattern of decline over 
time, they would show some convergence in IHD mortality rates until 2030. For 
example, the low French mortality levels of 2005 would be reached by the Dutch 
and the Danish in 2030. Because mortality rates of men showed slightly stronger 
declines than rate of women in all countries, there would be a convergence in 
mortality from IHD among men and women in most countries.  
The projected PGLE will decrease in 2030 for both men and women in all 
countries. The declines in PGLE are generally smaller than those for age-adjusted 
mortality rates, because estimates for PGLE are positively influenced by the 
higher levels of total life expectancy in 2030 (due to decreasing levels of total 
mortality). Among men, the PGLE would decline between 2005 and 2030 by 25 
to 50 percent in most countries, with a smaller (10 percent) declines in France. 
About similar declines are projected for women, although with greater variability 
between countries.  
Figure 4.2 shows the projected absolute number of deaths from IHD for 
men and women from 2005 until 2030. In all seven countries, absolute number of 
IHD deaths will not substantially decrease, and in some cases even increase, 
because of the ageing of European populations. An increase in absolute numbers 
of IHD deaths is expected to occur especially after 2020, when the post-war Baby 
Boom cohort will enter old age.  
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Table 4.1– Age standardized IHD mortality rates (per 100 000) and potential 
   gained in life expectancy (PGLE), projections in seven European 
  countries by sex from 2005 to 2030  
 
Country  Year 
Denmark United 
Kingdom 
Finland France Netherlands Norway Sweden 
 
Men 
        
Mortality 2005 209.25 267.40 313.07 93.64 133.74 182.20 230.93
rates 2030 90.13 120.22 163.25 55.55 61.43 102.74 104.70
Ratio 2030/2005* 0.43 0.45 0.52 0.59 0.46 0.56 0.45
    
PGLE 2005 1.97 3.31 3.98 1.17 1.38 2.12 2.85
 2030 1.01 2.23 3.03 1.05 0.76 1.60 1.86
Ratio 2030/2005 0.51 0.67 0.76 0.90 0.55 0.75 0.65
 
Women 
   
Mortality 2005 119.51 146.00 171.96 42.38 65.38 92.42 121.31
rates 2030 52.52 69.76 121.52 26.36 31.22 61.91 55.44
Ratio 2030/2005 0.44 0.48 0.71 0.62 0.48 0.67 0.46
    
PGLE 2005 1.76 2.35 4.10 0.98 1.05 1.79 2.34
 2030 0.77 1.44 3.62 0.84 0.49 1.42 1.29
Ratio 2030/2005 0.44 0.61 0.88 0.86 0.47 0.79 0.55
 
* The figure of 2030 divided by the related figure in 2005. 
For Denmark, the values for 2005 are not observed but projected. 
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Figure 4.1- Age-standardized IHD mortality rates (per 100000) in seven 
European countries by sex: 1980-2005 * $ 
$.  Data for Denmark until 2001.  *. Corresponding estimates of annual mortality changes (%) 
for men (women) are for Denmark -4.17(-3.67), United Kingdom -3.40(-2.72), Finland -3.30   
(-1.89), for France -2.70(-2.57), the Netherlands -4.11(-3.53), Norway -3.46 (-2.56), and 
Sweden -3.97(-3.64).                      
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Figure 4.2- Absolute number of deaths (thousands) from IHD in seven European 
countries, by country and sex: 2005-2030 
For Denmark, the values for 2005 are not observed but projected. 
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4.4. Discussion 
The dramatic and persistent decline in IHD mortality observed for the 
1980s and 1990s was found to continue at an undiminished pace until 2005 in 
each of the seven European countries included in this study.  If this decline were 
to continue, IHD mortality rates would reach unprecedented low levels. In most 
populations, age-adjusted mortality rates would have declined by about 50 
percent in 2030 as compared to 2005.  
While IHD mortality rates have halved over recent decades, because of 
population ageing, the total numbers of deaths have not declined 
correspondingly. Our projections showed that numbers of deaths are likely to 
remain constant or even increase in some European populations, especially after 
the year 2020, when the Baby Boom generation will reach old age. The future 
burden of IHD mortality will increasingly affect older groups, who thus may 
stretch health care systems 13. 
This contrast between declining age-specific mortality rates and constant 
absolute numbers of deaths raises question on how to evaluate the importance of 
IHD as a cause of death. In any generation, people will have to die anyhow. The 
main issue is therefore not whether people will die, but until what age they can 
expect to live. Similarly, the importance of IHD as a cause of death should not 
only be measured by the number of people dying from this disease, but also by 
taking into account the number of years of life that they lose due to death from 
IHD. We observed that the effect of IHD on life expectancy would decline by 
about 25 to 50 percent in most populations. IHD mortality rates would decline 
especially at younger ages, thus transforming IHD increasing more into an old-
age disease with a limited impact on life expectancy at birth. 
Although the extrapolation of past trends is not the only means of making 
projections, explorations of the future should also be fairly realistically based on 
trends observed in the past. Extrapolation-based projections provides a basis for 
more specific scenario studies that would focus on the effect of specific risk 
factors or health care 14. The trends that we projected may provide a new 
perspective to appreciate the future implications of currently observed trends, and 
the likely impact of new epidemiological trends and health care policies.    
The three main potential explanations for the recent reduction in IHD 
mortality are the primary prevention in the general population, interventions that 
reduce the case fatality rate from acute events, and secondary prevention to 
prolong life in patients with diagnosed disease 15. Lifestyle factors affecting past 
IHD mortality trends include cigarette smoking, dietary habits (e.g. energy 
intake, consumption of fruit and vegetables), and physical activity 16. Attributing 
past falls in IHD mortality to risk factor changes or effective medical 
interventions is difficult because favorable trends in both have occurred 
simultaneously. The relative contributions may vary widely from country to 
country, and from time to time 17. Evidence is accumulating that the early 
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declines in IHD mortality are, to a large extent, due to changes in diet and other 
lifestyle factors whereas the more recent declines are also due to improvements in 
modern cardiovascular treatment 5. 
Only time will tell whether these factors will together ensure a similar pace 
of decline in IHD mortality until 2030. Future declines in IHD mortality would 
be expected to follow from the introduction of new treatments and increased 
uptake of existing treatments, both in the treatment for acute IHD and in the long 
term care for IHD survivors. However, medical treatment may reach limits 
especially among the oldest old, because of persisting problems such as high 
levels of co-morbidity. Limitations to efficacious live-saving treatment of older 
IHD patients is reflected by much slower rates of decline of IHD mortality 
among 80 years old since 1980, which were taking into account in our projections 
until 2030. 
Further improvement with regards to life style might occur thanks to 
growing awareness on the importance of relevant behaviors among more well-
informed and better educated populations of the future. This may stimulate for 
example further declines in smoking prevalence, which is likely to be backed up 
by far-reaching tobacco control policies. On the other hand, other risk factors 
may become more important, such as diabetes mellitus (DM) 18, 19. The envisaged 
effect on IHD mortality may however be counteracted by efficacious medical 
treatment of diabetic people, thus reducing case fatality rates. Evidence from 
clinical trials for example support the value of lipid-lowering therapy for patients 
with DM 20.  
The increasing prevalence of DM is driven largely by increasing 
prevalence rates of obesity and overweight 22, 24-26, with its increased risk of death 
from IHD 20. Obesity prevalence is expected to further increase in the in the near 
future 21, 22. In further calculations, we therefore estimated what would happen to 
future IHD mortality trends if (a) recent trends in average body mass index 
(BMI) levels in western Europe would continue between 2005 and 2030 and (b) 
the relationship between BMI and IHD mortality as observed in recent studies 
would also persist in the future. We found that the effect would be to increase 
IHD mortality by about 10 percent between 2005 and 2030. This increase is 
important, but relatively small as compared to the 50 percent declines in IHD 
mortality rates that we projected based on trends in IHD mortality in the past 25 
years.  
The decline in IHD mortality in the future is unlikely to be paralleled by a 
similar decline in IHD incidence, especially when incidence rates will be affected 
by the obesity epidemic. Declining case-fatality rates, thanks to improved 
treatment of IHD patients, are likely to make substantial contribution to falling 
mortality rates. As a result, while IHD mortality is likely to decline, especially at 
younger ages, the age-specific prevalence of IHD among elderly populations may 
increase.  
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The observed sharp decline in mortality might lead one to expect a 
decrease in health care utilization. In reality, however, health care providers are 
facing increases in demand 23. As with the trends in absolute number of IHD 
deaths, part of this increase in hospitalizations will be prompted by the ageing of 
Baby Boomers 24. Generally, the ageing of the population and the demographic 
changes projected for 2030 will have a major impact on the prevalence of and 
cost of care for IHD 25, with different slopes between populations 26.     
In conclusion, if current IHD mortality trends would continue, IHD 
mortality would lose much of its importance in the future and become mainly a 
death related to old age. On the other hand, the prevalence of IHD is likely to 
increase, and so is the related demand for health care. The priority of prevention 
and treatment of IHD therefore will have to be shifted from prevention of death 
to prevention of disability.  
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Abstract  
Background and objectives: If the secular decline in stroke mortality is to 
continue in the near future, the importance of stroke mortality would reduce to 
some unknown extent. This paper aims to make projections of future trends in 
stroke mortality in the year 2030 based on recent trends in stroke mortality in 
seven Western European countries. 
Methods: Annual rates of decline in stroke mortality from 1980 to 2005 were 
determined for men and women in United Kingdom, France, Netherlands and 
four Nordic countries on the basis of regression analysis. Estimated rates of 
decline were extrapolated until 2030. Cause-elimination life tables were used to 
determine the effect stroke in 2030 in terms of potential years of life lost (PYLL). 
The absolute numbers of stroke deaths in 2030 were estimated using national 
population projections of Eurostat. 
Results: In all countries, stroke mortality rates declined incessantly until 2005 
among both men and women. If these trends were to continue, age-adjusted 
mortality rates would decline by about one half between 2005 and 2030, with 
larger declines in France (about two thirds), and smaller declines in the 
Netherlands, Denmark and Sweden (about one quarter). Similar rates of decline 
would be observed in terms of PYLL. Because of population ageing, the absolute 
number of stroke deaths would decline slowly in United Kingdom and France, 
and stabilize or even increase in other countries.  
Conclusions: In the near future, stroke may lose much of its importance as a 
cause of premature death, but remain a frequent cause of death among elderly 
populations. For these populations, the prevention of stroke-related disability 
instead of mortality may become increasingly more important. 
 
Key Words: Stroke, mortality, secular trends, future, projections 
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5.1. Introduction 
 
Stroke mortality has strongly declined during the 20th century. Studies 
from Western Europe 1-3, Northern America 4, Australia 5 and New Zealand 6 
consistently showed that mortality from stroke declined until the most recent 
years of observation. International reviews showed that this mortality decline is 
paralleled by declines in both incidence rates and case-fatality rates 7. Whereas 
declining incidence rates are likely to reflect improvements in life styles and 
environmental exposures in different phases of life, declining case-fatality rates 
also reflect ongoing progress in secondary prevention and treatment of stroke. 
The strong declines in the past raise important questions about the future of 
stroke mortality. A possible continuation of these declines may or may not imply 
that stroke would cease to become an important cause of premature death, and 
that its effect of life expectancy would become marginal too. Further, the rapid 
ageing of European populations in the next decades may or may not compensate 
for this mortality decline. If it were, the number of elderly people dying from 
stroke would increase rather decrease in the next decades.  
To our knowledge, only a few international publications have reported on 
projections of future trends in stroke mortality 8. In addition, some of the 
projections are based on stroke mortality trends in the 1980s or early 1990s 9, and 
therefore could not take into account trends in stroke mortality since the mid 
1990s. Taking into account recent trends can however change future perspectives. 
For example, stroke mortality decline was reported to stagnate in the early 1990s 
in some countries, including the USA, but a reinforcement of stroke mortality 
decline was observed afterwards. In order to create a stable empirical basis for 
projections of future trends, and avoid dependency on short-term irregularities, it 
is important to consider stroke mortality trends over long span of years 10. 
Similarly, the empirical basis for future projections could be expanded by also 
considering trends in countries with similar levels of socioeconomic 
development. 
The aim of this paper is to present projections of future trends in stroke 
mortality in seven Western European countries until 2030. Future trends will be 
projected on the basis of a careful assessment of past trends among men and 
women in seven countries. Based on this assessment, projections are made of 
future trends in stroke mortality. Two complementary measures will be used to 
express the importance of stroke mortality: the potential years of life lost 
(PYLL), and the absolute number of deaths with stroke as the underlying cause. 
The PYLL aims to express the importance of future level of stroke mortality rate 
as a cause of premature death, through its effect on life expectancy at birth. 
Compared to this measure, projections the absolute number of deaths also takes 
into account the rapid ageing of the European populations in the next decades.   
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5.2. Materials and Methods:  
Data for Denmark, Finland, France metropolitan (i.e. mainland France), 
the Netherlands, Norway, Sweden and England and Wales on the number of 
deaths from stroke (ICD codes 430-434 and 436-438 for ICD-8 and ICD-9, and 
I60-I69 for ICD-10 11, 12) by sex and five-year age groups for the years 1980 to 
2005 have been obtained from national data sources (1980-1999) and from 
Eurostat (Denmark from 1999-2001, France from 1998-2005, and other countries 
from 2000 to 2005) 13.   Corresponding numbers of population at risk were 
obtained from similar sources. As the study period included different revisions of 
the WHO International Classification of Diseases (ICD), we adjusted for effects 
of coding changes using a regression-based method that is reported elsewhere 11, 
12.   The historical national data for England and Wales and France were 
transformed into data for United Kingdom and France metropolitan, by applying 
age and sex-specific correction factors, based on the comparison of stroke 
mortality rates in 1995.  
To describe trends in stroke mortality between 1980 and 2005, sex-specific 
age-standardized mortality rates were calculated using direct standardization, 
taking the average national male and female populations by five year age groups 
over 2000-2005 (2000-2001 for Denmark) as the standard populations. In 
addition, we estimated sex- and country-specific annual mortality changes (%) 
over the period 1980-2005 by means of log-linear regression analysis. The 
dependent variable was the number of deaths, with the person-years at risk 
(estimated by the midyear population) as offset variable. The regression model 
included five-year age groups (from 0 to 80+) as a categorical variable, and 
single calendar year as a continuous variable. Annual mortality changes (%) were 
calculated as 100*(exp (b)-1), in which b is the regression coefficient to the 
calendar year variable.   
To project age-specific mortality rates until 2030, we assumed that the 
mortality trends from 1980 to 2005 would continue for the next 25 years. We 
therefore applied the estimates of the annual rate of change in mortality in the 
period 1980-2005 to the national age-specific mortality rates in 2005. This 
projection was made for each sex and county separately. The projection formula 
was: 
 
t
xn
t
xn
tt
xn cMM )1(
*00 x  , where  
 
nMx is mortality rate in the age interval x, x+n; 
t0 is the baseline year 2005; 
t is the length of the projection period, with 2006=1 and 2030=25 years; 
c* is the annual rate of mortality change observed over the period 1980-2005. 
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In general, past mortality declines were larger in younger age groups. In 
order to take this age effect into account, the factor c* above was estimated for the 
age groups 40-59, 60-79 and 80+ years separately. For this, the c* value for all 
age groups combined was multiplied by three ratios expressing the annual decline 
in, respectively, the age groups 40-59, 60-79, and 80+ years relative to the annual 
decline for all age groups. To reduce the effect of chance fluctuations, these 
ratios were averaged estimated across all seven countries. The resulting values 
for men were 1.10, 1.17, and 0.79 for the age groups 40-59, 60-79, and 80+ 
years, respectively. The ratios for women were 1.15, 1.41, and 0.79.  
The absolute number of stroke deaths was projected by applying the 
projected age-specific mortality rates to the projected age-specific numbers of 
men and women living in the different countries up to 2030. The future 
population numbers of the EU member states were obtained from Eurostat, taking 
the baseline demographic variant. For Norway, data were obtained from Statistics 
Norway, taking the medium national Growth variant 
(http://statbank.ssb.no/statistikkbanken).  
The importance of stroke mortality was expressed by means of two 
complementary measures. First, we expressed the impact of stroke mortality on 
life expectancy by means of the potential years of life lost (PYLL) measure. This 
measure expresses the extent to which life expectancy were to increase in case of 
the hypothetical elimination of stroke in the years 2005 and 2030. For 2005, we 
prepared cause-elimination life tables using all-cause mortality rates and stroke 
mortality rates observed for 2005. For 2030, we used our own projections of 
stroke mortality; while we also projected all-cause mortality rates for 2030 using 
the same methodology as used for stroke mortality.  
For Denmark, stroke mortality data were available until 2001 instead of 
2005. Therefore, the year 2001 was used as the end year for the analysis of past 
trends in stroke mortality, and the baseline year for future projections of stroke 
mortality. All-cause mortality rates for Denmark for 2002-2005 were however 
available from the Human Mortality Database (www.mortality.org).  
 
5.3. Results:  
Figure 5.1 shows changes in stroke mortality rates in seven Western 
European countries according to year of death from 1980 to 2005. In all seven 
European countries, stroke mortality rates declined among both men and women. 
In the United Kingdom, Norway and Finland, stroke mortality rates declined by 
almost 3 percent per year. Relatively strong declines were observed in France 
(more than 4 percent per year). Declines were smallest in Denmark and Sweden 
(about 1 to 1.5 percent per year) followed by the Netherlands (about 2 percent). 
The declines persisted until 2005. Even though each country shows irregularities 
in the pace of decline, there is no consistent evidence for a deceleration of the 
mortality decline in recent years. 
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Table 5.1 presents the projected age-standardized mortality rates for men 
and women in the seven countries in 2030. In all countries, age-adjusted 
mortality rates would have substantially declined in 2030 compared to 2005 if 
past trends were to continue. Age-adjusted mortality rates would decline by about 
one half between 2005 and 2030. Larger declines would occur in France; with the 
rate ratio of 0.33 for men indicating a two thirds decline. Smaller declines would 
occur in the Netherlands, Denmark and Sweden, for which the rate ratios of about 
0.70 to 0.80 indicate a decline by about one quarter. In each country, mortality 
rates are projected to decline a bit more strongly among men than among women.  
 In terms of PYLL, the importance of stroke mortality would also decline to 
an important extent. When averaged across all countries, the PYLL estimates for 
men decline from 0.87 years in 2005 to 0.48 years in 2030. For women, the 
PYLL declines from 1.35 to 0.81 years. Thus, in 2030, the hypothetical 
elimination of stroke mortality would increase life expectancy at birth by about 
0.5 years for men, and 0.8 years for women. This effect has an about similar 
magnitude in most countries. A PYLL close to one year would be observed only 
among Swedish and Danish women. Much smaller estimates are projected for 
France only (0.23 years for men and 0.41 years for women). 
Figure 5.2 shows the projected absolute number of stroke deaths from 
2005 until 2030. The rate of change strongly varies between countries and over 
time. The absolute number of stroke deaths is projected to decline in the United 
Kingdom and in France in the first 15 or 20 decades. In both countries, this 
decline would however stagnate and even reverse after 2020, when the post-war 
Baby Boom cohort will enter old age (70 years and over). In Netherlands, 
Sweden and Denmark, increases in the absolute number of stroke deaths are 
projected to occur over the entire period, but especially after 2020. Relative 
stable numbers of deaths are projected for Norway and Finland.      
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Table 5.1. Age standardized stroke mortality rates and potential years of life 
lost (PYLL) observed in 2005 and projected for 2030. Men and women 
in seven European countries. 
 
Country Sex 
Index 
Year * 
Denmark United 
Kingdom
Finland France Nether-
lands 
Norway Sweden
 
Men 
        
         
Mortality rate 2005 74.38 81.33 64.72 45.40 47.34 64.45 77.81
(per 100,000) 2030 54.63 39.00 32.27 15.03 30.61 35.87 59.36
 2030/2005 0.73 0.48 0.50 0.33 0.65 0.56 0.76
     
PYLL 2005 0.87 1.10 0.98 0.70 0.69 0.84 0.88
(in years) 2030 0.63 0.51 0.48 0.23 0.43 0.45 0.65
 2030/2005 0.72 0.46 0.49 0.32 0.63 0.53 0.74
 
Women 
    
     
Mortality rate 2005 104.40 131.57 94.51 58.78 73.99 92.73 105.02
(per 100,000) 2030 81.84 71.96 52.75 22.65 53.89 54.24 86.27
 2030/2005 0.78 0.55 0.56 0.39 0.73 0.58 0.82
     
PYLL 2005 1.27 1.69 1.56 1.10 1.16 1.35 1.30
(in years) 2030 0.97 0.85 0.83 0.41 0.82 0.74 1.04
 2030/2005 0.76 0.50 0.53 0.37 0.71 0.55 0.80
  
 
*  2030/2005 = value for 2030 as ratio to value for 2005. 
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Figure 5.1. Trend between 1980 and 2005 in age-standardized stroke mortality 
rates (per 100,000 person years). Men and women in seven European 
countries *  
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* Corresponding estimates of percent annual decline for men (women) are for: Denmark -1.26 (-1.01), 
United Kingdom -2.89 (-2.34), Finland -2.91 (-2.81), France -4.66 (-4.35), Netherlands -2.25 (-1.78), 
Norway -2.76 (-2.68), Sweden -1.54 (-1.46). 
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Figure 5.2. Projected trends between 2005 and 2030 in the absolute number of 
stroke deaths (men and women combined) in seven European countries 
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5.4. Discussion 
Summary 
 
We observed a strong decline in stroke mortality in the past decades, both 
among men and women, in each of the seven countries studied. If these trends 
were to continue in the future, stroke mortality rates in 2030 would be 
substantially lower than they were in 2005. Similarly, strong declines would be 
observed in the effect of stroke on life expectancy. In 2030, the effect of stroke 
on life expectancy would be less than 1 year in nearly all female populations, and 
about 0.5 years in most male populations.  
Despite this decline in stroke mortality risk, the absolute number of deaths 
from stroke will not substantially decline, and even increase at the shorter and 
longer term. This increase is due to the ageing of the national populations, 
especially after the year 2020, when the Baby Boom generations will reach old 
age. Though, less important as a cause of premature death, stroke remains a 
common cause of death in Western Europe’s ageing populations. 
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Data limitations 
 
An important potential problem relates to the coding of underlying causes 
of death in national published data. Problems related to changes in revisions of 
the ICD have been evaluated by our team and taken into account where necessary 
11, 12. Changes over time in certification practices by physicians are another area 
of concern, although they are unlikely to explain the observed decline in stroke 
mortality 14. Moreover, similar rates of mortality decline have been observed in 
epidemiological studies with standardized ascertainment of stroke cases within 
registration areas 15. 
Our results for seven Western European countries cannot be generalized to 
other regions of the world. Recent trends in stroke mortality in Eastern European 
countries strongly differed from those in the West 16, implying that the East may 
differ also with regards to future trends in stroke mortality. Similarly, trends in 
stroke incidence and case-fatality in low income countries were found to strongly 
differ from the trends in high income countries 7, 17. On the other hand, in the 
USA, stroke mortality has declined over recent decades with about 0.3-2.9 
percent per year 18, suggesting similar trends as in Western Europe with about 
0.43-4.11 13 and 2.3 14  percent per year. 
 
Evaluation of projection method 
 
Two acknowledged demographers, Wilmoth 10 and Oepen and Vaupel 19, 
argue that future trends in mortality can best depart from extrapolations of past 
trends in mortality as observed over a longer period. We therefore based our 
projections on the declines in stroke mortality as observed in the seven European 
countries over a 25 years period. The precise rate of mortality decline strongly 
varied between countries, as it did between subsequent decades. This variability 
warns us that it is difficult to accurately predict future mortality trends for 
specific countries during specific decades. Rather than on time-period specific 
projections, we concentrated on longer-term projections and similarities in these 
projections across the seven countries. The generalized decline in stroke 
mortality projected for all seven countries basically reflects the substantial and 
persistent decline in stroke mortality found among both sexes and all countries in 
the past 25 years.   
As our projection model concentrates on stroke mortality, it does not take 
into account stroke incidence or case-fatality, nor does it model the 'driving' role 
of risk factors such as smoking and hypertension. The great advantage of the 
mortality data, as compared to stroke incidence or case fatality data, is that 
mortality data cover long periods of time for a large number of countries. Even 
though cross-national comparability of data is suboptimal, international 
overviews of stroke trends can be made with mortality data but not with 
incidence data 8. Models based on stroke incidence and case fatality have much 
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higher requirements to the available empirical input, especially if the disease 
process is to be modelled in some detail. Our mortality projections provided in 
this paper can be used as the baseline or yardstick against which to check the 
outcomes of more sophisticated projection models for individual countries. 
 
Interpretation 
 
The strong decline in stroke mortality in past decades is likely to be 
attributable to declines in both case-fatality rates and in incidence rates. For case-
fatality rates, there is consistent evidence from a large number of epidemiological 
studies for a steady improvement in survival rates of stroke patients. From an 
analysis of the complete data of the MONICA study, it was estimated that the 
stroke mortality decline was attributable for about two thirds to declining case-
fatality rates, with declining incidence explaining the rest 20. However, as this 
study is limited to individuals 35-64 years, it is uncertain whether this high 
estimate is representative for the older ages where most stroke deaths occur. 
With regards to stroke incidence, the evidence is less consistent, as several 
studies reported no decrease over time in incidence rates. However, a systematic 
review of all available evidence concluded that stroke incidence substantially 
declined between the 1970’s and the 2000’s in high income countries 7. The 
potentially large contribution of stroke incidence to stroke mortality trends is 
suggested by the fact that variations in stroke mortality trends between high 
income and low income countries, and between Eastern and Western Europe, are 
paralleled by similar variations in trends in the incidence of stroke. Further 
support comes from the finding that key risk factors for stroke incidence (e.g. 
smoking, hypertension, and raised serum cholesterol) could explain at least one 
half of the secular decline in stroke mortality in some countries. 
In view of the past experiences, future reductions in stroke mortality are 
likely to be contingent on declines in both incidence and case-fatality rates. With 
regards to stroke incidence, further declines may follow reductions in the 
prevalence of risk factors such as smoking, hypertension, and cholesterol. New 
vigorous tobacco control policies in Western Europe since the 1990s are likely to 
decrease tobacco exposure rates of generations that will reach old age in the mid 
21st century. Moreover, improvement in environmental and socioeconomic 
determinants, such as the rising educational levels of generations born in the 20th 
century, may contribute to continued declines in stroke incidence in the 21st 
century. Further evidence to expect such a continued decline comes from a cohort 
analysis that we performed of the same mortality data, and from which we 
concluded that the mortality declines persisted until the youngest generations, 
possibly due to improved environmental conditions in early life 13.  
Declines in stroke incidence may however be halted by increasing 
prevalence of some other risk factors, notably excess weight 21. We estimated 
what the potential effect on future stroke mortality levels assuming (a) that recent 
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trends in increasing average body mass index (BMI) levels in Western Europe 
would continue between 2005 and 2030 and (b) the relationship between BMI 
and stroke mortality as observed in recent studies would also persist in the future. 
We found that stroke mortality in 2030 would be 10 percent higher as compared 
to the situation of no increase in BMI. This increase is important, but relatively 
small as compared to the about 50 percent decline in stroke mortality rates that 
we projected for most of the seven countries.  
With regards to case-fatality of stroke, future declines depend on continued 
progress in treatment of stroke patients. Starting treatment immediately is an 
important opportunity posing logistic challenges, but it may save lives and reduce 
the likelihood of disabilities. We expect the optimal level of drug treatment yet to 
arrive, including the application of additional drugs to dissolve clots (like TPA), 
to slow the degeneration of the nerve cells (like Sipatrigine and Chlormethiazole), 
and to replace brain cells damaged by a previous stroke (like Stem Cells). 
Intensified secondary prevention as with myocardial infarction may further 
decrease long term case-fatality rate of first-stroke cases. 
 
Implications 
 
A main challenge to stroke prevention and treatment is to maintain the rate 
of decline in stroke mortality observed in the past 25 years. If these declines were 
to continue for the next 25 years, stroke would loose much of its importance as a 
cause of premature death, as it would only modestly affect the life expectancy of 
men and women in Western Europe in 2030.  
A continued decline in stroke mortality rates would not be paralleled by a 
similar decline in the number of people dying from stroke. Due to ageing of the 
population, the absolute number of stroke deaths would remain at approximately 
the same level. Moreover, the average age of death of stroke patients will 
unavoidably increase. Thus, the absolute number of elderly patients in need of 
intensive or terminal treatment is unlikely to diminish in the next decades. 
To the extent that declines in mortality are achieved by improved survival, 
the future number of stroke patients would increase at a larger rate that the 
number of stroke deaths. This would imply that the future burden of stroke will 
gradually shift from a (more or less constant) mortality burden towards a (rising) 
morbidity burden. To respond to this shift, the treatment of stroke patients may 
need to give increasingly more emphasis to avoid disability and discomfort, 
rather than only averting death. 
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Abstract 
 
Mortality from stomach cancer has fallen steadily during the past decades. The 
aim of this paper is to assess the implication of a possible continuation of the 
decline in stomach cancer mortality until the year 2030. Annual rates of decline 
in stomach cancer mortality from 1980 to 2005 were determined for the 
Netherlands, United Kingdom, France, and four Nordic countries on the basis of 
regression analysis. Mortality rates were extrapolated until 2030, assuming the 
same rate of decline as in the past. The absolute numbers of deaths were 
projected taking into account data on the ageing of national populations. Cause-
elimination life tables were used to determine the importance of stomach cancer 
in terms of potential gained in life expectancy (PGLE). Stomach cancer mortality 
rates declined between 1980 and 2005 at about the same rate (3.6-4.9 percent per 
year) for both men and women in all countries. The rate of decline did not level 
off in recent years, and it was not smaller in countries with lower overall 
mortality rates. If this decline were to continue into the future, stomach cancer 
mortality rates would decline with about 66 percent between 2005 and 2030 in 
most populations. A two-thirds decline would also be observed in terms of 
PGLE, while the absolute number of stomach cancer deaths would diminish by 
about 50 percent. Thus, in view of the strong, stable and consistent mortality 
declines in recent decades, stomach cancer is likely to become increasingly less 
important as a cause of death in Europe in the future.  
 
 
Key Words: Stomach cancer, mortality, trends, Europe, projections 
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6.1. Introduction  
 
Stomach cancer is the fourth most frequent cancer 1, 2 and the world’s 
second leading cause of cancer mortality 1. However, it has been fallen 
throughout Europe during the past decades in terms of both incidence and 
mortality rates 3 4, mainly as a result of remarkable improvement of living 
conditions in European societies 5-8. Efforts to reduce global cancer disparities 
begin with an understanding of geographic patterns in cancer incidence, mortality 
and prevalence, by studies such as GLOBOCAN 9, 10, EUROCARE 11, and Five 
Continents databases 12. Survival increased and mortality decreased through the 
combination of earlier detection, better access to care and improved treatment 13. 
There has also been a concomitant change in lifestyle and environmental 
exposures over successive generations 14, including changes in exposures to risk 
factors in early life 15. 
Several studies conducted projections of future trends in stomach cancer 
mortality in European countries 7,12,14-17. Mortality rates were generally expected 
to decline further. Based on the cancer mortality trends in the European Union 
until 2000, one study projected a further fall by 11% in age-standardized cancer 
mortality from 2000 to 2015 16. A Dutch study also projected a substantial 
decline in stomach cancer mortality until 2015, based on trends until 2000 17. 
Similarly, an Irish study predicted mortality from stomach cancer to fall further 
in the near future, although at a slower rate than in the recent past 18.  
European studies included projections of the absolute number of cancer 
deaths, thereby taking into account the rapid ageing of European populations in 
the forthcoming decades 14-16. Population ageing alone may induce a strong 
increase in the absolute number of incident cases and deaths for many types of 
cancer. However, in the case of stomach cancer, this demographic effect may be 
offset by an opposite epidemiological effect if the recent decline in age-specific 
mortality rates were to continue in the future.  
The aim of this study was to assess, for seven European countries, the 
implications of a possible continuation of the recent declines in stomach cancer 
rates. Future trends were evaluated not only in terms of mortality rates, but also 
in terms of potential years of life gained – a measure used to assess the 
importance of a cause of death for people’s life expectancy. In addition, we 
assessed future trends in absolute numbers of death, thereby taking into account 
the ageing of national populations. 
Projections of future mortality trends should be based on a careful analysis 
of trends in the past 19, 20.  We therefore started the analysis with a description of 
trends in stomach cancer mortality over a long period, from 1980 up to 2005, in 
order to check whether mortality declines continued undiminished until recent 
years. In addition, we assessed whether the rate of decline was similar for all 
seven countries and both sexes, despite differences in overall levels of stomach 
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mortality rates. We thus aimed to identify a stable and consistent long-term 
mortality trend that could serve as a basis for projections into the future.  
 
6.2. Material and Methods  
 
Data for Denmark, Finland, France metropolitan, the Netherlands, Norway, 
Sweden and England and Wales on the number of deaths from stomach cancer 
(ICD code 151 for ICD-8 and ICD-9, C16 for ICD-10 21) and corresponding 
numbers of population at risk, by sex and five-year age groups for the years 1980 
to 2005 have been obtained from Eurostat (Denmark from 1999-2001, France 
from 1998-2005, and other countries from 2000 to 2005) and national data 
sources (1980-1999) 22. The historical national data for England and Wales and 
France were transformed into data for United Kingdom and France metropolitan, 
by applying age and sex-specific correction factors, based on the comparison of 
stomach cancer mortality rates in 1995. 
To describe trends in stomach cancer mortality between 1980 and 2005, 
sex-specific age-standardized mortality rates were calculated using direct 
standardization, taking the average national male and female populations by five 
year age groups over 2000-2005 (2000-2001 for Denmark) as the standard 
populations. In addition, we estimated sex- and country- specific annual mortality 
changes (%) over the period 1980-2005 by means of age-period log-linear 
regression analysis. The dependent variable was the number of deaths, with the 
person-years at risk (estimated by the midyear population) as offset variable. We 
used age by five year age groups (from 0 to 80+) (categorical) and single 
calendar year (continuous) as independent variables. Annual mortality changes 
(%) were calculated by this formula: 100*(exp (b)-1), in which b is the parameter 
estimate of the calendar year variable.  
The observed declines vary by age. To project age, sex, and country-
specific mortality rates until 2030, we applied the estimated annual changes (%) 
in mortality in the period 1980-2005 for all age groups combined to average 
national age-specific mortality rates in 2000-2005 (average year used as t0). The 
formula we used (country and sex-specific): txntxnttxn cMM )1( *00 x  . Where c* is the 
annual decline (exp(b)-1) for all age groups multiplied by a ratio expressing the 
annual decline in the age groups 40-59, 60-79, and 80+ relative to the annual 
decline for all age groups (unweighted average over all countries). The applied 
ratios that express the annual decline in age group relative to annual decline for 
all age groups, for men were 0.92, 1.03, and 0.99 for the age groups 40-59, 60-
79, and 80 and more, respectively. The ratios for women were 0.85, 0.97, and 
1.09, respectively. We thus assumed that the mortality trends in the past 25 years 
(from 1980 to 2005) would continue for the coming 25 years, thereby taking into 
account age differences in the mortality decline.
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Looking into the projected mortality rates, absolute number of deaths, and 
potential gained in life expectancy (PGLE) in 2030, it can be measured if 
stomach cancer is a less important cause of death in the future.  
Future stomach cancer mortality numbers were estimated by applying the 
future sex and age-specific rates to the projected age-specific population sizes for 
the different countries up to 2030. These future population numbers have been 
obtained from Eurostat (baseline variant), except for Norway for which the data 
have been obtained from Statistics Norway (medium national Growth variant) 
(http://statbank.ssb.no/statistikkbanken).  
The impact on life expectancy is assessed by means of PGLE due to 
stomach cancer. We calculated the gain in life expectancy due to the elimination 
of stomach cancer in the years 2005 and 2030. For each year, we prepared cause-
elimination life tables using all-cause mortality rates for 2005 and using stomach 
cancer mortality rates for each respective projection year (2005 to 2030). The all-
cause mortality rates were obtained from Eurostat. For Denmark, all-cause 
mortality rates were used from the Human Mortality Database 
(www.mortality.org). For each country, the same set of all-cause mortality rates 
was used over the years in order to maintain comparability between these years. 
 
6.3. Results 
Figure 6.1 shows trends in age-standardized mortality rates between 1980 
and 2005. In all countries, stomach cancer mortality rates declined steadily. The 
average rate of decline is within a narrow range, from 3.61 percent per year for 
Norwegian men to 4.90 percent for Danish and Finnish women. The overall 
average rate of decline was 4.2 percent per year. The rate of decline remained 
similar over time for both sexes in most of these countries. There was no 
indication that the rate of decline (expressed in percent decline per year) had been 
levelling off in recent years. A main exception is the strong decline in mortality 
among Finnish women in the 1980’s, when Finnish women were catching up 
with other countries.  
In Figure 6.2, the rate of declines in stomach cancer mortality over the 
period 1980 to 2005 is plotted against the age-standardized mortality rates in 
1980. The aim of this scatter plot is to assess whether the decline in stomach 
cancer mortality was higher in populations with higher initial mortality rates. 
However, both among men and women, no such positive association was found.  
Table 6.1 presents projections for 2030 of stomach cancer mortality rates, 
absolute number of deaths, and potential gained in life expectancy (PGLE). 
Values projected for 2030 are compared to values observed for 2005 by means of 
ratios with 2005 as reference. In all seven European countries, age-standardized 
mortality rates would have declined in 2030 compared to 2005 if past trends were 
to continue. This decline would be substantial in all populations. Rate ratios are 
between 0.28 for Finnish women and 0.41 for Norwegian men, with an average 
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of 0.34. The latter value represents a 66 percent decline in age-standardized 
mortality rates between 2005 and 2030.  
Similar declines were observed in terms of PGLE. This implies that, in 
terms of its effect on life expectancy, the importance of stomach cancer would 
decrease by about two thirds between 2005 and 2030. 
The decline in the absolute number of deaths would be substantial as well, 
although with more variability between countries. Rate ratios would be between 
0.38 for Danish women and 0.73 for Norwegian men, with an average of 0.48. 
The latter value implies that the absolute number of stomach cancer deaths would 
decline by 48 percent despite the ageing of the national populations.  
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Figure 6.1- Age-standardized stomach cancer mortality rates (per 100,000) in 
seven European countries by sex: 1980-2005 *  
 
* Corresponding estimates of annual declines (%) for men (women) are for Denmark 4.60 
(4.90), United Kingdom 3.96 (4.16), Finland 4.68 (4.90), France Metropolitan 3.67 (4.32), 
Netherlands 3.92 (3.81), Norway 3.61 (3.90), and Sweden 4.06 (4.11). 
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Figure 6.2- Annual declines (%) in stomach cancer mortality 1980-2005 
against age-standardized mortality rates in 1980, by sex and country  
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Table 6.1– Stomach cancer mortality rates (age standardized, per 100,000), 
absolute number of deaths, and potential gained in life expectancy (PGLE), 
by country and sex, for 2005 (observed) and 2030 (projected) 
 
Country  Year 
Denmark United 
Kingdom 
Finland France Netherlands Norway Sweden 
 
Men 
        
    
2005 7.22 12.95 11.09 9.87 11.40 10.37 10.27Mortality 
rates 2030 2.23 4.36 3.20 3.80 4.00 4.28 3.50
 2030/2005
* 0.31 0.34 0.29 0.39 0.35 0.41 0.34
 
2005 204 3914 301 3045 963 242 470
 
Number 
of deaths 2030 95 2117 156 1880 580 177 241
 2030/2005 0.47 0.54 0.52 0.62 0.60 0.73 0.51
 
PGLE 
 
2005 33.45 60.99 58.47 54.43 60.13 52.36 46.36
 2030 10.36 20.54 16.67 21.01 21.10 21.61 15.76
 2030/2005 0.31 0.34 0.29 0.39 0.35 0.41 0.34
 
Women 
        
    
2005 4.59 8.02 8.69 5.49 6.70 8.44 6.22Mortality 
rates 2030 1.32 2.44 2.46 1.80 2.67 2.69 2.42
 2030/2005 0.29 0.30 0.28 0.33 0.40 0.32 0.39
 
2005 127 2475 240 1789 566 196 284
 
Number 
of deaths 2030 48 1066 100 872 335 91 146
 2030/2005 0.38 0.43 0.42 0.49 0.59 0.47 0.51
 
PGLE 
 
2005 22.84 37.85 52.78 36.95 39.24 48.92 31.35
 2030 6.76 11.74 14.53 12.10 15.92 15.64 12.58
 2030/2005 0.30 0.31 0.28 0.33 0.41 0.32 0.40
  
* The figure for 2030 divided by the related figure for 2005.  
For Denmark, the values for 2005 are not observed but projected. 
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6.4. Discussion 
 
The strong decline in stomach cancer mortality was found to continue at an 
undiminished rate until 2005 in each of the seven European countries. If this 
decline were to continue into the future, stomach cancer mortality rates would 
decline with about 66 percent between 2005 and 2030. A two-thirds decline 
would also be observed in terms of the effect of stomach cancer on people’s life 
expectancy at birth. The absolute number of stomach cancer deaths would 
diminish by about 50 percent despite the ageing of national populations. Thus, by 
extrapolating the strong, stable and consistent mortality declines in recent 
decades, stomach cancer was projected to become increasingly less important as 
a cause of death in Europe in the next decades. 
A key factor for the past declines in stomach cancer mortality is a decrease 
in the exposure to Helicobacter pylori infection 23.  H. pylori prevalence had been 
found to decline in parallel with the decrease of incidence of stomach cancer 24. 
However, H. Pylori infection may not be the only factor. It has been estimated to 
account for only half of the global total burden of stomach cancer because of 
synergistic or antagonistic roles of dietary and other exogenous factors 25. 
Complementary explanations for the observed declines in stomach cancer 
mortality may include better food preservation and refrigeration, improvement in 
environmental conditions and lifestyle changes 27,26.  
Improved medical treatment may also have contributed to the decline in 
mortality from stomach cancer 26, 27 like it contributed to the observed differences 
in stomach cancer mortality between European countries 27. This role is 
supported by the observation that, while the incidence of stomach cancer had 
declined as well, mortality rates seemed to have declined at faster rates, 
indicating a decline in case fatality rates 14. Therefore, further advances in the 
treatment for stomach cancer and H. pylori infections may be important to 
maintain a strong decline in stomach cancer mortality rates in the future. 
However, declines in the near future may still be largely driven by recent 
improvements in the living conditions that current generations had experienced 
during their childhood and adulthood. 
Empirical support for the expectation that the decline in mortality from 
stomach cancer will continue in the future comes from the trends that were 
observed for the past 25 years. Firstly, there is a strong consistency in the recent 
trends in stomach cancer mortality among both sexes and among each of the 
seven European countries. Second, these declines had persisted up to recent years 
in each of these populations, including those with the lowest initial mortality 
rates. Furthermore, steady declines in stomach cancer mortality were observed in 
the middle-aged and the young population as well, suggesting that they are likely 
to continue in the near future 4, 5, 16. The latter observation is consistent with 
observations of cohort-wise patterns of decline in stomach cancer mortality in 
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European countries 28 14, 29, which may reflect the effects of improvement in 
living conditions in childhood 28.  
It should be emphasized that, even though future declines may seem likely, our 
study was primarily aimed at exploring possible future trends by extrapolating 
past trends. This extrapolation provides a baseline scenario against which new 
studies may formulate more specific scenarios of future trends. For example, 
policy-based scenarios may focus on the potential effects of specific preventive 
policies or advancement in the treatment of stomach cancer. As the stomach 
cancer may become ever less important in terms of mortality, scenario studies 
will need to also include measures of incidence, prognosis and prevalence of 
stomach cancer. 
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General Discussion 
 
This final chapter first briefly addresses the research questions of this 
thesis, and evaluates the methodological approach in obtaining these results. 
Subsequently, it elaborates on the general background of observed trends, the 
role of IMR and GDP as explainers for cohort mortality, and the potential of 
eternal improvement of mortality risks. Next we discuss briefly the choice for 
IMR and GDP as proxy for living conditions relevant for health, and at some 
length the extrapolation methods. We end with, some recommendations for future 
care and research.  
 
7.1. Main findings 
 
 7.1.1. Past trends   
  
The first research question addressed the past trends in mortality of IHD, 
stroke and stomach cancer in seven European countries. In general, we observed 
an overall decline in mortality from these three diseases from 1950 to 2005 in all 
countries, for all ages and both men and women, with the important exception of 
a period epidemic of IHD in 1950 to 1970. From a cohort perspective, we 
observed steady declines for cohorts born between 1860 and 1939 in most causes, 
again with the exception of IHD. 
Ischemic Heart Disease (IHD) mortality increased between the 1950s and 
1970s in all countries for both men and women, except for younger women in 
France and Finland. This increase was generally followed by a decline between 
the 1970s and 1990s, in particular among younger people. In most countries, the 
decline started earlier among women than among men. However, in all countries, 
the decline was slightly larger for men, in particular in the Netherlands, Sweden 
and Denmark. The overall decline persisted until 2005, with no consistent 
evidence for a deceleration.  
Mortality from stroke declined from the 1950s to the 1990s in all age 
groups, and both sexes, in most countries, often with larger declines in more 
recent decades. The rate of these declines greatly differed according to birth 
cohort, country and sex, with mostly higher declines for the youngest birth 
cohorts, suggesting cohort effects related to possibly the smoking epidemic. 
Relatively strong declines were observed in France, compared to smaller declines 
in Sweden. The observed declines persisted until 2005. 
In all countries, stomach cancer mortality rates declined steadily for all 
birth cohorts, all ages, and both sexes. The smallest decline was observed in 
Norwegian men and the largest decline in Danish and Finnish women. In 
particular in the 1980s, the Finnish mortality declined to attain levels as in other 
countries. The rate of decline remained similar over time in most of other 
countries. The decline in stomach cancer over successive cohorts was generally 
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stronger among women than among men.  For both sexes, the observed declines 
persisted until 2005. 
  
7.1.2. The impact of IMR/GDP 
 
The second research question was on the role of living conditions in early 
childhood. We often observed strong relationships with measures of living 
conditions (IMR and GDP) with cohort-specific trends in mortality from stroke 
or stomach cancer. However, past changes in living conditions in childhood were 
not always consistently related to cohort-wise trends in either stroke or stomach 
cancer mortality. 
Before discussing these results in more detail, we first summarise the time 
tends of the two determinants between 1860 and 1940. Infant mortality rate 
(IMR) showed a general tendency to decline, especially after 1900, a tendency 
that started much later in some countries (e.g. Denmark and England & Wales) 
than in others (e.g. The Netherlands). Regarding Gross Domestic Product (GDP), 
a general increase can be observed for all countries.   
For stroke, when data for all countries are pooled, and associations across 
countries are also taken into account, the overall correlation between IMR and 
mortality is strong. This strong association with stroke mortality may reflect the 
relation between early life factors and adult hypertension, which is rather strong 1 
and which in turn may contribute to associations with stroke mortality. In 
separate analyses in which we made comparisons across countries, instead of 
across birth cohorts, the relationship was slightly positive when comparing 
countries for birth cohorts born before 1900. However, for birth cohorts born 
after 1900 this association was slightly negative. This inconsistency in patterns 
will be discussed below.  
The relationship of IMR to IHD mortality is more complex. A variable and 
sometimes inverse relationship was observed in different countries. After pooling 
all countries, and also taking into account the associations across countries, the 
overall correlation with IMR was not significant for IHD mortality. Clearly the 
'epidemics' of IHD - of which the rise and fall still are ill-understood 2, 3 - do not 
parallel the ending of the 'epidemics' of IMR.  
A strong association was found between stomach cancer and IMR across 
different cohorts in all countries. We also studied GDP in relationship to stomach 
cancer. For GDP and stomach cancer, a strongly negative association existed at 
all ages. The association between stomach cancer mortality and GDP at birth was 
stronger for older ages. When the different countries are pooled, the overall 
correlation with stomach cancer mortality was positive for IMR and negative for 
GDP at the time of birth. However, irregularities in time trends for GDP did not 
neatly parallel the irregularities in the decline in mortality for stomach cancer. 
The lack of an entirely consistent relationship is discussed below. 
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7.1.3. Future trends if past trends were to continue 
 
The third research question was on future trends in the burden of mortality 
of the three diseases. Scenarios were formulated based on extrapolation of recent 
trends in mortality. According to the extrapolation-based scenarios, both IHD and 
stroke will lose much of their importance as causes of premature death in the near 
future. And this applied even more so for stomach cancer, which was projected to 
become a minor cause of death in Europe by 2030. We also demonstrated that 
trends are similar in terms of Potential Gained in Life Expectancy (PGLE), but 
much less favourable in terms of absolute numbers of deaths. 
In all seven European countries, age-adjusted IHD mortality rates would 
substantially decline until 2030 if past trends were to continue. In general, trends 
between 1980 and 2005 showed annual mortality declines of about 3.5% in men 
and 2.5% in women for IHD; while stroke and stomach cancer declines continued 
at annual rates of about 3% and 4%, respectively (with small differences for 
gender). Projected on the relevant populations, during 2005-2030 an overall 
decline would be observed in IHD mortality of 40-60 % in men and 30-55% in 
women, in stroke mortality of 25-70% in men and 20-60% in women, and of 60-
75% for stomach cancer mortality. As projected trends slightly differed among 
the seven European countries, with generally large decline in countries with 
higher mortality levels at onset, these projected changes would generally result in 
cross-national convergence of mortality rates in 2030. 
The projected trends in mortality rates are, given the ageing populations, 
different when evaluated in terms of absolute deaths. The absolute number of 
deaths for IHD and stroke will decline slowly or even increase at the longer run. 
This warns that declining age-specific mortality rates do not imply that the future 
number of deaths from the three important diseases must decline. Rather, future 
deaths will occur later in life. 
Meanwhile, the declines in PGLE are only slightly different from the age-
adjusted mortality rates. The projected declines are up to 5% stronger compared 
to the mortality rates. This slightly larger increase reflects relatively large decline 
in mortality at younger ages, and expected rises in the life expectancies of the 
European populations. 
 
7.2. Discussion of principal findings 
 
Here we provide some comments on three issues: explanation of past 
trends, the tenability of the general relation of IMR/GDP with mortality trends, 
and the issue of the 'eternal improvement' in mortality. 
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7.2.1. Explanation of past trends 
 
A key issue is whether the observed declines in mortality are due to 
declines in the incidence of diseases and/or in their case-fatality. In developed 
countries, both the incidence and mortality of IHD and stroke continued to 
decline in both sexes in recent decades 4-6. However, for IHD and stroke, there is 
evidence for declines in case-fatality as well. Incidence decline may be 
determined by changes in the cardiovascular risk factor profile in the community, 
while variations in case fatality rate can be explained directly by changes in 
medical care and indirectly by changes in the severity of the disease 7. The 
declining case fatality may be due in particular to advances in diagnosis and 
treatment 8, 9 including rapid dissemination of CT and MRI technology since 
1970s 10.  
The classic risk factors might not be the largest contributors to the 
observed trends in mortality and incidence, as societal factors 11 and 
environmental changes 12 do matter too. In addition, attributing the falls in 
mortality to risk factor changes or effective medical interventions separately is 
difficult because favourable trends in both have occurred simultaneously. In a 
computer-simulation model, Hunink found that primary and secondary risk factor 
reductions of IHD mortality explain about 50% of the decline in  USA but that 
more than 70% of the overall decline in mortality has occurred among IHD 
patients 13. On the other hand, Unal concluded that compared with secondary 
prevention, primary prevention (especially tobacco control and healthier diets) 
achieved a fourfold larger reduction in deaths in England and Wales 14. In a study 
in Finland, the  contribution of different factors in mortality decline for both 
genders were estimated to be about 8.8% (smoking), 37% (high cholesterol), 
7.5% (high blood pressure), 53.3% (three risk factors combined), and 23.1% 
(treatment) for stroke mortality decline 15. 
In spite of declining incidence rates, stomach cancer is still the second 
most important cause of death from cancer worldwide 16, with an overall rate 
close to lung cancer. Improvements during the 20th century in environment and 
nutrition may have resulted in a gradually lower incidence of stomach cancer, 
while more accessible and effective facilities for cancer therapy may have helped 
to reduce its case fatality 17. Changes in diagnosis and treatment may have made a 
contribution to the declining incidence and mortality rates of stomach cancer 18, 
19. Factors related to treatment and general management of cancer patients are 
also expected to be important, as they for example explain part of variability in 
survival between European countries 20, 21. 
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7.2.2. IMR/GDP and mortality 
 
Despite the fact that many of the relations between the three diseases and 
IMR/GDP were as expected, some irregularities were observed (see also above), 
in particular for IHD and stomach cancer.  
The cohort-wise decline in IHD mortality shows a hill-like shape, which 
disturbs the relation with the universally declining IMR. After an initial decline, 
there is for decades a temporary increase which, together with the subsequent 
decline, can be described as the rise and fall of the IHD epidemic in general. The 
causes of this epidemic are not entirely understood. The smoking epidemic is an 
insufficient explanation, if only because the smoking epidemic affected men and 
women in very different ways, whereas the timing of the IHD epidemic was 
similar for both sexes. Some have pointed to the potential role of adaptation to an 
entire different life and food pattern during the first half of the 20th century 22, 23.  
In addition, period-wise changes in medical care may have confounded the 
study of the associations between IHD mortality trends and early life factors. 
These associations may have been obscured amongst others by large changes in 
effective medical care during the second half of the 20th century 22, 23. In stroke 
and stomach cancer, change in care may have been more gradual, although the 
invention and introduction of life saving therapies (ambulance transport, CCU, 
thrombolytics, etc) may also have introduced large period-wise changes in some 
of the countries studied.   
Even though IMR and stroke were strongly related, the irregularities in the 
decline in IMR did not clearly correspond to similar irregularities in the decline 
in stroke. Stroke mortality levels were relatively stable in birth cohorts from 1860 
to 1880, but declined in subsequent cohorts, but not as rapidly as IMR. We can 
only speculate about why the general IMR improvement did not translate as 
quickly into a cohort-wise decline in stroke mortality. It could be the case that 
late IMR improvement is based on factors with broader health effects (with 
lasting effects also on stroke incidence and mortality) compared to the factors 
most important earlier in IMR improvement (e.g. reduction of exposure through 
new sewerage systems). Or, the elderly population in general changes over time, 
with a more heterogeneous group entering old age in later cohorts, which in turn 
may change the time relation between initial IMR and stroke mortality in later 
birth cohorts.  
For stroke mortality, another confounding factor may have been introduced 
by the rapid decline in IHD mortality. It was hypothesized that the course of the 
IHD epidemic has influenced trends in stroke mortality. If less people die from 
IHD, and if survivors have generally a higher exposure to risk factors for stroke, 
this would act to increase incidence from stroke. However, this hypothesis was 
not supported by a study of Peeters et al 24.  
Several studies have shown the association between IHD and adverse 
living conditions in early life 25-29, but not always 2, 3. For stroke, some studies 
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have observed this relationship 28, 30, whereas others have not 26, 29. We believe 
that our own findings, which are not fully consistent either, deserve further study 
with systematic data on IHD and stroke treatment added to data on trends in 
incidence and mortality. For the moment, the discrepancies that we observed 
between IMR trends and trends for IHD and stroke mortality warns against too 
strong statements regarding an overriding effect of early life conditions on 
population-wide trends in these diseases.  
Our study suggested the importance of “environment” in early life in 
determining the risk for stomach cancer 16, 31, in particular childhood social 
circumstances 32-34; which is consistent with the strong geographical correlation 
between mortality from stomach cancer in adulthood and infant mortality around 
the time of birth 3, 35. However, some of our results indicate that the secular trends 
in stomach cancer are not neatly related to trends in IMR, suggesting that 
mortality trends were partly determined by changes in adult socioeconomic 
circumstances and lifestyles, rather than childhood 17.  
 
7.2.3. Future trends: eternal improvement? 
 
Our predictions are based on the assumption of a continued reduction of 
age-specific mortality rates with the same tempo as observed in recent decades. 
Such an assumption in our view is plausible given fact that recent changes are 
linked, not just to advances towards more efficacious medical treatment, but also 
to a growing awareness on the part of the general public regarding of the crucial 
role played by life style (including dietary habits and smoking). This awareness, 
which prevails among more recent, well-informed and better educated cohorts, 
essentially represents an investment in the future, by decreasing the accumulation 
of risks known from the older cohorts. The evidence supporting this hypothesis is 
suggestive: decreasing prevalence of cigarette smoking 36, decreasing use of 
butter on bread and increasing use of vegetable oil in cooking  36, and decreasing 
cholesterol levels and hypertension 36, which in turn could be related to better 
medical control of biological risk factors 37. We also expect a contribution from 
the introduction of new treatments and the increased uptake of and compliance to 
existing treatments, and better access with fewer persons untreated 38.  
Is this continued improvement yielding eternal life? While the increase in 
life expectancy was largely propelled by the decline in infant and child mortality 
up until the middle of twentieth century, it has since then been sustained by the 
decline in mortality among elderly people, in particular through better survival 
from cardiovascular diseases and some cancers, thanks to progress in medical 
care 39.  
Therefore, at one hand, further improvement may here be expected through 
the further improvement of medical care which - as we believe - is far from 
exhausted; to this we add the permanent improvement of the living environment: 
the impressive change in work and working conditions, and the better conditions 
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at life's start. Part of this improvement will rest on the ability to attain better 
outcomes among socioeconomic groups who are worse off. 
On the other hand, levelling off of this improvement may perhaps be 
expected from the inevitable greater role of comorbidity at higher age. In elderly 
patients with heart diseases, the high prevalence of non-cardiovascular 
comorbidity may affect prospects for substantial improvements of the survival of 
patients. Obesity (overweight) might also be so important to take into account, 
because of  direct or indirect effects 40, 41. It should be noted that secular trends 
toward increasing prevalence of obesity have been occurring also in childhood 42; 
thus, the evidence of increasing mean values of BMI in the adult population 
suggests the importance of preventive measures at earlier ages 43; which in turn 
suggests necessity of further improvement of dietary patterns and reduction of 
physical inactivity for prevention of obesity at the population level. To the extent 
that we succeed in reducing comorbidity through lifestyle related diseases, we 
may hope to prevent a leveling off of the mortality decline in the near future. For 
stomach cancer, future speculation should most likely differentiate between 
adenocarcinoma of the cardia, and subcardia cancers, where adenocarcinoma of 
the cardia might follow a similar trend as oesophageal adenocarcinoma. The 
different relation to comorbidity (e.g. adenocarcinoma of the cardia is related to 
hypertension, subcardia cancer to other comorbid diseases) suggests  at least 
some etiological heterogeneity, which easily translates in different future 
development 44. 
 The trend towards improvement does not represent a physical law but is 
the result of human endeavours. A sustained positive direction of future trends 
will therefore require support from public health policies directed towards 
maximal use of the available preventive options, but also towards the full use of 
clinical care options for those with a chronic disease.  
 
 7.3. Methodological issues 
 
Here we take opportunity to discuss two issues for which are not addressed 
to a full extent in the separate papers: the measurement of early life conditions, 
and the choice of a forecasting method. 
 
7.3.1. The measurement of early life conditions  
 
In our analysis, the IMR and GDP were used as indicators of general 
conditions of living in different periods, and indeed provided a partial 
explanation of long-term changes in mortality at adult ages.  
The choice for these indicators was based on expected relevance and on the 
availability and comparability of data for seven European countries over a long 
period of time. For a possible alternative indicator, body length, continuous 
historical time series were only available for four countries 45. It should be 
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acknowledged that both IMR and GDP are only approximate indicators of the 
concept of “general living conditions”46. Nonetheless, the IMR is one of the most 
important indicators of social development and health 47, 48. 
The correspondence between the findings for IMR and those for GDP 
suggest that improvement in general living conditions in childhood are modestly 
related to the secular decline in stomach cancer mortality in western European 
countries. However, it is important to recognize that both our measures of general 
living conditions in childhood cannot measure in detail all specific elements that 
may be relevant for stomach cancer. For stomach cancer, which is strongly 
related to H. pylori infection in early life, we would need to acquire data on the 
prevalence of H. pylori infection in childhood in the different birth cohorts. These 
data were not available for any of the countries considered.  
 
7.3.2. The choice of a forecasting method 
 
In this section, we first discuss the classification of forecasting methods 
and then continue with an inventory of the methods used in different projection 
studies. We end this section by a summary of the main results obtained with 
some of the projections studies.   
 
7.3.2.1. Classification of forecasting methods 
 
To make future projections, besides the extrapolation of the past trends, a 
variety of models have been applied 49-53. For example, APC models have been 
applied to stroke mortality in Sweden 7, disease-state simulation models to IHD 
incidence, mortality and cost in USA 54 and to heart disease in the Netherlands 55, 
whereas risk-factor based model was applied to the projection of incidence of 
myocardial infarction (MI) in Australia 56and in Sweden 39.  
Several authors discussed the classification and naming of predictive 
mortality models. Olshansky divided forecasting methods into two categories, 
namely methods based on extrapolation and procedures based on mortality in a 
more ‘advanced’ populations 57. Manton suggests a classification into empirical 
or extrapolation procedures and explicit procedures based on theories of human 
mortality and ageing 58, 59. Willekens distinguishes extrapolation methods and 
methods based on epidemiological and biomedical research, and suggests that 
forecasting should go from pattern-oriented to process-oriented forecasts 60. This 
suggestion has also been discussed by European Association for Population 
Studies which concluded that it seems inevitable to continue forecasting using 
extrapolation 61. Wilmoth concluded that the most reliable method for predicting 
the future mortality remains to extrapolate past trends 62. 
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7.3.2.2. Previous forecasting studies  
Here we present the most important projection studies using a variety of 
forecasting/projection methods. We distinguish four basic models including 
incidence-alone models, mortality-alone models, incidence-mortality models, and 
incidence-prevalence-mortality models. Depending on the data analysis 
underlying the study, we can further divide these models into age-period (AP), 
age-cohort (AC), or age-period-cohort (APC). Models may use regression 
approaches or simulation models. Gender is always added as an explanatory or 
stratifying variable. Table 7.1 summarizes the methods and results of these 
projection studies. 
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Table 7.1- Summary of projection studies 
 
Type of 
projection 
Model Author 
(year) 
Purpose of 
projection 
(disease) 
Place, Time 
and Data 
Key results 
Incidence- alone AP using   
regression 
Malmgren 63 
(1989) 
Future burden of 
long-term care of  
patients 
(stroke) 
England and 
Wales, 
Up to 2023, 
Population-based 
study in 1983 
using incidence 
and disability data 
 
Increased burden 
of health care of 
patients with first 
ever strokes in 
2023 
Mortality- alone AP and APC 
using 
regression and 
(cause-
elimination) 
life table 
 
 
AP using 
regression 
 
 
 
 
APC using 
regression 
 
 
 
APC using 
regression 
 
 
 
AP and APC 
using 
regression 
 
 
 
 
AP using 
regression 
Amiri 
(2010) 
 
 
 
 
 
 
Gondos 64 
(2009) 
 
 
 
 
Quinn 65 
(2003) 
 
 
 
Huovinen 66 
(2006) 
 
 
 
Caselli 67 
(2006) 
 
 
 
 
 
Sonnenschein 
and Brody 68  
(2005) 
 
 
Future death and 
PGLE 
(IHD, stroke, 
stomach cancer) 
 
 
 
 
Survival trends 
(15 common cancers) 
 
 
 
 
Examine mortality 
trends (cancers) 
 
 
 
Predict future 
mortality 
(IHD) 
 
 
Comparison of 
extrapolation 
methods; i.e. AP, 
APC and regression 
(cardiovascular and 
cancers) 
 
Project the effect of 
ageing on future 
mortality 
(heart diseases and 
cancers) 
 
Seven European 
countries, 1950-
2000, 1980-2005, 
up to 2030, 
Mortality data 
(historical and 
Eurostat data) 
 
11 European 
populations, 2005-
2009, Based on 
data of 1990-1994 
and 2000-2004 
 
20 EU countries, 
Up to 2015, WHO 
Cancer mortality 
data  1950s-2000 
 
Finland, Up to 
2030, data from 
Finnish official 
statistics 
 
England and 
Wales, Up to 2050,  
data on population 
60 to 85 years 
1950 to 2000 
 
 
USA, Up to 2050, 
Data of 1999 US 
census 
IHD, stroke and 
stomach cancer 
will lose much of 
their importance as  
causes of 
premature death in 
the near future 
 
The importance of 
care in future 
 
 
 
 
Survival estimates 
for 2005-2009 
 
 
 
Future importance 
of people 80 and 
more 
 
 
APC reproduces 
reality (highest 
quality).AP for 
changing trends 
(less validity) 
 
 
Ageing will 
increase heart 
diseases and will 
decline cancers 
 
Incidence-
Mortality 
AP using 
(multi)state-
event 
transition 
 
 
 
 
Niessen 69 
(1993) 
 
 
 
 
 
 
Determine the range 
of incidence and 
fatality decline 
(stroke) 
 
 
 
 
The Netherlands, 
1985-2005, Data 
of 1979 to1989 on 
national hospital 
admissions and 
mortality rates  
 
 
Survival increase 
and population 
ageing could partly 
explain the 
declines  
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AC using 
regression 
 
 
 
 
 
APC using 
regression 
 
 
Bonneux 
and Looman 
70  (2003) 
 
 
 
 
Murray and 
Lopez 71 
(1997) 
 
 
 
Predict future health 
care needs 
(IHD) 
 
 
 
 
Projection of future 
health status 
(IHD, stroke, cancers 
and …) 
The Netherlands, 
Up to 2015, Dutch 
data on number of 
deaths and hospital 
admissions 1970 to 
1999  
 
47 countries, Up to 
2020, Data of 1950 
to 1990 in nine 
cause-of-death 
clusters 
Heart health care 
needs will increase 
among middle-
aged women 
 
 
 
Future importance 
of ageing 
Incidence-
Prevalence-
Mortality 
AP using 
simulation 
 
 
 
 
 
 
 
 
AP using 
simulation 
 
 
 
 
 
 
 
 
 
AP using a 
multistate life 
table 
Dunning 72 
(1987) 
 
 
 
 
 
 
 
 
Bonneux 55 
(1994) 
 
 
 
 
 
 
 
 
 
Struijs 73 
(2005) 
Examination of about 
19 alternative 
scenarios including 3 
scenarios for general 
lifestyle, 6 for acute 
care, 6 for chronic 
care, and 4 scenarios 
for patients’ lifestyles 
(IHD) 
 
To make a 
quantitative analysis 
of the heart disease 
epidemic by 
combining morbidity 
and mortality data of 
Framingham and 
project to Dutch 
population  
(IHD) 
 
Determine future 
number of patients 
(stroke) 
 
 
The Netherlands, 
Up to 2010, Data 
on incidence, 
prevalence, and 
mortality of Dutch 
population in 1980  
 
 
 
 
USA, Up to 2020, 
Framingham data 
 
 
 
 
 
 
 
 
 
The Netherlands, 
Up to 2020, Dutch 
data  
Future importance 
of life style 
changes  
 
 
 
 
 
 
 
Increasing future 
morbidity and 
health care needs 
 
 
 
 
 
 
 
 
Increasing future 
number of stroke 
patients 
IHD Projections Dunning 72, 
Bonneux and Looman 70,  
Huovinen 66, and 
Sonnenschein and Brody 68 
 
General projection of an overall decline in IHD mortality in the 
future, due to medical improvements, with fewer declines (and 
even slightly increase) in older persons than middle-age people, as 
a result of ageing of population 
Stroke projections Niessen 69, Struijs 73, and 
Malmgren 63 
An overall decline in stroke incidence and mortality in the future, 
but increase in the number of patients, due to the factors such as  
ageing of the population and an increase in cardiovascular survival 
leading to a further increase in major stroke prevalence among the 
oldest age groups, 
 
(Stomach) cancer 
projections 
Quinn 65, Gondos 64, and  
Sonnenschein and Brody 68 
Fewer mortality from cancers in the future, due to decreasing age-
specific mortality trends, more effective screening programs (on 
breast, cervical and colorectal cancers), on smoking prevention, 
and better treatments 
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7.3.2.3. Evaluation of our own projection method 
  
We would like to distinguish between 'static' regression-based methods 
like employed in our thesis, and more detailed 'dynamic' models. Dynamic 
models might result in more accurate results in the long run due to taking into 
account survival of patient’s changes over time, the occurrence of events over 
time, and the health state transitions. To the extent that a disease model is used 
and the determinants and relations are included, including their time trends, such 
models allow for non-linear changes. However, for the same reason they have an 
intrinsically higher risk for misprojection as their need for specification of the 
causal pathways always requires several assumptions regarding mortality and 
morbidity, separating the modeled dynamics from the unspecified changes, and 
requiring detailed information about conditional probabilities on mortality and 
morbidity. The more a disease as a process is understood, and its determinants 
and changes thereof, and the more a disease safely can be regarded as 'isolated' 
from other diseases, the better the dynamic models may perform. However, the 
diseases of this thesis do not easily qualify for dynamic modeling: despite many 
papers with dynamic models, one might argue that without an adequate 
explanation of the cardiovascular epidemic at large, it is hazardous to rely on 
dynamic modeling. In view of this arguments, in this thesis, regression models 
have been used. We thereby followed Wilmoth's recommendation 62 and 
European Association for Population Studies 61 and our preference to using 
observed trends (not synthetic trends). Besides long-term morbidity data are 
unavailable, and the epidemiological knowledge on stomach cancer provides 
little opportunities for explicit modeling. We should also note that the projections 
used in this thesis are not forecasts in the literal sense, but projections that 
explore possible future trends on the basis of specific assumptions 74.  
  
7.4. Recommendations 
 
Our recommendations fall into two parts: policy implications and future 
research: 
 
Policy implications 
 
In view of future increase in future hospitalization numbers (not: age-
specific rates) and the related demand for health care, we recommend that: 
x The health care providers and insurance companies should be informed that 
they are facing increases in the future demand; as most likely the proportion 
of comorbidity of those contracting diseases will increase (in absolute terms 
due to the age shift), medical costs will rise even in excess of the mere 
increase of numbers. 
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x To achieve ongoing improvement especially in IHD and stroke, investments 
are required in prevention (primary, secondary) with special emphasis on 
decreasing treatments’ gaps, as inequalities might set a limit to improvement 
in general.  
x Further attention should be given to verification of stroke subtypes, because 
management and prevention strategies for different stroke types vary. 
Improvement in the quality of routinely available stroke mortality data is also 
important. 
x Given the ageing population, particular attention should be given to covering 
all age groups but especially the oldest old. The priority of care for the studied 
diseases should be shifted from prevention of death to prevention of disability.  
 
Future research 
 
For future studies, we recommend the following research topics to pay 
attention to: 
x The role of early life circumstances in mortality from IHD, stroke or stomach 
cancer; including the specific measurement of early life conditions including 
prenatal data; the explanation of the observed differences between populations 
in cohort-wise trends; and the study of migrants (first and second generations).   
x In addition to the individual-based simulation forecasting models, the 
development of more robust population health projection models aiming to 
incorporate exogenous influences on the occurrence of disease and the effect 
of population-wide preventive measures.  
x The pursuit of more cohort studies - like ERGO and LASA- including the 
oldest old  with information to elucidate in more detail disease dynamics; and 
information about distribution of blood glucose concentrations, diabetes, 
hypertension and other risk factors, including genetic predispositions. 
x For stomach cancer, future studies should determine the contribution of more 
specific factors, such as H. pylori infection, on top of (or instead of) general 
living conditions in early life.  
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Summary 
 
 
The aim of this PhD thesis was to describe long term trends in mortality 
from three diseases (Ischemic Heart Disease (IHD), stroke, and stomach cancer) 
in developed countries, to assess the relationship among these trends and early 
life conditions (measured by infant mortality rate (IMR) and gross domestic 
product (GDP) around the birth year), and to extrapolate the mortality from these 
three diseases until 2030, based on the observed mortality trends from 1980 to 
2005.  
We selected these three diseases because of the role of IHD and stroke as 
first and second leading causes of deaths, in spite of their declining trends in 
mortality in recent years; and the possible relation of stomach cancer with early 
life conditions and therefore potential cohort effects. In addition, as stomach 
cancer had only few adult risk factors in common with the other selected 
diseases, its study promised further insights into the effects of early life 
conditions.  
We studied mortality from IHD, stroke, and stomach cancer with data from 
1950 to 1999 (historical analysis) and from 1980 to 2005 (extrapolation base). 
We applied a life-course analytical perspective (focusing on both period and 
cohort effects), and we performed comparative studies among seven European 
countries, i.e., Denmark, England and Wales, Finland, France, the Netherlands, 
Norway, and Sweden.  
Five datasets were used. For Chapters 2 and 3 we used three datasets, i.e. 
dataset A, B, and C respectively. Data of dataset A, on IHD, stroke, and stomach 
cancer mortality and the population at risk, were obtained by year of death (1950-
1999), sex, and five-year age group for Denmark, England & Wales, Finland, 
France, the Netherlands, Norway, and Sweden. For Denmark, Finland and 
Norway data were available only from 1951, and for Sweden, from 1952. For 
France, data were only available until the year 1997 and for Denmark, until 1998. 
These data were obtained from national statistical offices and related institutes. 
Data of dataset B, on IMR, defined as the number of deaths during the first year 
of life per 1000 live-born babies, for the period 1860-1969. Dataset C consists of 
the data for GDP. To reconstruct trends in real national GDP, i.e. GDP expressed 
at constant 1995 prices in millions of national currency units, between 1865 and 
1939, the historical national accounts data were used. For the Netherlands, these 
historical data were available only from 1900 onwards, and for the earlier years 
data on national accounts from Statistics Netherlands were obtained. For 
Chapters 4 to 6, we used dataset D. Data on IHD, stroke, and stomach cancer 
mortality for Denmark (not for stroke in Chapter 5), Finland, France 
metropolitan, the Netherlands, Norway, Sweden and the United Kingdom on the 
number of deaths and corresponding numbers of population at risk, by sex and 
five-year age groups for the years 1980 to 2005 have been obtained from Eurostat 
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(Denmark from 1999-2001, France from 1998-2005). And finally, dataset E, 
containing future population numbers, were used for projection, was obtained 
from Eurostat (baseline variant), except for Norway for which the data have been 
obtained from Statistics Norway (medium national growth variant). 
 
The first part of this thesis, i.e., Chapters 2 and 3, describes the past 
mortality trends in IHD, stroke, and stomach cancer in seven European countries. 
In these chapters, the role of period and cohort effects in the observed trends in 
mortality between 1950 and 1999 was identified. Furthermore, we estimate the 
role of early life conditions and environmental factors (measuring with IMR and 
GDP at birth) to cohort-specific trends in mortality from IHD, stroke and 
stomach cancer. 
Chapter 2 describes the trends of mortality from IHD and stroke in 
relation to infant mortality rate (IMR). We found that IHD mortality increased for 
successive cohorts up to 1900, and then started to decline. Stroke mortality levels 
were virtually stable among birth cohorts up to 1880, but declined rapidly among 
later cohorts. A strong positive association was found between cohort-specific 
IMR levels and stroke mortality rates. There were no strong cohort-wise 
associations between IMR and IHD mortality. These results support other studies 
in suggesting that living conditions in early childhood influence stroke mortality 
rates, also at the level of national populations, with potential differences among 
countries. Future studies should determine the contribution of specific early life 
factors to the recent declines in mortality from IHD and stroke. 
In Chapter 3, we relate the secular trends in mortality from stomach cancer 
to trends in IMR and GDP. Our results showed large differences between 
successive birth cohorts in mortality from stomach cancer. In each country, these 
cohort differences were closely related to IMR and GDP levels at the time of 
birth. However, stronger associations were observed with measures of living 
conditions during later life. In comparisons between countries, stomach cancer 
mortality rates were not consistently related to national levels of IMR and GDP. 
As a result, general living conditions in childhood did not seem to have had a 
predominant effect on secular trends in stomach cancer mortality. The mortality 
decline is likely to be related to more specific factors, such as declining H. pylori 
prevalence.  
 
In the second part of the thesis, Chapters 4 to 6, the future trends in 
mortality from the above mentioned disease are explored by projecting the 
mortality trends until 2030, based on the observed mortality trends between 1980 
and 2005 in seven European countries. The projected mortality rates, the absolute 
numbers of deaths, and the potential years of life lost (PYLL) in 2030 are 
compared to the corresponding figures in 2005.  
Chapter 4 illustrates the possible declines in IHD mortality in seven 
European countries until 2030. In all countries, IHD mortality rates among both 
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sexes declined incessantly from 1980 until 2005. Age-adjusted mortality rates 
would have declined by about 50 percent in 2030 as compared to 2005 if these 
past trends were to continue. The impact of IHD on life expectancy at birth 
would decline by about 25 to 50 percent in most populations. The absolute 
numbers of IHD deaths would decline slowly or even increase in some countries, 
because of population ageing. In conclusion, if current IHD mortality trends 
would continue, IHD would lose much of its importance as a cause of premature 
death in the near future.  
In Chapter 5, we extrapolate the future trend of mortality from stroke. In all 
countries, stroke mortality rates declined incessantly until 2005 among both men 
and women. If these trends were to continue, age-adjusted mortality rates would 
decline by about one half between 2005 and 2030, with larger declines in France 
(about two thirds), and smaller declines in the Netherlands, Denmark and Sweden 
(about one quarter). Similar rates of decline would be observed in terms of 
PYLL. Because of population ageing, the absolute number of stroke deaths 
would decline slowly in United Kingdom and France, and stabilize or even 
increase in other countries.  
In Chapter 6, we explore possible future trends in mortality from stomach 
cancer until 2030. Stomach cancer mortality rates declined between 1980 and 
2005 at about the same rate (3.6-4.9 percent per year) for both men and women in 
all countries. The rate of decline did not level off in recent years, and it was not 
smaller in countries with lower overall mortality rates by 1980. If this decline 
were to continue into the future, stomach cancer mortality rates would decline 
with about 66 percent between 2005 and 2030 in most populations. A two-thirds 
decline would also be observed in terms of PYLL, while the absolute number of 
stomach cancer deaths would diminish by about 50 percent. Thus, in view of the 
strong, stable and consistent mortality declines in recent decades, stomach cancer 
is likely to become increasingly less important as a cause of death in Europe in 
the future.   
Chapter 7, summarizes the main results, and elaborates on the 
determinants of the mortality decline in early life in the past and possible 
projections in the coming years. We concluded that cohort-wise patterns of 
decline in mortality were found, with some irregularities over the time, for each 
of the three diseases and in all countries. Our findings support the expectation of 
an association between changes in living conditions in early childhood and 
changes in population levels of stroke mortality. However, no strong evidence 
was observed for IHD or for stomach cancer mortality. If current IHD and stroke 
mortality trends would continue, they would lose much of their importance as the 
causes of premature death in the near future. The same applies, but to even a 
larger extent, to stomach cancer mortality.  Especially for IHD and stroke, their 
incidence and disabling impact might decline to a much lesser extent. As a result, 
the prevention of IHD or stroke related disability instead of mortality may 
become increasingly important in the future. 
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Samenvatting 
 
 
Het doel van dit proefschrift was om lange termijntrends in mortaliteit als 
gevolg van drie ziekten (Ischemic Hartziekte (IHD), cerebrovasculair accident en 
maagkanker) in ontwikkelde landen te beschrijven, om de relatie tussen deze 
trends en vroege levensomstandigheden te evalueren (door kindersterftecijfer 
(IMR) en bruto binnenlands product (GDP) rond het geboortejaar gemeten) en 
om de mortaliteit van deze drie ziekten te extrapoleren tot 2030, op basis van de 
geobserveerde mortaliteitstrends van 1980 tot 2005. 
Wij selecteerden deze drie ziekten vanwege het belang van IHD en 
cerebrovasculair accident als eerste en tweede doodsoorzaken, ondanks hun 
afnemende trends in mortaliteit in recente jaren; en de mogelijke relatie tussen 
van deze ziekten en maagkanker met vroege levensomstandigheden. Bovendien, 
omdat maagkanker slechts weinig risicofactoren op volwassen leeftijd 
gemeenschappelijk heeft met de andere geselecteerde ziekten, kan bestudering 
ervan meer inzicht verschaffen in effecten van vroege levensomstandigheden.  
Wij hebben de mortaliteit van IHD, cerebrovasculair accident en 
maagkanker bestudeert met behulp van gegevens van 1950 tot 1999 (historische 
analyse) en van 1980 tot 2005 (als basis voor extrapolatie). Wij pasten een 
levensloop perspectief toe die zich op zowel periode- als cohortresultaten 
concentreert. Bovendien maakten wij een vergelijkende studies tussen zeven 
Europese landen, d.w.z., Denemarken, Engeland en Wales, Finland, Frankrijk, 
Nederland, Noorwegen en Zweden.  
Er werden vijf datasets gebruikt. Voor hoofdstuk 2 en 3 hebben wij drie 
datasets gebruikt, namelijk dataset A, B en C. Gegevens van dataset A, met 
betrekking tot IHD, cerebrovasculair accident, maagkankermortaliteit en de 
risicopopulatie, werden verkregen naar jaar van overlijden (1950-1999), geslacht 
en 5-jaars leeftijdsgroepen voor Denemarken, Engeland & Wales, Finland, 
Frankrijk, Nederland, Noorwegen en Zweden. Voor Denemarken, Finland en 
Noorwegen waren de gegevens alleen vanaf 1951 beschikbaar en voor Zweden 
vanaf 1952. Voor Frankrijk waren de gegevens beschikbaar tot en met 1997 en 
voor Denemarken tot en met 1998. Deze gegevens werden van nationale 
statistische organisaties en gerelateerde instituten verkregen. Gegevens van 
dataset B, met betrekking tot IMR, gedefinieerd als het aantal overlijdens 
gedurende het eerste levensjaar per 1000 levendgeboren baby's, werden voor de 
periode 1860-1969 verkregen. Dataset C bestaat uit de gegevens voor GDP. Om 
trends in reëel nationaal GDP te reconstrueren, d.w.z. GDP uitgedrukt in 
constante 1995 prijzen in miljoenen van nationale munteenheden tussen 1865 en 
1939, werden de historische nationale rekeningsgegevens gebruikt. Voor de 
hoofdstukken 4 tot 6 hebben wij dataset D gebruikt. Gegevens over IHD, 
cerebrovasculair accident en maagkankermortaliteit voor Denemarken, Finland, 
continentaal Frankrijk, Nederland, Noorwegen, Zweden en het Verenigde 
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Koninkrijk over het aantal doden en overeenkomstig aantal personen dat risico 
loopt, per geslacht en 5-jaars leeftijdsgroepen voor de jaren 1980 tot 2005 zijn 
van Eurostat  verkregen. En ten slotte dataset E, die toekomstige 
bevolkingsaantallen bevat, werd van Eurostat (basis variant) verkregen, behalve 
voor Noorwegen, waarvoor de gegevens van Statistiek Noorwegen zijn 
verkregen. 
 
Het eerste deel van dit proefschrift, d.w.z., Hoofdstukken 2 en 3, beschrijft 
de mortaliteitstrends uit het verleden voor IHD, cerebrovasculair accident en 
maagkanker van zeven Europese landen. In deze hoofdstukken is de rol 
geïdentificeerd van periode- en cohortpatronen in de geobserveerde trends in 
mortaliteit tussen 1950 en 1999. Verder schatten wij de rol van vroege 
levensomstandigheden (gemeten met IMR en GDP bij geboorte) bij cohort-
specifiek trends in mortaliteit van IHD, cerebrovasculair accident en maagkanker. 
 
Hoofdstuk 2 beschrijft de trends in mortaliteit van IHD en 
cerebrovasculair accident in relatie tot het kindersterftecijfer (IMR). Wij vonden 
dat IHD mortaliteit voor opeenvolgende cohorten tot 1900 toenam en daarna 
begon af te nemen. Sterfte aan cerebrovasculair accident was praktisch stabiel 
onder de geboortecohorten tot 1880, maar nam snel af onder latere cohorten. Een 
sterke positieve relatie werd gevonden tussen cohort-specifiek IMR niveaus en 
Cerebrovasculair accident sterftecijfers. Er waren geen sterke cohortwijze relaties 
tussen IMR en IHD mortaliteit. Deze resultaten steunen andere studies in de 
suggestie dat omstandigheden in de vroege kindertijd invloed hebben op sterfte 
aan cerebrovasculair accident, ook op het niveau van nationale populaties. 
Toekomstige studies zouden de bijdrage van specifieke vroege levensfactoren 
aan de daling van mortaliteit van IHD en cerebrovasculair accident moeten 
vaststellen. 
In Hoofdstuk 3 hebben wij de seculiere trends in mortaliteit van maagkanker 
aan trends in IMR en GDP gerelateerd. Onze resultaten toonden grote verschillen 
tussen opeenvolgende geboortecohorten in mortaliteit van maagkanker aan. In elk 
land waren deze cohortverschillen gerelateerd aan IMR en GDP niveaus ten tijde 
van de geboorte van opeenvolgende cohorten. Echter, sterkere associaties werden 
geobserveerd met indicatoren van levensomstandigheden gedurende latere 
leeftijd. In vergelijkingen tussen landen hingen maagkankersterftecijfers niet 
consistent samen met nationale niveaus van IMR en GDP. Dientengevolge lijkt 
het dat algemene levensomstandigheden geen overheersend effect hebben gehad 
op seculiere trends in maagkankermortaliteit. De mortaliteitsafname is 
waarschijnlijk gerelateerd aan meer specifieke factoren zoals het verminderen 
van het voorkomen van H. pylori. 
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In het tweede deel van het proefschrift, Hoofdstukken 4 tot 6, worden de 
toekomstige trends in mortaliteit van de bovenstaande ziekten geëxploreerd door 
de mortaliteitstrends tot 2030 te projecteren, gebaseerd op de geobserveerde 
mortaliteitstrends tussen 1980 en 2005 in zeven Europese landen. De 
geprojecteerde sterftecijfers, het absolute aantal overlijdensgevallen en de 
potentiëel winst in levensverwachting (PGLE) in 2030 zijn vergeleken met de 
overeenkomende cijfers voor 2005.  
 
Hoofdstuk 4 beschrijft de mogelijke afname van IHD mortaliteit in zeven 
Europese landen tot 2030. In alle landen daalde de IHD mortaliteit onder beide 
geslachten onophoudelijk tussen 1980 en 2005. Voor leeftijd gecorrigeerde 
sterftecijfers zouden zijn afgenomen tot ongeveer 50 procent in 2030 in 
vergelijking met 2005 indien deze recente trends zich zouden voortzetten. De 
invloed van IHD op levensverwachting bij de geboorte zou met ongeveer 25 tot 
50 procent afnemen in de meeste populaties. Het absolute aantal gevallen van 
sterfte aan IHD zou langzaam afnemen of zelfs toenemen in sommige landen 
door vergrijzing van de bevolking. Concluderend, als huidige IHD 
mortaliteitstrends zouden continueren, zou IHD veel van zijn belang als oorzaak 
van voortijdige dood in de nabije toekomst verliezen. 
In Hoofdstuk 5 extrapoleren wij de naar de toekomst de recente trends van 
mortaliteit van cerebrovasculair accident. In alle landen verminderde het niveau 
van sterfte aan Cerebrovasculair accident onophoudelijk tussen 1980 en 2005, 
onder zowel mannen als vrouwen. Indien deze trends zouden continueren, zouden 
sterftecijfers afnemen met ongeveer de helft tussen 2005 en 2030, met een 
grotere afname in Frankrijk (ongeveer twee derde) en een kleinere afname in 
Nederland, Denemarken en Zweden (ongeveer een kwart). Vergelijkbare afnames 
zouden worden geobserveerd in termen van PGLE. Door bevolkingsvergrijzing 
zou het absolute aantal gevallen van sterfte aan Cerebrovasculair accident 
langzaam afnemen in het Verenigd Koninkrijk en Frankrijk en stabiliseren of 
zelfs toenemen in andere landen.  
In Hoofdstuk 6 onderzoeken wij mogelijke toekomstige trends in mortaliteit 
van maagkanker tot 2030. Maagkankermortaliteit nam af tussen 1980 en 2005 
met ongeveer hetzelfde tempo (3.6-4.9 procent per jaar) voor zowel mannen als 
vrouwen, en in alle landen. Deze afname is niet afgezwakt in recente jaren en de 
afname was bovendien niet zwakker in landen met al lagere sterftecijfers in 1980. 
Indien deze afname zou doorzetten in de toekomst, zouden 
maagkankersterftecijfers tussen 2005 en 2030 in de meeste populaties met 
ongeveer 66 procent afnemen. Een twee-derde afname zou ook in termen van 
PLGE optreden, terwijl het absolute aantal maagkankerdoden met ongeveer 50 
procenten zou afnemen. Dus gezien de sterke, stabiele en consequente 
mortaliteitsafname in recente decennia wordt maagkanker waarschijnlijk steeds 
minder belangrijk als een doodsoorzaak in West Europa in de komende jaren.  
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Hoofdstuk 7, vat de resultaten van dit proefschrift samen en bediscussieert de 
oorzaken van de waargenomen mortaliteitsafname, met bijzonder aandacht voor 
determinanten in het vroege leven. Ook bespreken wij projecties voor 
toekomstige jaren. Wij concluderen dat cohortwijze patronen werden gevonden 
in de daling van mortaliteit, zij het met enkele onregelmatigheden, voor elk van 
de drie ziekten en in alle landen. Onze bevindingen steunen de verwachting van 
een realatie tussen veranderingen in vroege levensomstandigheden en 
veranderingen Cerebrovasculair accident mortaliteit op populatieniveau. Echter, 
er werd geen sterk bewijs gevonden voor een vergelijkbare relatie met sterfte aan 
IHD of maagkanker. Indien recente trends in sterfte aan IHD en Cerebrovasculair 
accident zich zouden voortzetten, zouden deze ziekten veel van hun belang als 
oorzaak van voortijdige dood in de nabije toekomst verliezen. Hetzelfde geldt, 
zelfs in sterkere mate, voor maagkanker. Vooral wat betreft IHD en 
cerebrovasculair accident zal hun incidentie, prevalentie en effect op kwaliteit 
van leven naar verwachting veel minder afnemen. Dientengevolge zal niet het 
voorkómen van sterfte, maar het voorkómen van de morbiditeit als gevolg van 
IHD of cerebrovasculair accident in de toekomst steeds belangrijker worden. 
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ϪϣΎϧ ϥΎϳΎ̡  ϪλϼΧ 
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 Ϟμϓ2ϪϠλΎΣ ήϴϣϭ ̱ήϣ Ϊϧϭέ   ί΍  ΎΑ ϪτΑ΍έ έΩ ΍έ ̵ΰϐϣ ϪΘ̰γ ϭ ΐϠϗ ̶ϧΎϘΘΣ΍ ̵έΎϤϴΑ ϥΎ̯ΩϮ̯ ήϴϣ ϭ ̱ήϣ
ΪϳΎϤϧ ̶ϣ ϒϴλϮΗ ϝΎδ̰ϳ ήϳί . ί΍ ̶ηΎϧ ̱ήϣ Ϫ̯ ϢϴΘϓΎϳέΩ Ύϣ ΪϟϮΗ ϩϭή̴Ϥϫ ΎΗ  ΐϠϗ ̶ϧΎϘΘΣ΍ ̵έΎϤϴΑ1900 ϪΘϓΎϳ ζϳ΍ΰϓ΍ 
˭Ζγ΍ ϩΩϮϤϧ ζϫΎ̯ ϪΑ ωϭήη ϝΎγ Ϧϳ΍ ί΍ ̶ϟϭ ̱ήϣ ΡϮτγ Ϫ̰ϴϟΎΣ έΩή̴ϤϫΎΗ ̵ΰϐϣ ϪΘ̰γ ί΍ ̶ηΎϧ  ΪϟϮΗ  ϩϭ1880 ΖΑΎΛ 
Ζγ΍ ϪΘϓΎϳ ζϫΎ̯ Ύόϳήγ ΪόΑ ϪΑ ϝΎγ Ϧϳ΍ ί΍ ̶ϟϭ ˬ ϩΩϮΑ .̶λΎμΘΧ΍ ΡϮτγ ϦϴΑ ̵Ϯϗ ΖΒΜϣ ϪτΑ΍έ ̮ϳ - ϥ΍ΰϴϣ  ϩϭή̴Ϥϫ
 ̶ΒϠϗ ϪΘ̰γ ̱ήϣ ̵ΎϬϧ΍ΰϴϣ ϭ ϝΎδ̰ϳ ήϳί ϥΎ̯ΩϮ̯ ̱ήϣ) ̵΍ήΑ Ϫϧ ̶ϟϭ ΐϠϗ ̶ϧΎϘΘΣ΍ ̵έΎϤϴΑ (Ϊη ΖϓΎϳ. ήϳΎγ ˬ ΞϳΎΘϧ Ϧϳ΍
΍ήη ϦϴΑ ρΎΒΗέ΍ ή̴ϧΎϳΎϤϧ ΕΎόϟΎτϣ ΖϳΎϤΣ ̶Ϡϣ ΢τγ έΩ ̶ΘΣ ˬ ΍έ ̵ΰϐϣ ϪΘ̰γ ί΍ ̶ηΎϧ ̱ήϣϭ  ̶̳Ϊϧί Ϟϳ΍ϭ΍ έΩ Ζδϳί ςϳ
Ωέ΍Ω ̶ϧ΍ϮΨϤϫ ΎϬϧ΁ ΎΑϭ ΪϨ̯ ̶ϣ. ̱ήϣ ήϴΧ΍ ̵Ύϫ ζϫΎ̯ ϭ ̶̳Ϊϧί Ϟϳ΍ϭ΍ Ϟϣ΍Ϯϋ ̶λΎμΘΧ΍ Ζ̯έΎθϣ ΪϳΎΑ ϩΪϨϳ΁ ΕΎόϟΎτϣ
 ί΍ ̶ηΎϧ ήϴϣϭ̵ΰϐϣ ϪΘ̰γϭ ΐϠϗ ̶ϧΎϘΘΣ΍ ̵έΎϤϴΑΪϨϳΎϤϧ ϦϴϴΒΗ ΍έ . 
Chapter 8: Summary (Persian) 
137 
  έΩϞμϓ3ϭέ ρΎΒΗέ΍ Ύϣ ˬ Ϊϧϭέ ΎΑ ΍έ ϩΪόϣ ϥΎσήγ ί΍ ̱ήϣ ̵΍ ϩέϭΩ Ϊϧ ΪϴϟϮΗ ϭ ϝΎγ ̮ϳ ήϳί ϥΎ̯ΩϮ̯ ̱ήϣ ϥ΍ΰϴϣ
ϢϳΩϮϤϧ ̶γέήΑ  ΪϟϮΗ ϝΎγ έΩ ̶Ϡϣ κϟΎΧΎϧ . ήϴϣϭ ̱ήϣ ήψϧ ί΍ ΪϟϮΗ ̵Ύϫ ϩϭή̴Ϥϫ ϦϴΑ ΍έ ̵΍ ϩΪϤϋ ̵Ύϫ ϑϼΘΧ΍ ˬ Ύϣ ΞϳΎΘϧ
Ω΍Ω ϥΎθϧ ϩΪόϣ ϥΎσήγ.ΡϮτγ ΎΑ ̶̰ϳΩΰϧ ϪτΑ΍έ ̶ϫϭή̴Ϥϫ ΕΎϓϼΘΧ΍ Ϧϳ΍ ˬέϮθ̯ ήϫ έΩ  ̮ϳ ήϳί ϥΎ̯ΩϮ̯ ̱ήϣ ϥ΍ΰϴϣ
Ζη΍ΩΪϟϮΗ ϝΎγ έΩ ̶Ϡϣ κϟΎΧΎϧ ΪϴϟϮΗ ϭ ϝΎγ . ̶ϟϭΪη ϩΪϫΎθϣ ήΗϻΎΑ ϦϴϨγ έΩ ̶̳Ϊϧί ςϳ΍ήη ΎΑ ήΘϳϮϗ ̵Ύϫ ρ ΎΒΗέ΍ . έΩ
 ̶Ϡϣ ΡϮτγ ΎΑ ̵έ΍ϮΘγ΍ ϪτΑ΍έ ϩΪόϣ ϥΎσήγ ί΍ ̱ήϣ ̵ΎϬϧ΍ΰϴϣ ˬ ΎϫέϮθ̯ ϦϴΑ ϪδϳΎϘϣ ϝΎγ ̮ϳ ήϳί ϥΎ̯ΩϮ̯ ̱ήϣ ϥ΍ΰϴϣ
Ύγ έΩ ̶Ϡϣ κϟΎΧΎϧ ΪϴϟϮΗ ϭΪϨΘη΍Ϊϧ ΪϟϮΗ ϝ. ήΑ ̵΍ ϩΪϤϋ ήϴΛΎΗ  ̶̳Ϊϧί Ϟϳ΍ϭ΍ έΩ ̶̳Ϊϧί ςϳ΍ήη Ϫ̯ Ϊγέ ̶ϣ ήψϧ ϪΑ ˬϪΠϴΘϧ έΩ
ΪηΎΑ ϪΘη΍Ϊϧ ϩΪόϣ ϥΎσήγ ̱ήϣ ̵΍ ϩέϭΩ Ϊϧϭέ. ζϫΎ̯ ϞΜϣ ̵ήΗ ̶λΎμΘΧ΍ Ϟϣ΍Ϯϋ ΎΑ ςΒΗήϣ ϻΎϤΘΣ΍ ήϴϣϭ ̱ήϣ ζϫΎ̯
ΪηΎΑ ̶ϣ ̵έϮϠϴ̡ ήΘ̯ΎΑ Ϯ̰ϴϠϫ ωϮϴη  . 
 
  έΩ ϡϭΩ ζΨΑ ̵Ύϫ Ϟμϓ ˬϪϣΎϧ ϥΎϳΎ̡4Η  Ύ6 ϝΎγ ΎΗ ϻΎΑ ϩΪηή̯Ϋ ̵ΎϬϳέΎϤϴΑ ί΍ ̱ήϣ ϩΪϨϳ΁ ̵Ύϫ Ϊϧϭέ  ˬ2030 ήΑ  ˬ
 ϦϴΑ ϩΪη ϩΪϫΎθϣ ̱ήϣ ̵ΎϫΪϧϭέ αΎγ΍1980 ϭ 2005Ϊϧ΍ ϩΪη ̶ϨϴΑ ζϴ̡ ˬ ̶΋Ύ̡ϭέ΍ έϮθ̯ Ζϔϫ έΩ . ̱ήϣ ̵Ύϫ ϥ΍ΰϴϣ
  ϝΎγ ̵΍ήΑ ϩΪη ̶ϨϴΑ ζϴ̡ ϪΘϓέ ΖγΩ ί΍ ϩϮϘϟΎΑ ̵Ύϫ ϝΎγ ϭ ˬ ̱ήϣ Ω΍ΪόΗ ˬήϴϣϭ2030Ω ϪΑΎθϣ ϡΎϗέ΍ ΎΑ   ϝΎγ έ2005 
Ϊϧ΍ ϩΪη ϪδϳΎϘϣ. 
  Ϟμϓ4  ί΍ ̶ηΎϧ   ήϴϣϭ ̱ήϣ έΩ ̶ϟΎϤΘΣ΍ ̵Ύϫ ζϫΎ̯  ϝΎγ ΎΗ ΍έ ̶΋Ύ̡ϭέ΍ έϮθ̯ Ζϔϫ έΩ ΐϠϗ ̶ϧΎϘΘΣ΍ ̵έΎϤϴΑ
2030ΪϫΩ ̶ϣ Ρήη . ί΍ ̱ήϣ ̵Ύϫ ϥ΍ΰϴϣ ˬ ΎϫέϮθ̯ ϪϴϠ̯ έΩ ί΍  βϨΟ ϭΩ ήϫ έΩ ΐϠϗ ̶ϧΎϘΘΣ΍ ̵έΎϤϴΑ1980 ΎΗ 2005 ϪΑ 
Ζγ΍ ϪΘη΍Ω ζϫΎ̯ ϪΘγϮϴ̡ έϮσ.ϥ΍ΰϴϣ ϝΎγ έΩ  ̶Ϩγ ϩΪη ϖϴΒτΗ ̱ήϣ ̵Ύϫ 2030)  ϝΎγ ΎΑ ϪδϳΎϘϣ έΩ2005( ΩϭΪΣ ΎΗ
50%ΪϨΑΎϳ Ϫϣ΍Ω΍ ϪΘηά̳ ̵Ύϫ Ϊϧϭέή̳΍ ˬΪΑΎϳ ̶ϣ ζϫΎ̯ .  ήϴΛΎΗΐϠϗ ̶ϧΎϘΘΣ΍ ̵έΎϤϴΑ ήΜ̯΍ έΩ ΪϟϮΗ ϭΪΑ έΩ ̶̳Ϊϧί ϪΑ Ϊϴϣ΍ ̵ϭέ 
 ΩϭΪΣ ΎΗ Ύϫ ΖϴόϤΟ25 ΎΗ 50ΪΑΎϳ ̶ϣ ζϫΎ̯ Ϊλ έΩ .Η ˬϥ΍ΪϨϤϟΎγ  ΖϴόϤΟ ζϳ΍ΰϓ΍ ΖϠϋ ϪΑ  ί΍ ̱ήϣ Ω΍Ϊό ̶ϧΎϘΘΣ΍ ̵έΎϤϴΑ
Ζη΍Ω Ϊϫ΍ϮΧ ̶θϳ΍ΰϓ΍ ̶ΘΣ Ύϳ ϭ ϪΘδϫ΁ ̶θϫΎ̯ Ϊϧϭέ ΐϠϗ. ̱ήϣ ̶ϧϮϨ̯ Ϊϧϭέ ή̳΍ ˬϪΠϴΘϧ έΩ  ί΍ Ϫϣ΍Ω΍ ΐϠϗ ̶ϧΎϘΘΣ΍ ̵έΎϤϴΑ
ˬΪΑΎϳ ˬ ̮ϳΩΰϧ ̵΍ ϩΪϨϳ΁ έΩ αέΩϭί ̱ήϣ έΩ ̶Ϡλ΍ ΖϠϋ ̮ϳ ϥ΍ϮϨϋ ϪΑ ΍έ ζΘϴϤϫ΍ ϩΪϤϋ ζΨΑ  ΐϠϗ ̶ϧΎϘΘΣ΍ ̵έΎϤϴΑ ί΍ 
Ω΍Ω Ϊϫ΍ϮΧ ΖγΩ. 
 έΩ  Ϟμϓ5ϢϳΩϮϤϧ ̶ϨϴΑ ζϴ̡  ̵ΰϐϣ ϪΘ̰γ ̵΍ήΑ ΍έ ̭ήϣ ϩΪϨϳ΁ Ϊϧϭέ Ύϣ  ˬ . ˬβϨΟ ϭΩ ήϫ έΩ ϭ ΎϫέϮθ̯ ϪϤϫ έΩ
 ϝΎγ ΎΗ ϪΘγϮϴ̡ έϮσ ϪΑ  ̵ΰϐϣ ϪΘ̰γ ί΍ ̱ήϣ ̵Ύϫ ϥ΍ΰϴϣ2005Ζγ΍ ϪΘη΍Ω ζϫΎ̯  . ̵ΎϬϧ΍ΰϴϣ ˬΪϨΑΎϳ Ϫϣ΍Ω΍ ΎϫΪϧϭέ Ϧϳ΍ ή̳΍
 ϝΎγ έΩ ̶Ϩγ ϩΪη ϖϴΒτΗ ̱ήϣ2030 ϝΎγ ̵Ύϫ ϥ΍ΰϴϣ ϒμϧ ϥ΍ΰϴϣ ϪΑ 2005 έΩ ήΘθϴΑ ̵Ύϫ ζϫΎ̯ ΎΑ ˬΪϴγέ ΪϨϫ΍ϮΧ 
 Ϫδϧ΍ήϓ)ϡϮγ  ϭΩ   ΩϭΪΣ έΩ(Ϊ΋Ϯγ ϭ ̭έΎϤϧ΍Ω ˬ ΪϨϠϫ έΩ ήΘϤ̯ ̵Ύϫ ζϫΎ̯ϭ ˬ)ϡέΎϬ̩ ̮ϳ ΩϭΪΣ έΩ.( ζϫΎ̯ ̵Ύϫ ϥ΍ΰϴϣ
Ζη΍Ω Ϊϫ΍ϮΧ ΩϮΟϭ ϪΘϓέ ΖγΩ ί΍ ϩϮϘϟΎΑ ̵ΎϬϟΎγ ̵΍ήΑ ̶ϬΑΎθϣ . ̶θϫΎ̯  ̵ΰϐϣ ϪΘ̰γ ̱ήϣ Ω΍ΪόΗ ˬ ΖϴόϤΟ ζϳ΍ΰϓ΍ ΖϠϋ ϪΑ
ϳήΑ έΩ ϪΘδϫ΁Ζη΍Ω Ϊϫ΍ϮΧ ΎϫέϮθ̯ ήϳΎγ έΩ ϩΪϨϳ΍ΰϓ΍ ̶ΘΣ Ύϳ ϭ ΖΑΎΛ ˬ   Ϫδϧ΍ήϓϭήϴΒ̯ ̵ΎϴϧΎΘ. 
  έΩ Ϟμϓ6 ϝΎγ ΎΗ ΍έ ϩΪόϣ ϥΎσήγ ̱ήϣ ̵Ύϫ Ϊϧϭέ Ύϣ    ˬ2030Ϣϳ΍ ϩΩή̯ ̶ϨϴΑ ζϴ̡  . ̱ήϣ ̵Ύϫ ϥ΍ΰϴϣ
ί΍ ί΍  βϨΟ ϭΩ ήϫ  ϭ ΎϫέϮθ̯ ϪϤϫέΩ ϩΪόϣ ϥΎσήγ1980 ΎΗ 2005 ΖΑΎΛ  ) ΩϭΪΣ4.9-3.6ϝΎγ έΩ ΪλέΩ  ( ϩΩϮΑ 
Ζγ΍. έΩ ήΗ Ϧϴ΋Ύ̡ ̱ήϣ ̵Ύϫ ϥ΍ΰϴϣ ΎΑ ̵ΎϫέϮθ̯ έΩ ϭ ϩΪθϧ ϒϗϮΘϣ ήϴΧ΍ ̵ΎϬϟΎγ έΩ ζϫΎ̯ ϥ΍ΰϴϣ1980 ήΘ̰̩Ϯ̯ ˬ
Ζδϴϧ. ϦϴΑ ˬ Ύϫ ϪόϣΎΟ ΐϠϏ΍ έΩ ϩΪόϣ ϥΎσήγ ̱ήϣ ̵ΎϬϧ΍ΰϴϣ ˬΪΑΎϳ Ϫϣ΍Ω΍ ΰϴϧ ϩΪϨϳ΁ έΩ ζϫΎ̯ Ϧϳ΍ ή̳΍2005 ϭ 2030 ΎΗ ˬ
 ΩϭΪΣ66ΪΑΎϳ ̶ϣ ζϫΎ̯ ΪλέΩ .̯ ϪΘϓέ ΖγΩ ί΍ ϩϮϘϟΎΑ ̵ΎϬϟΎγ ΎΗ  ̱ήϣ Ω΍ΪόΗ Ϫ̰ϴϟΎΣ έΩ ˬΖη΍Ω Ϊϫ΍ϮΧ ϡϮγ ϭΩ ΩϭΪΣ ̶θϫΎ
50ΪΑΎϳ ̶ϣ ζϫΎ̯ Ϊλ έΩ . ϥΎσήγ ˬήϴΧ΍ ̵Ύϫ ϝΎγ έΩ έ΍ϮΘγ΍ ϭ ΖΑΎΛ ˬ ̵Ϯϗ ήϴϣϭ ̱ήϣ ̵Ύϫ ζϫΎ̯ ήψϧ ί΍ ˬ Ϧϳ΍ ήΑ ΎϨΑ
 Ζη΍Ω Ϊϫ΍ϮΧ Ύ̡ϭέ΍ έΩ ̱ήϣ ϞϣΎϋ ϥ΍ϮϨϋ ϪΑ ̵ήΘϤ̯ ΖϴϤϫ΍ ˬϩΪϨϳ΁ έΩ ̶ϧϭΰϓ΍ ίϭέ έϮσ ϪΑ ϻΎϤΘΣ΍ ϩΪόϣ. 
  Ϟμϓ7ˬ ̶ϨϴΑ ζϴ̡ ϭ ϪΘηά̳ έΩ ̶̳Ϊϧί Ϟϳ΍ϭ΍ έΩ ήϴϣϭ ̱ήϣ ζϫΎ̯ ΪϟϮϣ Ϟϣ΍Ϯϋ ϭ ΪϨ̯ ̶ϣ ϪλϼΧ ΍έ ̶Ϡλ΍ ΞϳΎΘϧ 
ΪϳΎϤϧ ̶ϣ ̶γέήΑ   ΍έ ϭέ ζϴ̢ϳΎϫ ϝΎγ έΩ ̶ϟΎϤΘΣ΍ ̵Ύϫ. Ϫ̯ ˬΪη ϪΘϓΎϳ ̶ϫϭή̴Ϥϫ ζϫΎ̯ ̵ΎϫϮ̴ϟ΍ Ϫ̯ ϢϴΘϓή̳ ϪΠϴΘϧ Ύϣ
Ζη΍Ω ΎϫέϮθ̯ ϪϤϫ έΩϭ ̵έΎϤϴΑ Ϫγ ήϫ ̵΍ήΑ ϥΎϣί ϝϮσ έΩ ̶΋Ύϫ ̶ϧϮ̴ϤϫΎϧ. ήϴϴϐΗ ϦϴΑ ρΎΒΗέ΍ έΎψΘϧ΍  ˬΎϣ ̵Ύϫ ϪΘϓΎϳ 
ΪϨϨ̯ ̶ϣ ΖϳΎϤΣ ΍έ ̵ΰϐϣ ϪΘ̰γ ̶ΘϴόϤΟ ΡϮτγ  Ε΍ήϴϴϐΗ ϭ  ̶̳Ϊϧί Ϟϳ΍ϭ΍ Ζδϳί ςϳ΍ήη .  ̵΍ήΑ ̵Ϊϫ΍Ϯη ϪϧϮ̳ ̨ϴϫ ˬ̶ϟϭ
 ί΍ ̱ήϣΪθϧ ϩΪϫΎθϣ ϩΪόϣ ϥΎσήγ Ύϳ ΐϠϗ ̶ϧΎϘΘΣ΍ ̵έΎϤϴΑ . ̱ήϣ ̶ϧϮϨ̯ Ϊϧϭέ ή̳΍ ˬ  ί΍ ϪΘ̰γ ϭ ΐϠϗ ̶ϧΎϘΘΣ΍ ̵έΎϤϴΑ
 ̵ΰϐϣ)ϴϨ̪ϤϫϩΪόϣ ϥΎσήγ  Ϧ   (ˬΪΑΎϳ Ϫϣ΍Ω΍ ΎϬϳέΎϤϴΑ Ϧϳ΍ ̮ϳΩΰϧ ̵΍ ϩΪϨϳ΁ έΩ   ̵ΎϬΘϠϋ ϥ΍ϮϨϋ ϪΑ ΍έ ϥΎθΘϴϤϫ΍ ϩΪϤϋ ζΨΑ  
αέΩϭί ̱ήϣ έΩ ̶Ϡλ΍Ω΍Ω Ϊϫ΍ϮΧ ΖγΩ ί΍ .   ̵΍ήΑ ϩ̬ϳϭ ϪΑ̵ΰϐϣ ϪΘ̰γ ϭ ΐϠϗ ̶ϧΎϘΘΣ΍ ̵έΎϤϴΑ ̶ϧ΍ϮΗΎϧ ϭ ίϭήΑ ήϴΛΎΗ ˬ
ΪηΎΑ ϪΘη΍Ω ̵ήΘϤ̯ ζϫΎ̯  Ζγ΍ Ϧ̰Ϥϣ ΎϬϧ΁ .ϴ̰θϴ̡ ˬϪΠϴΘϧ έΩ ̵ήΰϐϣ ϪΘ̰γ ϭ ΐϠϗ ̶ϧΎϘΘΣ΍ ̵έΎϤϴΑ έϮσ ϪΑ ϩΪϨϳ΁έΩ
ήϴϣϭ ̱ήϣ ̵ΎΟ ϪΑ ΎΗ Ζγ΍ ̵έΎϤϴΑ ϪΑ ϪΘδΑ΍ϭ ̶ϧ΍ϮΗΎϧ ήΑ ̶̰Θϣˬ̶ϧϭΰϓ΍ίϭέ    . 
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Appendix 
 
          Causal mechanisms/trends in factors 
 
The factors underlying the favourable mortality trends are variable and 
multifactorial. They can be explained by primary 1 and secondary 2 preventions 
with widely variation from country to country 3. In addition, many interactions 
occur among these factors, and for each one of the factors a network of 
determinants is established or proposed in varying degree of detail. In this 
appendix, after explaining of the potential causal mechanisms behind the 
mortality trends from IHD, stroke and stomach cancer, the analysis on 
contribution of three important risk factors (i.e., smoking, hypercholesterolemia, 
and hypertension) on stroke mortality decline in Finland will be presented.  
   
A.1. Potential causal mechanisms 
 
A.1.1. IHD and stroke 
 
These two diseases have many common risk factors, with possible various 
effects on diseases, differ in the strength and even direction of association 4, and 
many of them widely accepted as being causal 5.  
Population differences in mortality from IHD and stroke are generally well 
documented in the report of WHO MONICA Project 6, which showed that two 
thirds of the decline in IHD and stroke mortality remains unexplained even after 
control for classical risk factors 7. A part of the unexplained trends might be due 
to changes in other risk factors, such as socioeconomic status, food consumption, 
or different combinations of some or all of these 7. Early life exposures might 
also be one of the other factors that contribute to trends in IHD and stroke 
mortality 8. In addition, findings from INTERHEART study suggested that nine 
modifiable risk factors explain most of the risk worldwide 9. Moreover, 
INTERSTROKE study suggested that ten risk factors are associated with 90% of 
the risk of stroke, especially blood pressure, smoking, physical inactivity, and 
diet 10. 
There are many determinants which could explain mortality trends of IHD 
and stroke such as:  
 
Age and gender: Each of these two factors serves as a marker for 
underlying behaviors, exposures, or other factors (cofactors) more directly related 
to disease risks and outcomes. In addition, they have two important aspects in 
common. The first aspect is that they are dimensions of diversity among 
populations, revealing health patterns- demonstrated variations in the distribution 
of disease or health-related conditions within or between populations- that may 
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be of public health importance. The second aspect is the presumption that each of 
them is ‘unmodifiable’, in contrast to such factors as dietary patterns, which are 
clearly responsive to intervention. However, association of any of these two 
factors with disease rates or risks may also reflect underlying environmental 
factors related to social conditions, behavioral patterns, specific exposures, or 
other characteristics. For example, increasing blood pressure in adulthood was 
long regarded as a natural or inevitable concomitant of aging.  
 
 Age: The important effect of age in mortality from IHD and stroke can be 
summarized in four main aspects:  
1) The effect of age throughout the life span, from determination of genetic 
makeup and the course of fetal development to the ages of IHD and stroke. With 
respect to stages of life, it is necessary to note the importance of distinguishing 
between a true effect of childhood (fetal and neonatal) factors and factors in 
adulthood in determining risks of adult cardiovascular diseases 11.  
2) There are different population patterns of change in blood pressure with 
age. In most populations, blood pressure does increase with age in adulthood; 
thus, if two populations were compared regarding the prevalence of high blood 
pressure, a finding of a higher prevalence in the population with the greater 
proportion of older adults would be uninformative. Therefore, age-specific 
comparisons are more informative than crude comparisons, which do not take age 
into account.  
 3) Morbidity and mortality data in the elderly differ from those for younger 
adult age groups in two respects. First, data on specific diagnoses and causes of 
death may be less reliable for older individuals. Second, the high prevalence of 
many cardiovascular disease risk factors in older persons tends to result in 
reduced estimates of relative risk for cardiovascular events or conditions, because 
even those who remain clinically free of these conditions are at greater risk than 
younger persons.  
4) Older age is still the most important risk factor for stroke 12. The potential 
relationships between older age and stroke include being a major cause of 
morbidity and mortality in an aging population 13, increasing the incidence rate of 
stroke exponentially with advancing age 12, and rising of the mean age of the 
stroke patients reflecting the increasing number of elderly persons in the 
population 14, 15.  
 
Gender: Discussion of differences by gender in the natural history of 
atherosclerotic and hypertensive diseases has focused on women and the 
disparities between their experience and that of men 16. This emphasis reflects in 
large part a sense of relative neglect of the problem of cardiovascular disease in 
women, for whom its cumulative lifelong burden is actually no less than that for 
men.  
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There are many sex differences in risk factors including lower mean value 
of  systolic and diastolic blood pressure and total cholesterol concentration 
(beginning in adolescence) but greater prevalence of physical inactivity and 
overweight 17, and  smoking behavior 17. Plausible bases for such effects include 
chromosomal, endocrinologic, or reproductive factors could be interpreted 
variously as evidence of biologic, social, cultural, or behavioral effects. There are 
also different patterns of activity, occupation, interpersonal relationships, 
exposure, and access to education, health information or health services. Access 
to long-term programs supporting risk factor assessment and management may 
also present different opportunities for women and men; for example, women 
received fewer prescriptions for post-hospital treatment 18 or received coronary 
angiography less often than men 19. 
 
High blood pressure: Blood pressure varies throughout the life span, and 
the distribution of blood pressure may vary over time within a population. 
Furthermore, the death rate of a population is determined in a significant part by 
its blood pressure distribution 20, 21. The risks specifically for IHD and stroke are 
related to blood pressure levels 22; which is explained well in MONICA Project 
23. Blood pressure is also a substantial factor in differential risks of these events, 
especially stroke, within populations; and interventions to control high blood 
pressure in whole communities or treat individuals to reduce or prevent high 
blood pressure have been shown to be effective 21.   
Collins and Peto remarked that the reduction in stroke events by treatment 
matches the prediction from the attributable risk of stroke due to blood pressure; 
however, for coronary events, only about two-thirds of the predicted treatment 
effect was found 24. They argued that stroke may reflect more immediate blood 
pressure effects that respond to treatment rapidly, whereas IHD may require 
longer time to exhibit the full benefit of blood pressure reduction. Casper et al 
discussed on the assumption that improved treatment of hypertension is the 
primary determinant of the decline in stroke deaths 25. Their analysis suggested 
that the trends for hypertension treatment or control and for stroke mortality rates 
were parallel over the longer periods, not within shorter periods. They concluded 
that mass drug treatment of hypertension cannot bring about the ‘optimal decline’ 
in stroke mortality, and suggested that cultural change was more relevant than 
medical management to hypertension prevention. They posed a socio-cultural 
hypothesis of the population causes of mass hypertension. In another study, 
Jacobs et al concluded that 1) the stroke mortality rate changes since 1960 have 
followed population blood pressure changes, influenced to some extent by the 
expanded use of antihypertensive medication, and 2) the full potential of this use 
in the population may not yet have been reached 26.  
Finally, other life-style factors have also probably influenced the decline of 
stroke deaths, both directly (e.g., the decreasing prevalence of cigarette smoking) 
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and indirectly (e.g., the effects of decreased sodium and alcohol intake on blood 
pressure). 
 
Blood lipid: It is clear that age-specific death rates from IHD have 
declined while decreases have occurred in mean total cholesterol concentration 27, 
with a significant variation between age patterns of cholesterol concentration 
among populations 28. The relation between dietary fat and cholesterol intake and 
blood cholesterol concentration has also been quantified 29.  
Increases of cholesterol with age in men are apparent from the 20s to the 
40s or beyond reflecting differences in lifetime history of the different age groups 
(cohort effects); for women, their age curve for total cholesterol concentration 
also fell at the oldest ages, like that for men, but with a peak in the curve at ages 
about 15 years older 28. In addition, the inverse relation of the concentration of 
high-density lipoprotein (HDL) cholesterol (popularly, the “good” cholesterol) to 
risk of IHD has been reported 30. It has been suggested that while in general both 
low-density lipoprotein (LDL) and HDL cholesterol relate to coronary risk in 
women as in men, the inverse risk gradient for HDL cholesterol is stronger for 
women and that LDL cholesterol of a given level may be less atherogenic for 
women 31. The implication of HDL cholesterol as having an independent and 
inverse relation to risk of IHD has long antecedents, as early as 1951, as reviewed 
in previous studies on IHD in different populations 32.   
  
Smoking: Unless the epidemic of cigarette smoking is controlled in 
developed countries 33, this may constitute the risk factor of the 21st century as 
well, especially for cardiovascular diseases 20. The reduction in prevalence trends 
of cigarette smoking in the population during the last decades imply large 
changes in the frequency of exposure to tobacco smoke 34; however, it is clear 
that cigarette smoking alone does not indicate the full extent of tobacco exposure 
in the population, especially among youth, although pipe and cigar smoking are 
generally much less prevalent than cigarette smoking.  
In addition, there is a relationship between smoking and two other major 
risk factors, i.e., blood pressure and cholesterol concentration, for IHD mortality 
35, and has interact with these risk factors in the development of atherosclerosis 
during adolescent and young adulthood 36. Therefore, these three major 
cardiovascular disease risk factors are closely interrelated and it is important that 
they be considered together and not in isolation.  
Furthermore, exposure to tobacco smoke is associated with several factors 
specifically relevant to cardiovascular diseases, including lipid abnormalities 
such as increased LDL cholesterol, very low-density lipoprotein (VLDL) 
cholesterol, and triglyceride and decreased HDL cholesterol, and increased blood 
pressure 34. The personal habit of cigarette smoking is most important for the 
occurrence of cardiovascular diseases due to its very high prevalence in many 
populations 33, with focus on the initiation of smoking mostly in childhood and 
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adolescence. Other important conditions of progression in smoking behavior are 
socioeconomic, environmental, behavioral, and personal factors as well as the 
role and tactics of the tobacco industry.  
Moreover, exposure to smoked tobacco occurs passively when 
nonsmoking persons share the environment of smokers; this form of exposure 
underlies studies of the effects of environmental tobacco smoke (ETS). For 
smokers, there is also often additional exposure to smoke generated by others. In 
addition, smokeless tobacco, commonly used by younger population, is toxic due 
to constituents of tobacco juices, even without tobacco’s combustion products; its 
use may result in higher nicotine due to the acidity of saliva and its prolonged 
contact with the tobacco 34. 
 
Genetic factors: Although genetic testing for certain of the lipid disorders 
is potentially applicable at birth for those with known family histories of such 
conditions, few if any recommendations for neonatal testing are proposed. 
Rather, family history is emphasized as a means of predicting increased risk for 
individual children and adolescents. Because parents and even grandparents of 
young children may not yet have reached the peak ages at risk of the risk factors 
themselves of for major cardiovascular events, updating the family history is 
needed and could then lead to more specific investigation if warranted.  
Furthermore, specific genetic determinants of risk could potentially be 
evaluated once an individual was found, for example, to have an elevated 
cholesterol concentration. A concern is that genetic heterogeneity of populations 
may be emphasized to such a degree that general recommendations lose 
acceptance in favor of individualization of all interventions, perhaps requiring 
genotyping before action is taken on behalf of any individual 37. Unless, such 
strategies became feasible on a very broad scale, great caution would be indicated 
in considering the implications for public health of dismantling population-wide 
recommendations. 
 
Family history: The family unit is important for prevention of the risk 
factors in the first place, in keeping with the cardiovascular prevention schedule. 
Family history has been championed as a key to identification of the coronary-
prone family 38. Persons or families to be at high risk may in principle be defined 
in four categories: those presently free of risk factors but especially likely to 
develop major risk factors in the future; those with established risk factors; those 
already experiencing acute cardiovascular disease events; or those surviving such 
events or otherwise recognized as having clinically detectable disease. With the 
possible exception of the first of these categories, recognition of high risk occurs 
mainly in the context of health care setting or in screening programs, which 
ideally provide referral for health care. Therefore, policies concerning high risk 
are closely related to aspects of clinical practice.  
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Diet: From a population perspective, there are many determinants of 
dietary behavior that influence the ultimate nutritional status of individuals. It 
should be noted that diet is complex, comprising countless specific nutrients, 
food sources, variations in preparation, and combinations of these. Within any 
population, there may be wide differences in typical dietary habits of individuals, 
and within individuals, diet may be highly variable from day to day or between 
periods of life. The diet of the individual in turn is strongly, and in some 
circumstances completely, determined by external factors of which he or she is 
hardly conscious. Even the choice of foods, the timing, and the company of 
others for a given meal may be largely passive or automatic, on a day-to-day 
basis. Diet can be described in various ways- in reference to specific nutrients, in 
terms of foods, and in terms of quality of dietary composition.  
In addition, the ascendancy of fat and sugar and the decrease in flour and 
fiber, and the very recent sharp increase in animal protein and fat through an 
unprecedented pattern of meat and milk consumption could demonstrate marked 
rates of dietary change. In addition, changes in food technology have brought 
about even more-accelerated dietary change in the most recent decades.  
Furthermore, dietary assessment of individuals or populations poses many 
difficulties; for example, there are several concepts of diet within and/or between 
populations, and one or more of these may be relevant to a particular question or 
investigation. However, despite these methodological difficulties in population 
studies of diet, extensive observations documenting adverse effects of the recent 
dietary patterns exist; especially for total and saturated fats, specific fatty acids, 
cholesterol, fiber, and salt  39. Moreover, it is clear that dietary patterns can be 
modified, at both population and individual levels 40. There is consistency in the 
general recommendations for prevention or reversal of dietary habits, by official 
international and national health agencies, to limit intakes of fats, saturated fats, 
and salt and to increase intake of fruits, vegetables, and legumes to maintain a 
balance between total energy intake and energy requirements 40. 
 
Physical inactivity: Mechanisms that either increase myocardial oxygen 
supply or decrease myocardial work and oxygen demand are emphasized, 
suggesting that the principle effects of physical activity on the heart would tend 
to reduce the risk of myocardial ischemia or decrease its severity, especially 
under circumstances of increases workload or diminished blood flow. Physical 
inactivity also affects many other aspects of physiology, metabolism, and 
psychology 41. The mechanisms by which physical activity could influence 
measures of occurrence of cardiovascular diseases are their effects on reduced 
risks of obesity and undesirable body fat distribution, adverse blood lipid profile, 
and high blood pressure 42, 43.  
Within populations, variation in risk of cardiovascular diseases in relation 
to physical inactivity, other levels of activity, and physical fitness has been 
reported from numerous studies 44. In addition, one of the important dimensions 
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of physical inactivity includes the distinction between occupational (work) 
activity and non-occupational or leisure time physical inactivity. Early studies, 
through the 1970s, focused on occupational activity, while more recent ones have 
emphasized non-occupational activity 45. 
Interventions to influence physical activity in populations can potentially 
affect both the incidence and the prevalence of physical inactivity; i.e., in short-
term, its prevalence could be reduced only by measures bringing about change to 
a physically active state for a substantial proportion of the population who are 
currently physically inactive 44. Reducing incidence of physical inactivity 
requires measures to establish non-sedentary habits early in life and maintain 
them. As a long-term result, prevalence of inactivity in adulthood would also 
thereby be reduced.  
 
Obesity and overweight: The risks of cardiovascular diseases that may be 
increased directly or indirectly through obesity are prominent health concerns. 
The question of whether population differences in rates of atherosclerotic and 
hypertensive diseases mortality are attributable to obesity has been addressed in 
few studies 46. At the population level, obesity may refer to the prevalence of a 
specified level of body mass index (BMI), waist-hip ratio (WHR), sum of 
skinfold thickness as measured at selected body sites, or some other measures 47. 
Furthermore, overweight connotes a relative excess of weight. One further aspect 
concerns the percent body fat changes markedly during infancy and childhood, 
compared to essentially constant body fat in adulthood 48. Furthermore, secular 
trends toward increasing prevalence of obesity have been occurring also in 
childhood; and there is little disagreement that childhood obesity is a significant 
health concern in the population 49; thus, the evidence of increasing mean values 
of BMI in the adult population suggests the importance of preventive measures at 
earlier ages 50. The population-wide measures advocated for improvement of 
dietary patterns and reduction of physical inactivity are the principal means 
proposed for prevention of obesity at the population level. In many countries, the 
secular trend toward increasing prevalence of obesity is evidence of failure of 
population-wide strategies against this disorder.  
 
Diabetes mellitus: Although the relation of diabetes or categories of 
baseline blood glucose levels and risk of IHD has illustrated before 51; however, 
the complex of blood glucose, insulin, and diabetes has not been examined for its 
possible role in explaining variation in coronary death rates among different 
populations 36. While blood insulin concentration is itself a risk factor for IHD 
has been studied with respect to both endogenous insulin (hyperinsulinemia or 
insulin resistance) and exogenous insulin (insulin therapy), the studies of both 
aspects can be described as inconsistent and the role of insulin as a heart disease 
risk factor remains controversial 52. Association between diabetes and stroke has 
also been demonstrated 53, and it is a potentially modifiable factor of stroke 54. 
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Therefore, because the presence of diabetes increases the risk of IHD and stroke, 
emphasis has increased on the prevention of  cardiovascular conditions as an 
important component of care in diabetes 55. Public health concern has therefore 
expanded to include a wider spectrum of disturbances of this regulatory complex.   
Moreover, non-insulin-dependent diabetes mellitus (NIDDM) and insulin 
resistance together are the most relevant aspects of diabetes for risks of 
atherosclerosis and hypertension in the population 56. Population studies have 
suggested a number of predisposing factors for diabetes such as physical 
inactivity, systolic blood pressure, high-density lipoprotein (HDL) cholesterol, 
smoking, and IHD 57. Other factors may also participate in the increased 
atherogenesis of insulin resistance and diabetes such as elevated blood 
concentrations of glucose, triglyceride, and fibrinogen; association of risk factors 
such as obesity, hypertension, and adverse blood lipid profiles with elevated 
insulin concentrations also is evident in early adulthood and even in childhood 58.  
  
 Socio-economic status (SES): Although SES has been found to be 
associated with cardiovascular diseases, with a changing patterns over time 59, the 
declines in cardiovascular mortality have not affected all socioeconomic groups 
equally, and several cardiovascular risk factors are also inversely associated with 
socioeconomic status 59. SES generally constitute “fundamental causes” of 
disease, not merely markers of true causes or pointers toward risk factors that 
operate more proximally in relation to disease 60.  
Among the commoner changes in social conditions taking place in recent 
decades, and presumably to continue, are changes in culture, lifestyle, and 
environment attendant on economic development, migration, or both 61. 
Furthermore, cultural change is a very important part of social condition 62. 
Factors such as urban residence, white-collar occupation, and geographic and 
occupational mobility are the most considerable factors; and their associations 
with cardiovascular diseases were independent of diet, relative body weight, 
blood pressure, smoking, and parental longevity 62, as well as education and some 
aspects of the origin of cardiovascular disease in childhood or adolescence 63, and 
social class, operating through variation in lifestyles, and specific exposures to 
produce differences in health 64.  
Low SES is marked by higher risks of many diseases and adverse health 
conditions such as atherosclerosis and hypertensive diseases. There is an overlap 
between concentration of cardiovascular risk factors and lower SES. The 
important issues in this regard include factors such as lower levels of literacy or 
education, less likelihood of employment, and more limited access to health care 
sources. 
 
Personal characteristics:  There are many factors which could be 
addressed in this regard such as: psychosocial patterns, pro- and anti- oxidants, 
and homocysteine.   
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Psychosocial Patterns: Adverse psychosocial patterns may be considered 
influential for causation of atherosclerotic and hypertensive diseases or for 
limiting the effectiveness of preventive measures 65. Conversely, favorable 
behavior patterns that occur spontaneously or as a result of health education, 
counseling, or other interventions are expected to reduce risks and to reinforce 
preventive strategies by favorable effects on patterns of diet, physical activity, 
medication adherence, and other such behaviors. The areas most extensively or 
recently investigated are Type A behavior pattern, occupational stress, and social 
support 66. These personal characteristics are primarily psychosocial rather than 
metabolic or physiological in nature.  
 
Pro- and Anti-oxidants: A metabolic mechanism has been proposed that 
strongly influences the behavior of LDL molecule and potentates its role in 
atherosclerosis 67; in addition, the distinction between dietary and supplementary 
intake of the antioxidants (such as vitamins A, C, and E) is important to 
interpretation of evidence. It is apparent that the various antioxidants differ in 
important respects in their relative potency and behavior as protective agents 
against LDL oxidation; and from this perspective, vitamin E and beta-carotene 
might be expected to have greatest potential benefit 68. If the action of 
antioxidants protects against transformation of LDL to an especially virulent 
promoter of atherosclerosis, antioxidants would be opposed by any factor whose 
action favors production of O-LDL, such as certain metals (like iron or copper) or 
their compounds, in which act as a pro-oxidant. Research has shown a role of 
excess dietary iron in increasing the risk of acute myocardial infarction in men 
and possibly postmenopausal women, explaining variation in the relation of LDL 
cholesterol to risk of IHD in some populations and suggesting that dietary 
guidelines should cautious against excessive iron intake 69.  
 
Homocysteine: Homocysteine is an amino acid in blood which its too 
much concentration in blood is related with increasing risk of IHD and stroke 70. 
There is a close link between homocysteine metabolism and the B vitamins in 
that either a pyridoxal phosphate-dependent enzymatic reaction or a transfer of 
methyl groups from vitamin B12 or folic acid is required to convert homocysteine 
to its immediate metabolic products 71. In addition, based on the estimated 
frequency of increased homocysteine concentration in the general population, it 
was concluded that 10% of the population risk of IHD was attributable to this 
factor 72. There is also a possibility that the potential reduction in IHD rates by 
increased folic acid intake, under the assumption that the reduction of 
homocysteine concentration known to result from folate administration, would 
reduce disease rates 72. Meanwhile, there is a strong argument that consideration 
of increased folate intake is a potential intervention to reduce the risk for IHD 73.  
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A.1.2. Stomach cancer 
 
Some of our results suggest that secular trends in stomach cancer are 
largely determined by changes in adult socioeconomic circumstances and 
lifestyles, rather than childhood 74. For example, the marked cohort pattern of 
stomach cancer mortality, which peaked among birth cohorts born around 1875, 
might be determined by cohort-specific trends in smoking, alcohol consumption 
and other factors related to later phases of the life course. Similarly, 
improvements during the 20th century in environment and nutrition may have 
resulted in a gradually lower incidence of stomach cancer, while more accessible 
and effective facilities for cancer therapy may have helped to reduce its case 
fatality 74.  
Stomach cancer rates throughout the world vary widely, implying that 
other factors are also important in its development 75, maybe because of the 
differences in gastritis patterns related to H. pylori 75. It affects by producing an 
environment conductive to carcinogenesis, interacting with other lifestyle and 
environmental exposures 76.  Furthermore, there is a strong association between 
H. pylori-associated gastritis and stomach cancer 77; and many epidemiological 
studies indicate that H. pylori infection plays an important role in stomach 
carcinogenesis by inducing chronic inflammation in the gastric mucosa 77. H. 
pylori might affect through facilitating the growth of nitrosating bacteria 78 or 
inhibiting gastric secretion of ascorbic acid 79, and by interacting with other 
factors, including dietary habits, host factors, and the virulence of the infection 80. 
H. pylori infection is a more important contributor of the observed 
mortality trends from stomach cancer, supported by previous epidemiological 
studies 77; however, H. Pylori would account only for half of the world total for 
stomach cancer by a probably synergistic or antagonistic role of dietary and other 
exogenous factors 81. Furthermore, evidence suggests that H. pylori infection 
mainly acquired during early childhood, and infection persists throughout the life 
75 reflecting the effects of environmental and lifestyle risk factors 82 such as the 
shared bed in childhood, lack of fixed hot water supply, lower educational 
attainment 75, low income, poor education and low living conditions during 
childhood such as poor sanitation and overcrowding 83. Chronic H. pylori 
infection is also associated with stomach cancer 84; therefore, control of this 
infection would reduce the occurrence of chronic gastritis and peptic ulcer and 
might substantially lower the risk of stomach cancer 85. In fact, treatment of H 
pylori infection is an appropriate target for prevention of stomach cancer 84, and 
by eradicating H pylori, gastric inflammation can be cured 77. Although, control 
of the H. pylori infection might substantially reduce the risk of stomach cancer 85; 
however, among several therapeutic regimens to cure H. pylori infection 75, none 
of them is able to cure H. pylori infection 100% 86, and the medication 
combinations were able to cure H. pylori infection in more than 85% of the 
patients 86. In addition, further improvement with regards to life style might 
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occur, and therefore, other risk factors may become more important, including 
dietary factors.  
Treatment is expected to play some role 87, and changes in diagnosis and 
treatment may have made a contribution to the declining incidence and mortality 
rates of stomach cancer 88, 89. Factors are related to treatment and general 
management of patient is also expected to explain the residual variability in 
survival between European countries 87. These factors include greater operative 
experience leading to more skilled surgeons, earlier diagnosis and different 
biology of stomach cancer between countries 90. Since the appropriate treatment 
is mainly surgical 91, the proportion of patients underlying surgical intervention is 
the factor most likely to help further interpretation of differences among 
countries 87. Thus, the surgical workload associated with stomach cancer is not 
declining 92; this is because the incidence has remained almost static, which may 
be due to the relative increase in the numbers of older people in the population, 
who are at greater risk of developing stomach cancer 92. Incidence and workload 
should determine resources allocated to this disease rather than mortality 
statistics 92. Treatment costs are strongly related to age, cancer type and stage of 
disease at diagnosis 93. The costs of surveillance and monitoring activities needed 
in the intermediate phase are much lower than costs for first and terminal 
treatment but, as they may continue for a long period of time, their impact on the 
total cost of cancer care is not negligible 94. 
 
A.2. The contribution of risk factors on stroke mortality in Finland 
 
A number of risk factors have associations with stroke mortality 4.  
Epidemiological studies showed that two thirds of the fall in mortality from 
stroke in men and half in women can be explained by changes in the three main 
risk factors, i.e., smoking, hypertension, and total cholesterol 95. It might be 
because of the fact that modification of classic risk factors in the population can 
affect the rates of stroke 96. Indeed, early declines in stroke mortality are due to 
changes in diet and lifestyle factors, while the more recent declines are due to 
improvements in modern cardiovascular treatment 97. It should also be noted that 
attributing past falls in stroke mortality to risk factor changes or effective medical 
interventions is difficult because favourable trends in both have occurred 
simultaneously. 
In order to reveal how important it would be to continue the achievements 
of primary prevention (as compared to curative care), the attributable effects of 
the contribution of main risk factors (i.e., smoking, hypercholesterolemia, and 
hypertension) on stroke mortality trends in Finland have been assessed.  
 To take into account the attributable effects to the contribution of main risk 
factors (smoking, hypercholesterolemia, and hypertension) in Finland, the 
previous research were considered for both genders; i.e., smoking (8.8%), high 
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cholesterol (37%), high blood pressure (7.5%), three risk factors combined 
(53.3%), and treatment (23.1%) on stroke mortality decline 98.  
To cover the potential possibilities, the following scenarios have been 
formulated including reference scenario (continuation of the past trends), 
smoking scenario (take into account only the effect of elimination of smoking), 
high blood pressure scenario (take into account only the effect of prevention of 
high blood pressure), high cholesterol scenario (take into account only the effect 
of elimination of high cholesterol), treatment scenario (take into account the 
effect of treatment), and finally three risk factors scenario (take into account the 
effects of these three risk factors combined). 
In table A.1., the projected mortality rates in 2030 in different scenarios 
have been compared to the rates in 2005. In this table, the contribution 
percentages of main risk factors (i.e., smoking, high cholesterol, and high blood 
pressure), as well as a combined contribution of these three risk factors, in 
mortality declines for both genders were compared with reference scenario (i.e., 
the observed mortality declines). The removal of the effects of high cholesterol in 
the population are substantially more effective than the removal of smoking or 
high blood pressure alone, even more effective than treatment alone, in both men 
and women. These effects would be even more effective when combining the 
effects of eliminating of these three risk factors altogether. However, even with 
combined effect, reference scenario shows more decline in all countries and for 
both genders, mainly because of the effect of other factors like unexplained 
factors. 
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Table A.1- Age standardized stroke mortality rates (per 100 000) in Finland, 
projections by sex and scenario from 2005 to 2030 
 
Year Scenario$ 
 
Men Women 
 2005 64.72 94.51 
    
Reference 2030 29.32 42.52 
 2030/2005* 0.45 0.45 
    
2030 31.78 46.31 No Smoking 
Contribution 2030/2005 0.49 0.49 
    
2030 31.41 45.73 No high BP 
Contribution 2030/2005 0.49 0.48 
    
2030 41.11 60.79 No high CHL 
Contribution 2030/2005 0.64 0.64 
    
2030 47.65 71.08 No  risk factors 
Contribution 2030/2005 0.74 0.75 
    
2030 36.22 53.18 No  treatment 
Contribution 2030/2005 0.56 0.56 
 
*. The figure of 2030 divided by the related figure in 2005. 
$. The contribution percentages of main risk factors in mortality decline for both 
genders are: smoking 8.8%, high cholesterol 37%, high blood pressure 7.5%, 
three risk factors combined 53.3%, and treatment 23.1% 98.  
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The changes in stroke mortality may be due to changes in disease 
incidence rate 99. While some studies have shown stable incidence rates of stroke 
15 (such as Sweden 100), other studies reported a continuing declining trend in 
incidence of stroke in western countries 101,  Norway 102, Finland 103 and Sweden 
104 through the 1970s and the early 1980s; but in the late 1980s and early 1990s 
this trend seemed to have come to end, and increased 101. During the first decade 
of the 21st century incidence trends have also been declining (Finland 105), or 
were stable (France 106). While declining incidence rates were explained mainly 
by cigarette smoking 107, stable stroke incidence rates could be related to control 
of risk factors 108. Meanwhile, the increasing incidence rates were explained by 
unfavourable changes in risk factor profile 107.  
Looking at the observed trends in the past, the decline in mortality from 
stroke will continue in the future, which supports by other studies 109.  It might be 
explained by two facts. First, there is a highly consistency in the recent trends in 
stroke mortality in western Europe 110. Our findings also showed that the declines 
had persisted up to recent years in these six populations. Second, the cohort 
patterns of declines are also very important. In our previous study, we have 
already confirmed the well-known cohort-wise decline in stroke mortality over 
time in these European countries 111. We have also discussed about the effects of 
living conditions in childhood before 111. 
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Name of PhD student:                Masoud Amiri 
Erasmus MC Department:          Public Health 
PhD period:                                2007 - 2010  
Promotor:                                    Prof. dr. G.J. Bonsel 
Supervisor:                                  Dr. A.E. Kunst 
 
1. PhD training Year Workload 
Days(ECTs) 
General academic skills  
- English Language 
- Introduction to Medical Writing  
- Working with SPSS for Windows 
- Integrity in Research 
- Writing Successful Grant Proposals 
 
 
2002 
2003 
2003 
2006 
2010 
 
4 (1.4) 
4 (1.1) 
1 (0.15) 
3  
1 
In-depth courses  
- Master of Epidemiology, Netherlands 
Institute for Health Sciences (NIHES), 
Erasmus MC, Rotterdam, Netherlands 
o Erasmus Summer Program 
 Clinical Decision Analysis 
 Cohort Studies 
 Analysis of repeated 
measurements 
 Principles of Research in 
Medicine and Epidemiology 
o Core Curriculum 
 Study Design 
 Classical Methods for data-
analysis 
 Public Health Research Methods 
 Qualitative Research and Survey 
Methods  
 Methodological Topics in 
Epidemiologic Research 
 Modern Statistical Methods 
 
 
 
 
 
 
2003 
2003 
 
2003 
 
2003 
 
2003 
 
2003 
2003 
 
2003 
 
2003 
2003 
 
 
 
 
 
 
2.5 (0.7) 
2.5 (0.7) 
 
2.5 (0.7) 
 
5 (0.7) 
 
8 (4.3) 
 
12 (5.7) 
8 (4.3) 
 
4 (1.4) 
 
4 (1.4) 
8 (4.3) 
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o Advanced short courses 
 Analysis of time-varying 
exposures 
 Environmental Epidemiology 
and Occupational Epidemiology 
 Medical Demography 
 Planning and Evaluation of 
Screening 
 Decision Making in Health Care 
 Cardiovascular Diseases 
Epidemiology (Cambridge 
University, UK) 
 
 
- Doctor of Science (D.Sc.) in Epidemiology, 
NIHES, Erasmus MC, Rotterdam, The 
Netherlands 
o Erasmus Summer Program 
 Bayesian Analysis 
 Conceptual Foundation of 
Epidemiologic Study Design 
o Advanced short courses 
 Design, Conduct and Analysis of 
Multicenter Studies 
 Psychiatric Epidemiology 
 Principles of Epidemiologic Data 
Analysis (Lunteren, Netherlands, 
By K. Rothman) 
 Operational Research Applied to 
Health Sciences 
 Internet Techniques for Health 
Care 
 
- COEUR courses, Dep. of Cardiology, 
Erasmus MC, Rotterdam, The Netherlands 
o Pathophysiology of Ischemic Heart 
Diseases 
o Cardiovascular Pharmacology 
o Cardiovascular Medicine 
o Cardiovascular Clinical Epidemiology 
o Cardiovascular Imaging and 
Diagnostics 
o Atherosclerosis Research 
 
 
2003 
 
2003 
2003 
 
2003 
2003 
 
 
2003 
 
 
 
 
 
 
2004 
 
2004 
 
 
2004 
2004 
 
 
2004 
 
2004 
 
2004 
 
 
 
 
2005 
2005 
2005 
2006 
 
2006 
2006 
 
 
2 (0.6) 
 
3 (0.9) 
5 (1.4) 
 
5 (1.4) 
5 (1.4) 
 
 
3 (0.9) 
 
 
 
 
 
 
2.5 (0.7) 
 
5 (1.4) 
 
 
2 (0.6) 
2 (0.6) 
 
 
5 (1.4) 
 
3 (0.9) 
 
4 (1.1) 
 
 
 
 
5 (1.5) 
5 (1.5) 
5 (1.5) 
5 (1.5) 
 
5 (1.5) 
5 (1.5) 
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Seminars (Attending and Presenting)  
 
- Bi-weekly seminars of Social Epidemiology 
Group 
- Weekly seminars of Department of Public 
Health 
- Weekly seminars of Department of 
Cardiology 
- Cardiology and Vascular Medicine: Updates  
- Cardiology and Vascular Medicine: Updates  
- Weekly seminars of Department of Public 
Health 
 
 
 
2003-2005 
 
2003-2005 
 
2005-2006 
2005 
2006 
 
2009-2010 
 
 
 
50  
 
80  
 
30  
 3 (1.5)  
 3 (1.5) 
 
15  
 
Presentation at International conferences    
 
- 12th Annual Public Health Forum, Brighton, 
UK 
- Heart Failure Update 2004, Wroclaw, Poland 
- The 5th International Heart Health 
Conference, Milan, Italy 
- SER’s 2004 meeting, Salt Lake City, USA 
- Third conference on Epidemiological 
Longitudinal Studies in Europe, CELSE3, 
Bristol, UK                                                         
- The 7th World Congress on Gastrointestinal 
Cancer, Barcelona, Spain         
- 1st International Cancer Control Congress, 
Vancouver, Canada 
 
 
 
2004 
2004 
 
2004 
2004 
 
 
2004 
 
2005 
 
2005 
 
 
4 (1.4) 
4 (1.4) 
 
4 (1.4) 
4 (1.4) 
 
 
4 (1.4) 
 
4 (1.4) 
 
4 (1.4) 
 
2. Other activities  No. of 
Reviews 
- Editorial Board of: 
o Stroke 
o Stroke 
o Preventive Medicine 
- Reviewer of : 
o Stroke 
o Journal of Epidemiology and 
Community Health (JECH) 
o American Journal of Epidemiology 
(AJE) 
 
 
 
2010-2011 
2009-2010 
Since 2009 
 
Since 2005 
 
Since 2005 
 
Since 2005 
 
 
 
 
 
 
 
55 
 
  8 
 
  5  
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o McMaster Online Rating of 
Evidence 
o European Journal of Clinical 
Investigation (EJCI) 
o Libertas Academica 
o Environmental Health Insights 
o Journal of Internal Medicine (JIM) 
o Journal of Isfahan Medical School 
(JIMS) 
o European Journal of Cancer (EJC) 
o Population Health Metrics Journal  
o Journal of Shahrekord Medical 
University 
o International Journal of Preventive 
Medicine (IJPM) 
o Journal of Developmental Origins 
of Health and Disease  
 
Since 2007 
 
Since 2008 
Since 2008 
Since 2008 
Since 2008 
 
Since 2008 
Since 2009 
Since 2009 
 
Since 2009 
 
Since 2010 
 
Since 2010 
 
77  
  
  3  
  1   
  1  
  1  
 
20  
  2  
  1  
  
  2 
 
  1 
 
  1 
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